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Abstract
Inflammation is the body’s response to injury and infection, and is aimed at 
eradicating the threat and repairing the tissue through the activation of the innate 
and adaptive immune systems. The innate inflammatory response is triggered by a 
surveillance network of broadly specific receptors. It is immediate and pre­
programmed, and involves the activation of phagocytic cells and the release of 
soluble anti-microbial mediators to eradicate infection as quickly as possible. It can 
also promote the subsequent adaptive response. The adaptive inflammatory 
response is regulated by antigen-specific T helper (Th) lymphocytes, and has 
memory to provide immunity against repeat Infection. These two arms of the 
immune system are often activated concurrently and communicate through the 
release of cytokines and chemokines to co-ordinate and regulate an appropriate 
response.
Th cells differentiate into various effector cell types and co-ordinate different 
responses, often directing innate immune cells to carry out effector functions. Th1 
cells produce IFNy and direct responses against intracellular pathogens through 
macrophage activation. Th2 cells produce ÎL-4, IL-5 and lL-13 and are important in 
resistance to parasites through mast cell and eosinophil activation. Th17 cells 
produce IL-17 and are important in sepsis through neutrophil activation. 
Dysregulation of these responses often contributes to the development of disease. 
Autoimmune diseases are characterised by Th1 and/or Th17 inflammation, whilst 
dysregulated Th2 responses result in allergy and asthma. Inflammatory diseases 
are often chronic and debilitating, and current therapies are either ineffective or 
have significant side-effects, so novel inflammatory mechanisms and therapeutic 
targets are required.
ST2L is a member of the IL-1 receptor family that was identified as a surface 
marker for Th2 cells, and is associated with Th2 cell activation and functions, 
although its precise role is unknown. IL-33 is a novel member of the IL-1 cytokine 
family, and has recently been identified as a ligand for ST2L. It promotes Th2 
cytokine release and eosinophil accumulation in  vivo. sST2 is a soluble form of 
ST2L that has broad immunosuppressive activity, although the mechanism is 
unknown. Therefore IL-33 and ST2 are potentially important inflammatory 
mediators, and in this thesis I aimed to demonstrate the role of IL-33 and ST2 in
innate and adaptive inflammation, using murine models of allergic airways disease 
and autoimmune arthritis.
I have shown that IL-33 administered directly to the airways provokes an innate 
Th2 type response in the lung with many characteristics in common with allergic 
airways disease. There was increased production of Th2 cytokines, except IL-4, 
chemokines and eosinophilic inflammation. ST2 gene knockout (ST2'^') mice 
demonstrated this response was dependent on ST2, and SCID mice demonstrated 
that whilst non-lymphoid cells were sufficient to initiate a response, lymphoid cells 
enhanced it. IL-33 exacerbated the effector phase of Th2 allergic airways 
inflammation, with increased eosinophils, Th2 cytokines and chemokines in the 
airway, and increased lymph node responses. ST2^ mice had reduced 
inflammation in the airway, despite normal lymph node responses, suggesting the 
role of IL-33 and ST2 is more important in the tissues. Pilot data also suggested 
that IL-33 exacerbates Th1/Th17 autoimmune collagen-induced arthritis (CIA), 
with increased disease severity and lymph node responses. ST2^ mice had 
reduced disease severity, again despite normal lymph node responses.
in summary, I have demonstrated that in the airway IL-33 is sufficient to induce a 
Th2 type innate response with pathological features similar to asthma. I have also 
shown that IL-33 can exacerbate Th2 mediated airway inflammation, and in 
addition, Th1/Th17 mediated arthritis. Thus it has general pro-inflammatory 
actions, and warrants further investigation to elucidate the mechanisms involved 
and fulfil its potential as a target for future therapeutic intervention.
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Chapter 1
Introduction
Chapter 1: 17
1.1. Inflammation In health and disease
Inflammation is the response of the body tissues to any insult, such as infection, 
toxins, trauma, or ischaemia. It is a complex process involving activation of the 
resident tissue cells and recruitment of immune cells from the circulation, co­
ordinated by the release of cytokines and chemokines, with resulting disruption to 
tissue structure and function. The process of inflammation is divided into distinct 
phases. The initial innate response is immediate and antigen non-specific, whilst 
the continued adaptive response is antigen-specific and has memory. Resolution 
of inflammation then aims to restore normal tissue structure and function. There is 
much overlap in these phases, and the same cells and mediators can have 
different roles in each phase. The innate and adaptive immune systems 
communicate throughout to direct the appropriate response to the insult.
The inflammatory process requires tight regulation to ensure an appropriate level 
of response, and then complete resolution. However, when the regulatory 
mechanisms break down chronic inflammation can arise, which leads to 
permanent tissue damage and dysfunction. Many human diseases are the result 
of chronic inflammation, contributing to much morbidity and mortality. Sensitisation 
to an exogenous antigen can result in allergic inflammation, typified by atopy and 
asthma. The immune system can also make inappropriate responses to self 
antigens, resulting in autoimmune disease, such as rheumatoid arthritis (RA). The 
underlying mechanisms of the dysregulation are not completely understood, and 
are likely to be multiple, which is reflected in the lack of effective treatments for 
many diseases. New mechanisms and targets for drug therapy are constantly 
being sought.
Interleukin 33 (IL-33) is a novel cytokine (1) with the potential to play an important 
role in inflammation. In this introduction I will discuss some of the key mechanisms 
of innate and adaptive inflammation, with particular reference to asthma and RA, 
and the possible role of IL-33 and its receptor, encoded by the ST2  gene. This will 
identify this interaction as an important target for further study and potential new 
therapies.
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1.2. Innate inflammation
The importance of the innate Immune system is underlined by the fact that only 
vertebrates have adaptive immunity, so most organisms survive effectively with 
only innate immunity (2). The innate response is immediate and efficient, but has 
no facility for memory. It was originally thought to be non-specific, though it is now 
recognised that a network of broadly-specific receptors is in place to activate the 
inflammatory response. Once activated, the innate response aims to eradicate the 
stimulus (eg an invading organism) quickly and effectively, and if required activate 
and shape the adaptive immune system.
1.2.1. Epithelial defences
The epithelial surfaces of the skin, lung and gut are particularly vulnerable as they 
interface with a constantly changing environment. Epithelial cells are bound 
together by tight junctions to prevent micro-organisms passing between them, thus 
acting as a physical barrier. They are continually turning over, particularly in the 
skin and gut, and breaches are quickly repaired. In the lung, soluble microbicidal 
mediators, such as immunoglobulin A (IgA), enzymes, defensins, surfactant and 
complement are present in the mucus lining layer, which also serves to trap 
particles and micro-organisms and transport them out of the lung via mucociliary 
clearance. As the epithelial surfaces are constantly presented with potential 
threats, and therefore potential immune activation, the regulatory mechanisms are 
particularly tight, and often specific to the site. For instance, alveolar macrophages 
are constitutively suppressed by epithelial bound transforming growth factor p 
(TGF(3)(3), and the gut is able to distinguish between commensal and pathogenic 
bacteria, although the mechanisms for this are less clear.
1.2.2. Sensing and signalling danger
One of the crucial functions the innate immune system must perform is to 
determine when and how to initiate a response. The innate immune system must 
distinguish between self and non-self (4) and/or between danger and non-danger 
(5), through a ubiquitous network of receptors. Non-danger signals, such as self­
antigens, and non-pathogenic commensal bacteria at epithelial surfaces, result in 
tolerance, whilst danger signals from invasion or tissue damage result in 
inflammation. Regulation is tight, particularly at epithelial surfaces, to prevent 
constant activation and tissue damage.
Chapter 1; 19
Sensing of pathogens relies on several principles. Microbes express a number of 
molecules and motifs which are highly conserved due to their critical roles in 
survival. These are termed pathogen associated molecular patterns (PAMPs), 
although they are not strictly limited to, nor do they define, pathogens. A 
complementary set of receptors known as pattern recognition receptors (PRRs) 
are encoded in the germline of organisms, which can bind to PAMPs and initiate 
immune responses. Their specificity is predetermined and often broad, and they 
do not undergo any gene rearrangement or somatic mutation. They fall broadly 
into two categories, those that are membrane associated, and those that are 
cytosolic.
1.2.2.1. ToINike receptors  -  membrane associated PRRs
Toll is a protein involved in dorso-ventral organisation and defence against fungi in 
the fruit fly {D rosoph ila  m elanogaster). Homologous toll-like receptors (TLRs) are 
members of the pro-inflammatory T0II/IL-IR (TIR) family (6)(see section 1.6.2.), 
and have been identified as PRRs in many species, particularly humans and mice 
(7). Ligand binding initiates signalling leading to the activation of NFkB and pro- 
inflammatory gene expression, or type 1 interferon, regulated by TIR adaptor 
proteins (8). They are expressed on a wide variety of cells involved in both innate 
and adaptive immunity, and through modulation of cytokine, chemokine, and 
receptor expression can initiate innate responses (7) and modulate adaptive 
responses (9). Signalling through TLRs can also contribute to human disease (10). 
For instance, immunosuppression in sepsis can arise from TLR2 and TLR4 cross 
tolerance (11), and host DNA in immune complexes may be recognised by TLR9 
and contribute to autoantibody production (12). TLR4 polymorphisms can result in 
hyporesponsiveness to lipopolysaccharide (LPS)(13), which increases 
susceptibility to Gram negative sepsis (14), but protects against atherosclerosis 
(15). Polymorphisms of TLR2 increases susceptibility to Gram positive sepsis (16).
1.2.2.2. NOD-like receptors  -  cytosolic PRRs
Many bacteria and viruses can invade the cytosol directly, thus bypassing 
detection by TLRs, and necessitating a different set of receptors to detect their 
presence and initiate responses. The NOD-like receptor (NLR) family includes 
over 20 members, and has some similarities with the TLR family (17). They all 
have an LRR domain for MAMP recognition, a nucleotide-binding oligomerisation 
domain (NOD), and a third, variable domain for signalling. Of this large family a
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few have been found to have roles in specific diseases. NOD1 and N0D2 
recognise components of peptidoglycan, and activate NFkB. Mutations in N0D1 
are associated with asthma (18), and NODI and N0D2 mutations are associated 
with inflammatory bowel disease (19,20). NOD-LRR and pyrin containing proteins 
(NALPs) recognise a number of bacterial and viral PAMPs, and activate the 
inflammasome caspases 1 and 5 to increase processing and release of the pro- 
inflammatory cytokines IL-1(S and IL-18. Mutations in NALP-3 result in IL-1- 
dependent auto-inflammatory disease, such as Muckle-Wells syndrome (21), 
characterised by recurrent systemic inflammation in the absence of infection.
1.2.3. innate effector mechanisms
Virtually all cells express PRRs, in particular TLRs, and so may be directly 
activated by sensing pathogens or danger. Once danger has been recognised, 
cells of the innate immune system have a number of effector mechanisms 
designed to neutralise and eradicate toxins and micro-organisms, and to shape 
the subsequent adaptive immune response. Whilst a complete review is beyond 
the scope of this introduction, some of the key cells and functions are highlighted 
in table 1.1. In addition, non-immune cells, such as endothelial cells, epithelial 
cells, bronchial smooth muscle cells and fibroblasts express TLRs and cytokine 
receptors, and can be activated to release cytokines and chemokines. Endothelial 
cells can also upregulate adhesion molecules, and epithelial cells produce anti­
microbial proteins such as defensins and surfactant in the lung.
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CELL TYPE MECHANISMS EFFECTS
NEUTROPHIL Phagocytosis
Granule proteins and enzymes 
Reactive oxygen and nitrogen species
Microbial killing
Granule proteins and enzymes Host tissue damage
Cytokines (especially IL-12) Thi cell differentiation
Chemokines Cell migration and activation
MACROPHAGE Phagocytosis
Reactive oxygen and nitrogen species
Microbial killing 
Removal of neutrophils
Chemokines Cell migration and activation
Cytokines
(TNFa, IL-13 and many others)
Cell activation 
T cell differentiation
Antigen presentation (MHCII) T cell activation
EOSINOPHIL Granule proteins and enzymes Parasite killing 
Host tissue damage
Chemokines Cell migration and activation
Cytokines (especially IL-4) Cell activation 
Th2 cell differentiation
Antigen presentation T cell activation
MAST CELL Degranulation (FceRI, FcyRIII, TLRs) Rapid release of preformed mediators
Fiistamine 
Lipid mediators
Increased blood flow and vascular 
permeability
Increased adhesion molecules 
Th2 differentiation 
Bronchoconstriction 
Increased gut motility
Proteases Matrix degradation 
Host tissue damage
Defensins Microbial killing
Chemokines Cell migration and activation
Cytokines
(TNFa, IL-13, IL-4 and others)
Cell activation 
T cell differentiation 
DC maturation
MYELOID DC Phagocytosis Antigen sensing and processing
Antigen presentation (MHCII) 
Costimulatory molecules
T cell activation 
T cell differentiation
Cytokines
(IL-2, IL-4, IL-12 and others)
T cell differentiation 
NK cell activation
Chemokines Cell migration and activation
PLASMACYTOID DC Type 1 interferons 
Cytokines and chemokines
Anti-viral response
NK CELLS Perforin and granzyme
“Missing se lf (detects lack of MHCI)
Tumour lysis 
Infected cell lysis
Cytokines
(IFNy, IL-4, IL-12 and others)
Macrophage activation 
T cell differentiation
NKT CELLS Rapid early cytokine release Cell activation 
T cell differentiation
Table 1.1 Innate effector mechanisms
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1.3 Adaptive inflammation
In contrast to innate responses, adaptive responses are antigen-specific, and 
exhibit memory. Specificity is achieved by the random recombination of genes 
encoding T cell receptors (TCR) and antibodies, and somatic hypermutation of 
antibodies during a response. Memory arises from the sustained presence of 
antigen-specific cells capable of immediate and effective responses if the antigen 
is encountered in the future. There is huge complexity to the processes of T and B 
cell repertoire selection, tolerance to self antigens, antigen presentation, 
lymphocyte activation and maintenance of memory, and in the development of 
different T and B cell subsets. Here I will restrict discussion to the processes of 
CD4"  ^ helper T cell differentiation and effector function, the key regulatory cells in 
the adaptive response.
1.3.1. CD4* T helper cell differentiation
Naïve CD4‘" T cells are pluripotent progenitor cells (Thp cells), activated by 
recognising antigen presented on MHCII, and differentiating into a range of 
effector cells. The main antigen presenting cells are dendritic cells (DCs), although 
other cells can also play a role. DCs express co-stimulatory molecules and 
cytokines necessary for the complete activation, proliferation and differentiation of 
T cells. The nature of these signals depends on signals received by the DC, such 
as PRR stimulation (especially through TLRs), the type of peptide presented, the 
dose of antigen, and cytokines and chemokines from innate cells in the micro­
environment.
Historically CD4"  ^ T cells were classified as T h i, releasing IFNy, and Th2, 
releasing IL-4 (22). However in recent years it has become apparent that that this 
is an oversimplification, and other subsets of effector cells and regulatory cells 
have been identified in mice and rats. It is also clear that although it is often 
possible to clearly define terminally differentiated subsets in experimental model 
systems, the reality in vivo  is that these cell types may co-exist in a response, and 
may be present at intermediate stages of differentiation. In addition, there is much 
less evidence that these subsets are so clearly defined in the human immune 
system. Although the cell fate pathways are not yet fully elucidated, some of the 
key effector cells and mediators are outlined in Figure 1.1. It is likely that further 
subsets of effector cells are yet to be identified.
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Figure 1.1 CD4* T effector cell differentiation
Naïve pluripotent CD4+ progenitor T cells (Thp) can develop into a number of functionally distinct T 
effector cells follo\A/ing stimulation by antigen-presenting cells (APCs). T helper 1 (Th1) cell 
differentiation is initiated by interferon y (IFNy), and maintained by IFNy, interleukin (IL)-12 and IL-18. 
Differentiated Thi cells produce the effector cytokines IFNy and IL-2, which promote natural killer
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(NK) cell, macrophage and CD8+ cytotoxic T cell activity against intracellular organisms. Th17 cell 
development is initiated by transforming growth factor (3 (TGFp) and IL-6, and maintained by IL-23. 
They produce IL-17, IL-6 and tumour necrosis factor a (TNFa) and promote neutrophil responses. 
The essential factors initiating Th2 cell development are less well defined, but include thymic stromal 
lymphopoietin (TSLP), lL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF). il-4 
also maintains the Th2 phenotype and is an important Th2 effector cytokine, along with IL-5 and IL- 
13. Th2 cells promote immunoglobulin E (IgE) and cellular (eosinophils, mast cells, basophils) 
responses against extracellular parasites. Th differentiation is a complex multi-step process that is 
not yet fully understood, expression of the lineage specific cross-regulatory transcription factors Tbet, 
RORyt and GATA3 is an irreversible step after which cells cannot be redirected to a different fate. In 
addition to these effector T cell subsets there are also a number of regulatory T cell subsets, the 
differentiation of which is less well understood. A constitutive population of CD25+ regulatory T cells 
(Tregs) matures in the thymus with expression of the transcription factor FoxP3 essential for 
regulatory function. They suppress autoreactive T cell responses through a cell-contact dependent 
mechanism and prevent autoimmunity. Other regulatory T cells can develop in the periphery during 
immune responses under the influence of Tregs. These include Th3 cells and Tri cells which act 
through the release of TGF|3 and IL-10 respectively. Follicular T helper cells (ThFH) are a novel 
subset which promote B cell antibody production through an inducible costimulatory molecule (ICOS) 
dependent mechanism.
1.3.1.1. Th i differentiation
Th1 cells secrete IFNy, and mediate cellular immunity against intracellular 
infection and tumours through activation of macrophages, NK cells and CD8^ T 
cells. Dysregulation of T h i responses can lead to autoimmunity, and destructive 
responses against self antigens, typified by type 1 diabetes mellitus. They may 
also contribute to the pathology of rheumatoid arthritis.
IFNy from antigen presenting DCs and macrophages initiates Th i differentiation 
by inducing the expression of the transcription factor Tbet, which is specifically 
expressed in Th i and not Th2 cells and correlates with IFNy expression (23). Mice 
deficient in Tbet spontaneously develop Th2 inflammation in the airways (24), and 
have severely impaired IFNy expression and T h i responses (25). Tbet induces 
the expression of IL-12R3 (26), exposes the IFNy gene through chromatin 
remodelling (27), and represses Th2 cytokine production (23). As well as being the 
key effector cytokine, IFNy is also important in maintaining the Th1 phenotype.
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This is illustrated by the observation that in  vitro  polarised Th1 cells from IFNy 
deficient mice can be redirected to produce IL-4, whereas wild type Th1 cells 
cannot (28).
11-12 is important in IFNy production in Th1 cells. It induces the expression of the 
IL-18R (29), and IL-18 augments IFNy production, and induces further expression 
of the IL-12R (30). Thus IL-12 and IL-18 together are potent Th i differentiation 
factors. IL-12 and IL-12R deficient mice have weak, but not absent, IFNy 
production and Th i responses (31,32). Thus IL-12 is not an absolute requirement, 
and other factors can replace it. IL-27 and IL-23, other members of the IL-12 
family, can induce proliferation and IFNy production from naïve and memory CD4+ 
cells respectively (33,34), and type 1 IFNs can also induce IFNy expression during 
viral infection (35).
1.3.1.2. Th2 differentiation
Th2 cells mediate humoral Immunity against extracellular parasites, in particular 
helminths, through the production of IgE from B cells, and the release of toxic 
mediators from mast cells, eosinophils and basophils. Thus an environment hostile 
to parasite survival is created, and an inflammatory reaction occurs to limit the 
spread or expel the organism. Dysregulation of Th2 responses results in allergic 
inflammation, such as atopic dermatitis and asthma.
The initiation of Th2 differentiation is less well understood than T h i. It is clear that 
IL-4 is important in commitment to the Th2 lineage, but may come from 
eosinophils, mast cells, NKT cells, or early Th2 cells themselves, rather than from 
antigen presenting cells. Recently it was shown that thymic stromal lymphopoietin 
(TSLP) can induce Th2 cytokine release from mast cells (36), condition DCs to 
differentiate Th2 cells (37,38), and can induce IL-4 expression in CD4* cells to 
promote Th2 differentiation (39). IL-4 induces the transcription factor GATA-3, 
which is present in Th2 cells and not Th i (40). GATA-3 upregulates the 
expression of IL-4, IL-5 and IL-13 as well as Itself (41,42), setting up a positive 
feedback loop. It also suppresses the expression of IFNy and IL-12R(3 (43). Mice 
deficient in IL-4 or IL-4R can still produce Th2 cells, albeit at a lower frequency 
(41,44), and can mount Th2 responses (45-47) so there are other pathways by 
which Th2 commitment can occur. For instance, granulocyte-monocyte colony- 
stimulating factor (GM-CSF) can induce Th2 responses in the absence of IL-4 
(48). The role of IL-33/ST2 in Th2 differentiation is discussed in section 1.6.8.
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1.3.1.3. T h i7 cells
Th17 cells increase neutrophil synthesis in bone marrow through GM-CSF, and 
specifically recruit and activate neutrophils through the expression of IL-17, IL-6, 
and TNFa, and so have an important role in the response to extracellular bacteria 
and in sepsis (49). The transcription factor RORyt is specific to T h i7 cells and is 
not expressed in Th i or Th2 cells (50). They have also been shown to play 
pathological roles in experimental models of autoimmunity, including experimental 
auto-immune encephalitis (EAE) (51), and collagen-induced arthritis (CIA), a 
model of rheumatoid arthritis (52). They appear to be a separate lineage of T cells, 
as they can develop when IL-4 and IFNy are blocked and do not express Tbet or 
GATA3 (53,54). TGF|3 and IL-6 are critical to early commitment to the T h i7 
lineage, enhanced by TNFa and IL-ip , whereas IL-23 is important in maintaining 
differentiated cells (55,56).
1.3.1.4. Follicular T helper cells
Follicular Th cells (ThFH) are a novel subset of CD4^ cells which migrate to the B 
cell area of lymph nodes after stimulation and play a role in supplying 
costimulation to B cells for antibody production through inducible costimulatory 
molecule (ICOS). High levels of ICOS leads to elevated numbers of ThFH, 
increased germinal centre formation, and resulted in autoimmunity (57).
1.3.2. Regulatory I  cells
In addition to pro-inflammatory effector cells, a number of CD4^ cells with 
suppressive functions have been identified. Approximately 5-10% of circulating 
CD4* cells are naturally occurring Tregs with constitutive expression of CD25 (IL- 
2Ra). They do not proliferate after antigen-specific TOR activation, but can 
suppress the activity of polyclonally stimulated effector T cells (58), as well as 
CD8* T cells, B cells and DCs, in a cell-contact dependent manner. Although the 
exact mechanisms are not fully elucidated, they may involve induction of 
apoptosis, cell lysis, and TGF(3 and IL-10 production (59). They play a vital role in 
peripheral tolerance and the prevention of autoimmunity, and are increasingly 
implicated in autoimmune disease and allergy (60,61). Expression of the 
transcription factor forkhead box P3 (F0XP3) is the critical event in the 
development of natural Tregs (62), and in humans, F0XP3 mutation leads to the 
IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) 
syndrome in humans, characterised by autoimmunity (63).
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Naturally occurring Tregs can also induce the development of other regulatory T 
cells in the periphery during a response, such as TGF(3 producing Th3 cells (64), 
and IL-10 producing T ri cells (65). Both of these cell types have been shown to 
suppress both T h i and Th2 responses in vivo (66,67).
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1.4 Asthma
Asthma is a common condition (68), and the incidence has been increasing (69). 
The clinical syndrome of asthma includes episodic wheeze, cough and shortness 
of breath, with increased mucus expectoration. These are the result of largely 
reversible narrowing of the airways caused by inflammation, goblet cell 
hyperplasia, airway hyper-responsiveness (AHR) and remodelling of the airway 
structure (70). Extrinsic (allergic or atopic) asthma, characterised by high serum 
IgE levels, accounts for the majority of patients, and intrinsic (non-atopic) asthma, 
with normal serum IgE, accounts for the rest (71). The pathology seen in both 
extrinsic and intrinsic asthma is similar, and is the result of an endogenous 
inflammatory process with superimposed exacerbations triggered by exogenous 
factors. It is characterised by a Th2 type inflammatory infiltrate consisting of 
lymphocytes, eosinophils, mast cells and sometimes neutrophils. The epithelium is 
denuded in some areas, and shows goblet cell hyperplasia with mucus 
hypersecretion. The airway exhibits remodelling, with subepithelial fibrosis and 
further thickening of the airway wall by smooth muscle hypertrophy (72). Some of 
these changes have been shown to be present even before the onset of 
symptoms (73), and may contribute to susceptibility to airway inflammation.
The innate and adaptive Immune systems are both important in the initiation and 
persistence of inflammation in asthma (see figure 1.2). In addition, structural 
elements of the airway are taking a much more prominent role in initiating and 
establishing inflammation. In this section I will outline some of the key mediators in 
asthma.
1.4.4. T lymphocytes and asthma
1.4.4.1. Th2 cells and cytokines -  key regulators o f inflammation and AHR
Elevated numbers of CD3'^CD4"‘ cells producing IL-4 and IL-5 have been found in 
BAL and bronchial biopsies from asthmatics (74). These have been presumed to 
be T helper (Th) 2 cells, but recent studies have now identified invariant natural 
killer T (INKT) cells, which also express CD3 and CD4 and produce Th2 cytokines, 
in the airway, so there is now some controversy over the exact contribution of 
each. The level of INKT cells in the normal airway has generally been found to be 
less than 1% of T cells, and this is increased in the asthmatic airway in children 
(75) and in adults with moderate to severe asthma, with levels of 10% (76,77) up
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to 60% (78) found in BAL. A further study, however, seems to show little difference 
in iNKT levels in mild to moderate asthma (79). This may reflect the method of 
detection, and the asthmatic phenotype of the patients studied. There is mounting 
evidence, then, that both Th2 cells and INKT cells feature in the asthmatic airway, 
and the relative function of each may help to determine the phenotype seen. 
Functional studies in mice have demonstrated differential roles for both iNKT cells 
(predominant in airway hyper-responsiveness (AHR); see section 1.4.6.2.) and 
Th2 cells (central regulator of inflammation; see below).
Elevated levels of Th2 transcription factors, such as GATA3 (80), have also been 
found in the airway of asthmatic patients, indicating Th2 cells play an important 
role. Adoptive transfer of antigen-specific Th2 cells is sufficient to cause allergic 
airways inflammation and AHR in naïve mice subsequently challenged with 
antigen (81), and absence of T cells abrogates these responses (82). Th2 
cytokines play a key role in airways inflammation and AHR, and often have 
overlapping functions. Whilst Th2 cells probably constitute an important source of 
these, it must be remembered that other sources, such as eosinophils, mast cells 
and NKT cells also contribute, and may particularly play a role in the early stages.
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Figure 1.2 The pathogenesis o f asthma
Allergen is taken up by dendritic cells (DCs) in the lung, which mature into Th2 differentiating DCs 
under the influence of thymic stromal lymphopoietin (TSLP) released from the epithelium in response 
to toll-like receptor (TLR) stimulation. Epithelial cells also produce pro-inflammatory lipid mediators
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such as ieukotriene (LT) B4 and LTC4. After uptake of allergen the DCs migrate to the local draining 
lymph nodes where they initiate T cell differentiation. Th2 cells migrate via the blood to the lung and 
produce interleukin (IL)-4, IL-5 and IL-13, the key regulators of airway inflammation. Natural killer T 
(NKT) cells may also play a role early in the response by producing Th2 cytokines. Th2 cytokines 
promote airway hyper-responsiveness (AHR) and remodelling, and inflammation through eosinophil 
accumulation and production of immunoglobulin (Ig) E and IgA. Eosinophils produce a large number 
of pro-inflammatory cytokines, chemokines and other mediators in the lung, and also contribute to 
tissue damage through the release of proteolytic enzymes. Subsequent inflammation can be 
triggered through allergen binding to IgE on the surface of mast cells, causing degranulation and de 
novo synthesis of mediators. This releases pro-inflammatory cytokines and chemokines, vasoactive 
mediators such as histamine and kinins, and proteolytic enzymes. In addition to Th2 cells, Thi and 
Thi 7 cells may play a role in asthma through the induction of neutrophilic Inflammation. This is 
though to be particularly important in virally-induced exacerbations and in steroid-resistant asthma. 
Regulatory T cells (Tregs) are able to suppress the inflammation seen in asthma through cell- 
contact, transforming growth factor p (TGF(3) and IL-10 dependent mechanisms. Many of the cells 
and mediators involved in the inflammatory response are not limited to the lung tissue itself, but 
migrate or diffuse to the airway surface where they can contribute to epithelial damage.
IL-4 is one of the central mediators of airway inflammation through its Th2 
differentiating properties, and promoting IgE production. IL-4 producing CD4'^ cells, 
probably a mix of Th2 and NKT cells, have been found in BAL, bronchial biopsies 
and blood of patients with established asthma (83,84). IL-4'^' mice have reduced 
airways inflammation and AHR compared to wildtype (85), but whilst adoptive 
transfer of Th2 cells from IL-4'^' mice resulted in less severe airway inflammation 
than Th2 cells from wildtype mice (86), AHR was unaffected (87). Neutralisation of 
IL-4 during sensitisation did reduce AHR (88), and IL-4 administered to the 
airways directly can induce airway inflammation and AHR in mice, even in Rag“^ “ 
lymphocyte deficient mice, and this effect is absent In IL-4Ra'^‘ mice (89). 
However, IL-4 shares !L-4Ra with IL-13, so this effect may be indirect. Overall, IL- 
4 has a clear pro-inflammatory role in asthma, but its role in AHR may be indirect 
or dispensable.
IL-5 has been found in BAL fluid and serum from asthmatic patients, and its levels 
correlate with CD4'' T cell activation (90,91). The major source of IL-5 in 
established disease is likely to be CD4"^ Th2 and NKT cells (74,78). Its key role is
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in the maturation, recruitment and differentiation of eosinophils (92). In mice, the 
enforced expression of transgenic IL-5 resulted in eosinophilic airways 
inflammation (93), and neutralising IL-5 inhibited both eosinophilia and AHR (94). 
However, although clinical trials of anti-IL-5 showed a marked reduction of 
eosinophils in sputum, there was no improvement in symptoms or AHR (95). In 
another model of transgenic IL-5 expression, this time restricted to the bronchial 
epithelium, AHR was actually reduced, and this effect abolished by anti-IL-5 
antibody (96). Thus the role of IL-5 and/or eosinophils in AHR remains 
controversial. However, IL-5 does appear to play a crucial role in airway 
remodelling, with anti-IL-5 antibodies having a beneficial effect in both mice and 
humans (97,98).
IL-13 shares a receptor chain with IL-4, but has independent and fundamental 
roles in the effector phase of inflammation through modulation of epithelial cells 
and smooth muscle. IL-13 is found in sputum and biopsies from human asthmatics 
(99,100), and is overexpressed in both atopic and non-atopic disease (101). There 
is also a strong link between IL-13 gene polymorphism and asthma (102). 
Administration of IL-13 alone to mice is sufficient to induce eosinophilia, AHR and 
mucus hypersecretion (89), and blocking IL-13 can reduce these features (103). 
The effects of IL-13 on eosinophil recruitment may be mediated by IL-5 and 
eotaxin, or independently of these (104,105). IL-13'^" mice fail to develop AHR or 
mucus hypersecretion in an allergic airways disease model, despite the presence 
of IL-4, IL-5 and eosinophilic inflammation (106). This perhaps demonstrates most 
clearly the dichotomy between inflammation and AHR, and the importance of IL-13 
in the latter.
Other Th2 cytokines such as lL-9, IL-25 and GM-CSF are also expressed in the 
asthmatic airway, and have been shown to promote either Th2 differentiation or 
effector mechanisms in airways inflammation (107). IL-25 in particular has recently 
been shown to have a potentially important role in asthma. Both IL-25 and its 
receptor, IL-17RB, are upregulated in atopic asthmatic patients (108). It is 
particularly produced by epithelial cells after allergen stimulation (109) and is also 
produced by eosinophils and basophils in the lung (108), and may have a role in 
the initial phases of Th2 polarisation. In naïve mice IL-25 instilled into the airway 
induces a profound increase in lung and BAL eosinophils, and increases in AHR 
(109,110). In addition, it is able to polarise naïve T cells towards the Th2
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phenotype in vitro through a GATA-3 mediated increase in early IL-4 production 
(109). Recent data has also shown that memory Th2 cells express IL-17RB, and 
IL-25 increases their proliferation and cytokine production after they are stimulated 
by anti-CD3 or by TSLP-treated DCs (108), thus demonstrating IL-25 may also 
play a role in promoting established inflammation. A recent study showing that a 
blocking anti-IL-25 antibody can substantially reduce eosinophilic airway 
inflammation in mice, and prevent the development of AHR, indicates It is a 
potentially exciting therapeutic target (111).
1.4.4.2. Thi cells and cytokines -  a biphasic effect mediated by TLRs
Thi cells and cytokines are generally regarded as counter-regulatory to Th2 
responses. Certainly, IFNy or IL-12 given to mice during sensitisation prevents or 
reduces airway inflammation and AHR (112,113), and Tbef^' mice develop 
spontaneous Th2 airway inflammation (24). IL-12 can also reduce inflammation 
and AHR when given during antigen challenge, probably by inducing IFNy 
production from pre-existing T h i, CD8^ and NK cells (113,114). However, T h i 
cells and cytokines can also promote established Th2 airways inflammation. CD4^ 
cells producing IFNy have been found at the same time as CD4^ cells producing 
IL-4 and IL-5 in human asthmatic airways (115), and transfer of T h i cells 
exacerbated established airway inflammation, probably by TNFa release and 
recruitment of neutrophils (81).
The ability of TLRs to translate innate signals into immunomodulatory signals 
allows an explanation for why the timing of Th i type responses may be important. 
Increased exposure to LPS or viral illness early in life protects against atopy and 
asthma, presumably by signalling through TLR4 (116). In established asthma, viral 
infections are the most common cause of an exacerbation, and LPS is present in 
many other triggers of asthma exacerbations, including house dust and cigarette 
smoke. In fact, levels of LPS in house dust correlate better with poor asthma 
control than DERpI, the house dust mite allergen, which does not correlate at all 
(117). These observations are borne out experimentally, as LPS administration 
during antigen sensitisation reduced airway inflammation (118), whereas low 
levels of LPS during antigen challenge increased it (119). Furthermore, inhalation 
of LPS in asthmatic patients caused exaggerated AHR compared to normal 
subjects (120). Thus, LPS appears to prevent sensitisation by biasing towards a
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Th1 response early on, but once Th2 inflammation and AHR are established, the 
Th1/pro-inflammatory response exacerbates them.
Whilst IL-18'^’ mice have enhanced airway inflammation (121), the role of IL-18 in 
asthma can be modulated by other cytokines present in the micro-environment. 
Co-administration with IL-12 reduced airway inflammation and AHR in mice (122), 
but administration of antigen with IL-18 alone induced severe eosinophilic airway 
inflammation after transfer of T h i cells in vivo, possibly dependent on Th i 
production of IL-9 and IL-13, and increased production of IFNy and TNFa (123). 
IL-18 can also induce expression of Th2 cytokines from T cells, NK cells and mast 
cells.
1.4.4.3. Th17 cells and neutrophilic infiammation
A role for T h i7 cells is emerging in mediating steroid resistant asthma, which is 
characterised by predominantly neutrophilic inflammation. CD4^ cells from mice 
lacking Tbet preferentially differentiate into T h i7 cells, and mediate neutrophilic 
airway inflammation (124). In keeping with this, IL-17 mRNA was elevated in 
sputum from asthmatic patients, and correlated with IL-8 and neutrophil levels, 
despite treatment with steroids (125).
1.4.4.4. Regulatory T cells and asthma
The role of regulatory T cells in preventing auto-immune diseases is well 
established, and evidence is accumulating that defective CD4^CD25'' Treg 
expansion may also play a role in allergy (61). Children with asthma or atopy have 
fewer circulating CD4^CD25^ Tregs than normal controls, although interestingly 
those with persistent symptoms had higher levels than those who were well 
controlled, which suggests a possible functional upregulation of Treg function 
(126). CD4"‘CD25"^ Tregs can suppress airways inflammation and AHR in mice, 
through cell-contact or IL-10 dependent mechanisms (127-129).
1,4.5. B cells and Immunoglobulin E
The main role for B cells in asthma is through the production of IgE. An increase in 
total and antigen-specific IgE is one of the hallmarks of atopic asthma, but is not 
essential for AHR or eosinophilic inflammation. IgE production is influenced by Th2 
cytokines, in particular IL-4 and IL-13, although they are not essential (130). Most 
IgE is attached to mast cells in the tissues through the high affinity IgE receptor
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FceRI. Antigen crosslinking of this cell-surface IgE results in degranulation with 
release of mediators of hypersensitivity. The importance of IgE in vivo  is illustrated 
by the successful use of omalizumab, a monoclonal antibody against IgE, in 
improving control of asthma symptoms in those with persistently elevated IgE 
levels (131). Subsequent studies have shown this is not just through a reduction of 
total IgE, but also a reduction in FceRF cells, and reduced infiltration of eosinophils 
and T and B cells (132).
1.4.6. Innate cells and asthma
Innate cells often play a dual role in asthma. They are involved in the initial 
response to allergens/pathogens, and thus set the scene for the subsequent 
response, but they are also co-opted by T cells to carry out the effector functions 
of inflammation. Some of these functions will be summarised below.
1.4.6.1. Dendritic cells
Dendritic cells (DCs) form a network under the epithelium and constantly ingest 
and process inhaled antigen, then mature and migrate to local lymph nodes to 
present it to T cells (133,134). Two main populations of dendritic cell exist within 
the lung, and the activation status and phenotype of the DC will influence whether 
the end result is tolerance or inflammation (135).
Myeloid (m)DCs, expressing MFICI and II and CD11c, generally promote 
inflammation by activating T cells to become effector cells. The presence of a 
danger signal (eg exogenous PAMPs or endogenous mediators) in addition to 
allergen triggers full maturation and migration to the lymph node. A high level of IL- 
6 production allows them to overcome naturally occurring CD4^CD25^ Treg 
suppression of immune activation (136). TSLP is produced by epithelial cells, is 
increased in the airways of asthmatics, and correlates with disease severity (137). 
It conditions mDCs to promote Th2 differentiation through expression of the co­
stimulatory molecule 0X40 ligand (138). T-bet and IL-12 expression in mDCs can 
promote T h i responses in the lung (139,140), which may have some regulatory 
role in Th2 inflammation. The importance of mDCs in  vivo is underscored by the 
observations that transfer of antigen primed mDCs into the airways of naïve mice 
leads to Th2 inflammation after antigen challenge (141), and absence of mDCs 
prevents airways inflammation (142). In addition to their key role in the initiation of 
Th2 responses, there is some evidence that they may play a role in secondary
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tissue responses by producing CCL17 (143), a powerful Th2 cell chemoattractant, 
and presenting antigen to T cells in the lung (144).
In the absence of a danger signal allergens do not induce inflammation, they 
induce tolerance instead. Ovalbumin (OVA) is an experimental allergen which 
induces tolerance to subsequent immunisation if administered alone to the airway, 
but allergic inflammation if administered in the presence of a low dose of LPS 
(119) or an adjuvant such a alum (145). Many clinically relevant allergens, such as 
Der p 1 from house dust mites, are proteolytic enzymes that can directly activate 
DCs to mature (146), whereas others probably become allergens due to the 
presence of exogenous microbial contamination (eg LPS). There is evidence that 
in the absence of danger mDCs do not fully mature and induce Tregs and 
tolerance (147). However, the second main DC subset in the lung, the 
plasmacytoid (p)DC, is probably more important in tolerance to allergens. They 
share expression of MHCI and II and C D IIc  with mDCs, but also specifically 
express 120G8 and PDCA-1. They produce large quantities of anti-viral type 1 
interferons after viral infection, but have also been shown to mature into antigen- 
presenting cells after activation of TLRs on their surface. It is though that the 
balance between mDC and pDC function is important in asthma. In keeping with 
this, induction of pDC differentiation in  vivo  by Flt-3 ligand reduced allergic airway 
inflammation (148), whereas depletion of pDCs from mice breaks inhalational 
tolerance to OVA and allows mDCs to be more immunogenic and induce allergic 
airway inflammation (149). The precise mechanisms are unknown but may be 
related to the immature phenotype, and involve the expression of programmed 
death ligand 1 delivering a negative signal to naïve T cells (149), or pDC 
production of indoleamine-2,3-deoxygenase, which inhibits T cell proliferation and 
airway inflammation (150,151).
1.4.6.2, NKT cells
NKT cells are a novel subset of lymphocytes expressing an invariant T cell 
receptor which recognises glycolipid antigen in the context of CD Id on presenting 
cells, such as epithelial cells. As discussed above, some of the CD4"^ cells 
producing Th2 cytokines in the airway in asthma are likely to be iNKT cells. There 
is some argument over the numbers of iNKT cells seen in asthma, but this may not 
be crucial as iNKT cells are rapid and efficient producers of many cytokines, 
including IL-4, IL-13 and IFNy. Although iNKT cells produce a variety of cytokines
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after activation, repeated activation leads to a predominance of Th2 cytokine 
production, suggesting a possible role in allergic disease (152,153). Mice deficient 
in iNKT cells demonstrated their crucial role in the development of AHR and 
inflammation through the production of IL-4 and IL-13, independent of 
conventional T cells (154,155). In patients with moderate to severe asthma (atopic 
and non-atopic) up to 60% of CD3'*'CD4^ cells in BAL, and almost all the 
CD3'"CD4‘^  cells in bronchial biopsies, were INKT cells rather than conventional 
Th2 cells (78). They produced large amounts of IL-4 and IL-13, but little IFNy. 
CCR9'^CD4^ INKT cells have also been seen in the blood of asthmatics, and 
numbers decreased after steroid treatment, and In well controlled patients. They 
were found to induce Th2 polarisation of naïve T cells through CCR9 and CD226 
dependent cell contact mechanisms (77). Thus iNKT cells may play both direct 
and indirect roles in IL-4 and IL-13 production, and the asthma phenotype.
1.4.6.3. Eosinophils
Eosinophils are another hallmark of atopy and allergy, and there is a large body 
evidence that not only are they present in the inflammatory process, they cause 
damage to the airways through release of toxic granular proteins, reactive oxygen 
species, and pro-inflammatory lipid mediators (92). They also contribute to its 
chronicity through secretion of T h i and Th2 cytokines (156), and possibly antigen 
presentation to T cells (157), and play a role in remodelling (158). Their role in 
AHR is controversial. Eosinophil deficiency in IL-5^^  and PHIL mice reduced AHR, 
and reconstitution of eosinophils restored AHR (159,160). However, in humans, 
depletion of eosinophils in the airway by anti-IL-5 had no effect on AHR (95), 
although it must be noted that eosinophil depletion was not complete (161). 
Dissociation of inflammation and AHR is also seen in mice, where the dblGATA 
strain of eosinophil-deficient mice demonstrated that AHR may arise by eosinophil 
independent pathways (158).
1.4.6.4. Mast cells
Mast cells are found in bronchial biopsies in human asthma (162), and 
degranulate after crosslinking of IgE bound to the high affinity FceRI on their 
surface. They rapidly release preformed and newly synthesised pro-inflammatory 
and bronchoconstrictive mediators such as histamine, proteoglycans, serine 
proteases, prostaglandin D2 (PGD2), ieukotriene C4 (LTC4) and platelet 
activating factor (PAF). In addition to mediating this early phase hypersensitivity
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response to allergen, they can promote Th2 differentiation and effector responses 
through Th2 cytokine and chemokine production (163,164) and TNFa production 
(165). However, some models have shown mast cells are not essential for allergic 
inflammation or AHR (166).
Mast cells are present in the submucosa of normal subjects, asthmatic patients, 
and patients with eosinophilic bronchitis -  a disease with a very similar 
inflammatory infiltrate to asthma, but no AHR (167). However, only the asthmatic 
subjects had increased mast cell numbers in the airway smooth muscle, implying a 
close relationship between these two cell types is important in the development of 
AHR in asthma, rather than just eosinophilic inflammation.
1.4.6.5. Neutrophils
Neutrophilic inflammation, which is promoted by TNFa and IL-17, is associated 
with some exacerbations and also different phenotypes of asthma. Including 
severe asthma and steroid resistant asthma (168). The possible role of T h i7 cells 
and IL-17 in neutrophilic airway inflammation has been discussed above. In 
addition, elevated levels of TNFa are seen in BAL and biopsies from asthmatics 
(169), inhalation of TNFa results in AHR and airway neutrophil infiltration (170), 
and treatment with etanercept, a TNFa antagonist, reduced AHR and asthma 
symptoms in a clinical trial (171). Thus there may be an important role for 
neutrophils in certain situations, promoted by Th i 7 cells and/or TNFa.
1.4.7. Structural cells and asthma
1.4.7.1. Epithelial cells
In addition to their role as a barrier, epithelial cells can also play an active role in 
the inflammatory process. Recently it was shown thymic stromal lymphopoietin 
(TSLP) is released after activation of epithelial cells by TLRs and other innate 
signals (36,172), thereby providing a link between innate and adaptive immunity, 
and initiation of inflammation. Overexpression of transgenic TSLP in the epithelium 
results in airway inflammation and AHR (143), and TSLPR deficient mice have 
reduced responses to inhaled antigen (173). Human bronchial epithelial cells have 
also been shown to produce leukotrienes after LPS stimulation, and may therefore 
contribute directly to AHR and inflammation (174).
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A relatively recent concept to develop is that in asthmatic patients the epithelium 
may be more susceptible to damage by viral infection (175,176), or toxins (177), 
and aberrant healing may contribute to the development of asthma (178). This 
may contribute to the early remodelling changes seen, and create an environment 
more susceptible to future infection/damage and inflammation. Whether these 
changes in epithelial function predate inflammation, or are caused by it, remains to 
be elucidated.
1.4.7.2. Smooth muscle and fibroblasts
Smooth muscle hypertrophy, under the influence of cytokines and inflammatory 
cells, contributes to airway thickening and remodelling (179). Structural elements 
have also been implicated in the pathogenesis of asthma by the identification of 
polymorphisms in the A D A M 33  gene (a disintegrin and metalloproteinase 33) that 
are strongly associated with asthma, AHR, and remodelling with a decline in lung 
function (180). Although the exact role of ADAM33 in asthma has yet to be 
elucidated, it is only expressed on smooth muscle and fibroblasts. Both smooth 
muscle cells and fibroblasts also release cytokines and chemokines contributing to 
ongoing inflammation.
1.4.8. Chemokines and asthma
Chemokines and their receptors are key mediators of the coordinated movement 
of cells into inflamed tissues in asthma (181,182), although adhesion molecules 
also play important roles. A full discussion of chemokine biology is beyond the 
scope of this introduction, but I will summarise some of the key concepts. They are 
broadly split into families based on the relative position of conserved cysteine 
residues:
• G-C family: CCL1 to CCL28 binding to CCR1 to CGR10
• G-X-G family: GXGL1 to GXGL16 binding to GXGR1 to GXGR6
• XGL1 and XGL2 binding to XGR1
•  GX3GLI binding to GX3GRI
In addition there are decoy receptors, such as D6, which bind to ligands and are 
internalised without signalling, thus removing them from the tissue. Kinetic 
changes in expression allow for movement of cells into specific sites at specific 
times. Different cell types tend to have specific patterns of chemokine receptors.
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and respond to the corresponding ligands. However, ascertaining which the most 
important interactions are is difficult, as chemokines are promiscuous and can bind 
to multiple receptors, and chemokine receptors can bind multiple chemokines. 
Also, expression in vitro  and in  vivo  may be different. There is a huge amount of 
data from experimental models, much of it examining very specific interactions in 
specific models, and is therefore often conflicting. Some of the key interactions in 
asthma are summarised in table 1.2
CELL RECEPTOR LIGANDS
Th2
Eosinophil 
Mast cell
CCR3
CCL11 (eotaxin) 
CCL24 (eotaxin-2) 
CCL26 (eotaxin-3)
Th2 CCR4 CCL17 (TARCy CCL22 (MDCr
Th2 CCR8 CCL1 (TCA-3)^
Th1 CCR5 CCL5 (RANTES)" 
CCL3 (M IP -la f
Th1 CXCR3 CXCL9 (MIG)*" 
CXCL10 (IP-10/
Table 1.2 Chemokines in asthma
thymus and activation regulated chemokine; 2 macrophage-derived chemokine;  ^T cell activation 
protein 3;  ^regulated on activation normal T-cell expressed and secreted chemokine; ® macrophage 
inhibitory protein 1a; « monokine induced by IFNy; 10 IFNy inducible protein 10.
Allergic asthma is associated with increased expression of CCR3 on eosinophils 
and CCR4 and CCR8 on T cells (183,184), and they may be expressed during 
different phases of inflammation (185). A role for these receptors is at least partly 
supported by experimental data. The eotaxins are all upregulated during allergen 
challenge (186), and whilst CCR3'^' mice have reduced eosinophils, the effect on 
AHR is variable depending on the involvement of mast cells (187,188). Whilst 
CCR4'^' had no effect on allergic airway inflammation or AHR (189), neutralisation 
of TARC or MDC did (190,191), suggesting that there may be an additional 
receptor for these chemokines. CCR8 and TCA-3 do not appear to play an 
important role in experimental asthma (192). RANTES is increased in the serum of 
patients with asthma, and correlates with severity, whereas IP-10 is reduced (193).
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1.5. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a relatively common inflammatory condition affecting 
up to 1% of the population in the UK (194). It is a systemic autoimmune disease, 
although the clinical features are usually limited to the joints. Chronic inflammation 
of the synovium leads to erosion of cartilage and bone and destruction of the joint. 
This results in pain, swelling, stiffness and joint deformity, with eventual loss of 
joint function. Chronic inflammation may also affect other organs, such as the lung 
and kidneys, and result in systemic features, such as cachexia and depressed 
mood.
Pharmacological treatment has focused on the control of pain and inflammation, 
with the use of non-steroidal anti-inflammatory drugs (NSAIDs), and early use of 
disease modifying anti-rheumatoid drugs (DMARDs) (195). However, these drugs 
have significant toxicity and side effects, and although they may slow down the 
process of joint destruction, they are not completely effective. Thus there is 
significant morbidity and excess mortality in patients with RA, and much focus on 
the inflammatory pathways present to identify new therapeutic targets. Hence 
agents targeting TNFa and IL-1 are being used a number of inflammatory 
diseases, including RA (196).
1.5.1. Autoimmunity in RA
The pathophysiology of RA is complex and heterogeneous (see figure 1.3). There 
is undoubtedly a genetic predisposition, as shown by the association of various 
HLA-DR alleles with RA (197). Other contributor polymorphisms in the gene loci of 
many of the cytokines involved in RA have also been found, and also in the gene 
for peptidyl arginine deiminase IV (PAD I4) (198), which may play a crucial role in 
the development of autoimmunity. Environmental factors have also been shown to 
be important, particularly smoking. Thus in susceptible individuals with the right 
environmental triggers, a pre-clinical phase of autoimmunity can arise. The precise 
mechanisms by which T and B cell tolerance are overcome is not clear. The best 
characterised autoantibodies are against cyclic citrullinated peptides (anti-CCP) 
and other citrullinated proteins, which are more sensitive and diagnostic of RA 
than rheumatoid factors (RFs). Citrullination of self-proteins is carried out by 
PAD 14, rendering them antigenic, and is promoted by smoking in susceptible 
individuals (199). RFs are anti-IgG antibodies that recognise the Fc portion of IgG
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autoantibodies to form immune complexes in the serum, which initiate and 
perpetuate inflammation through the activation of complement and binding to 
FcyRs on inflammatory cells. The mechanism by which this becomes localised to 
the joint is not known, but immune complexes are found prominently in synovial 
fluid, where they contribute to the pro-inflammatory milieu. It is also likely that the 
destruction of cartilage and bone results in the exposure of neoantigens which can 
also trigger autoimmunity.
1.5.2. Chronic synovitis in RA
The synovium is usually scarcely populated with cells, but in chronic synovitis in 
RA there is a marked increase in cellular infiltration and proliferation. There is a 
superficial lining layer comprised of macrophages and synovial fibroblasts, 
overlying an interstitial zone which consists of more of these cells, and also a 
cellular Infiltrate of T cells, B cells, neutrophils, mast cells, NK cells and NKT cells. 
Cytokines, chemokines, immune complexes and complement fragments play a 
key role in activating and regulating this process. Many of these cells and 
mediators are also present in the synovial fluid. The joint is a relatively hypoxic 
environment, and so angiogenesis Is also crucial, mediated by vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF).
Genetics Autoimmunity
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Figure 1.3 The pathogenesis o f rheumatoid arthritis
A preclinical Th1 mediated autoimmune phase arises due to a combination of genetic predisposition 
and environmental factors, resulting in autoantibody production. Rheumatoid factors (RF) and anti- 
cyclic citrullinated protein (aCCP) antibodies are the best characterised of these. These 
autoantibodies form immune complexes which localise to the joint by an unknown mechanism. This
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initiates a chronic inflammatory response in the synovium, which is augmented by the resulting 
tissue hypoxia and angiogenesis. Immune complexes are thought to initiate inflammation through 
activation of macrophages and synovial fibroblasts. Toll-like receptor (TLR) activation by 
endogenous tissue factors or pathogen-associated molecular patterns (PAMPs) may also play a role. 
Macrophages and synovial fibroblasts produce many proinflammatory cytokines. Interleukin (IL)-1 
and tumour necrosis factor (TNF) a act as a positive feedback mechanism, promoting further cell 
activation and cytokine release. B and T cells from lymphoid tissues are also recruited into the 
synovium. Transforming growth factor (TGF) p and IL-6 promote Th17 cell differentiation and IL-17 
release. IL-17 further activates macrophages and synovial fibroblasts, and stimulates dendritic cells 
in the joint to produce IL-23, which maintains the Thi7 cell phenotype, and also IL-12 and IL-18 
which promote Thi responses. Although Thi cells play a role in autoantibody production, their role in 
synovial inflammation is currently not clear. TNFa, IL-1 and IL-17 promote osteoclast maturation in 
the presence of macrophage colony stimulating factor (M-CSF) and receptor activator for NFkB 
ligand (RANKL), which leads to bone resorption. In the presence of immune complexes they also 
stimulate synovial fibroblasts to produce matrix metalloproteinases (MMPs) and other enzymes, and 
neutrophils and mast cells to produce proinflammatory mediators, all of which contribute to cartilage 
destruction. Destruction of bone and cartilage reveals previously hidden self antigens (neoantigens) 
which can provoke further autoantibody production and help to perpetuate the inflammation, 
inflammatory mediators released into the blood also cause systemic symptoms such as fatigue, 
pyrexia, anorexia and weight loss. Regulatory T cells (Tregs) have been shown to suppress joint 
inflammation through IL-10 and TGFp production.
1.5.2.1. T cells In RA
There is a large body of evidence implicating T cells as one of the key regulators 
of RA. In humans they are present in large numbers In the synovium, and MHCII 
alleles are strongly associated with the development of RA. This is backed up by 
the requirement for T cells in many animal models of RA. It was previously thought 
that RA pathology was mediated by Th i cells producing IFNy, TNFa and IL-17. 
However, more recently it has been recognised T h i 7 cells are probably the more 
important effector cell in the joint, it is not clear where T cells become 
differentiated. It may begin in the lymphoid tissues, but the presence of DCs and 
the rich cytokine milieu in the joint would support the expansion of both Th1 and 
T h i7 cells. However, Th i and T h i7 cells can mutually inhibit each other, which 
may further complicate the picture.
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In human RA, Th1 cells expressing IFNy are more prominent in the synovium in 
early disease, then reduce in frequency in established disease (200). IFNy levels 
are also low in the synovium and serum (201). In murine CIA, blockade of IFNy in 
early disease reduced anti-CII antibody levels and disease severity, but 
aggravated established disease (202). Flowever, blocking IFNy and deficiency of 
the IFNyR has also been show to result in earlier disease onset (203), mice 
deficient in IL-12p35 have exacerbated disease (52), and IFNy inhibits 
osteoclastogenesis and bone resorption (204). Thus the role of T h i cells and IFNy 
is not yet clear, but may be more important in establishing autoimmunity than in 
joint pathology.
There is no direct evidence of T h i7 cells in RA synovium, but IL-17 is present in 
the synovial fluid of RA patients and is produced by cells in the T cell area (205). 
In addition, mice deficient in IL-6 (206) and IL-23 (52) are resistant to CIA, and 
both of these are required for T h i7 differentiation. IL-17 is a potent pro- 
inflammatory cytokine with effects on many cell types in the synovium. In 
conjunction with IL-1 and TNFa it can attract and activate synovial DCs through 
increased MIP3a expression in the synovium (207). It drives neutrophil 
accumulation and activation (208), and activates synovial macrophages and 
fibroblasts to produce pro-inflammatory cytokines and chemokines, and tissue 
destructive enzymes such as matrix metalloproteinases (MMPs), as well as pro- 
angiogenic factors. IL-17 is not dependent on TNFa or IL-1 for its arthritogenic 
properties (208,209). In murine models of arthritis, neutralisation of IL-17 (210) 
and IL-17R deficiency (211) both reduce experimental arthritis, whilst 
overexpression of IL-17 exacerbates it (212). Additional cytokines such as IL-22 
and osteopontin from T h i7 cells may also have roles in promoting pro- 
inflammatory cytokine production in the joint. In addition to cytokine production, 
cell-cell contact between T h i7 cells and synovial macrophages and fibroblasts is 
important in promoting their activation, either through receptor-ligand interactions, 
or presentation of membrane-bound cytokines. T h i7 cells are therefore important 
in the induction and persistence of inflammation. They are also involved in bone 
destruction (213).
Naturally occurring Tregs (CD4^CD25^FoxP3^CD62L^) have also been detected in 
patients with RA, although they have reduced suppressive activity (214).
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Treatment with anti-TNFa antibodies overcome this by inducing a distinct subset of 
CD62L Tregs that act through IL-10 and TGF(3 production (215).
NKT cells are also present in RA, and much of the experimental data is conflicting 
(reviewed in (216)). However, on balance it would appear they are protective 
against autoimmunity, and so have a suppressive role in early disease. However, 
activation may exacerbate established disease, probably through the production of 
pro-inflammatory cytokines.
15 . 2. 2.  B cells in RA
An important role for B cells in RA was indicated by the clinical benefit of a B cell 
depleting monoclonal antibody (217). They produce autoantibodies In the joint that 
contribute to immune complex formation, which in turn bind to inflammatory cells 
through FcyR and activate them. They also trigger the formation of germinal 
centres, which results in increased affinity of auto-reactive antibodies, and are 
associated with a poorer outcome. B cell contact with synovial fibroblasts can 
promote pro-inflammatory cytokine and chemokine release, and MMP production 
(218).
1.5.2.3. Synovial macrophages and fibroblasts
As discussed above, synovial macrophages and fibroblasts may be activated by 
cell contact with T h i7 cells, IL-17, and immune complexes. They may also be 
activated by innate signalling through TLRs (219). Thus exogenous bacterial and 
viral PAMPs, and endogenous ligands such as heat shock proteins, could play a 
role initiating and perpetuating inflammation. Once activated they are the key 
source of many of the proinflammatory cytokines and chemokines. They are also 
activated by these cytokines, especially IL-1 and TNFa, and so a positive feedback 
loop is established.
TNFa is one of the key pro-inflammatory cytokines in RA. It is present in most 
synovial biopsies, and up to 70% of patients respond to anti-TNFa therapy. In 
addition to its autocrine activation of macrophages and fibroblasts, it also activates 
neutrophils, endothelial cells and adipocytes to release pro-inflammatory 
mediators, and plays a role in joint destruction. IL-1 has a similar range of actions 
and is a very potent pro-inflammatory cytokine. This is counterbalanced by the 
expression of IL-1RA, and the balance between them may affect the clinical
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outcome (220). 1L-1RA is now also being used clinically in RA, although with less 
success. It is more successful as a treatment for autoimmune diseases caused by 
N A LP 3  mutations and excess IL-1 (3 production (221).
There are many more cytokines and chemokines that also contribute to the rich 
pro-inflammatory milieu established in the joint (222), but for clarity I will only 
mention a few here. IL-6, IL-23 and TGF(3 contribute to T h i7 cell differentiation 
and proliferation in the joint. TGF(3 may also contribute to Treg development and 
repair mechanisms. IL-15 is important for T cell proliferation and survival, but also 
activates neutrophils and promotes B cell differentiation and isotype switching. IL- 
18 is present in the inflamed synovium (223), and IL-18' '^ mice have reduced 
incidence and severity of CIA (224).
1.5.2.4. Other innate cells in RA
Neutrophils are rapidly recruited into the arthritic joint, and are present in high 
numbers in both the synovium and synovial fluid. They are activated by TNFa, 
immune complexes, and complement fragments to produce cytokines (including 
TNFa, IL-1, IL-6 and IL15), chemokines, prostaglandins, and reactive oxygen and 
nitrogen species which contribute to inflammation In the synovium. Mast cells are 
present in the synovium, and are activated in similar ways to neutrophils. They 
also produce pro-inflammatory cytokines, and in addition protease enzymes, which 
break down matrix, but also activate macrophages. Mast cells produce IL-1 when 
stimulated through FCyRIII, and this may play a role in the initiation of synovial 
inflammation (225). Mast cell deficient mice are resistant to autoantibody induced 
arthritis (226). NK cells are also present in human RA, and release pro- 
inflammatory cytokines (227), but their role is not fully understood.
1.5.3. Cartilage and bone erosion in RA
Inflammation of the synovium triggers a cascade of events leading to cartilage and 
bone erosion. The current aim of treatment is to intervene in the inflammatory 
process as early as possible to avoid the inevitable joint destruction and 
irreversible deformity.
Activated synovial fibroblasts, neutrophils and mast cells produce matrix degrading 
enzymes, such as MMPs, which begin to break down cartilage and allows local 
influx of cells. Chondrocytes switch to a catabolic state and also produce matrix
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degrading enzymes and pro-inflammatory cytokines, thus speeding up the 
process. IL-1 seems to be the critical cytokine for cartilage damage. Direct 
injection of IL-1 into joints leads to cartilage erosion (228), and cartilage erosion is 
prominent in IL-1RA deficient mice with spontaneous arthritis (228,229). IL-17 
also promotes cartilage loss by TNFa and IL-1 dependent and independent 
pathways (230).
Under physiological conditions there is a balance between bone formation by 
osteoblasts, and bone resorption by osteoclasts. This balance is heavily tipped in 
favour of bone resorption in RA, through inhibition of osteoblast function and 
activation of osteoclast function. Osteoclast deficient mice develop inflammatory 
arthritis, but not bone erosion (231). Osteoclasts at the bone surface adjacent to 
the inflamed synovium are activated to resorb bone (232), which allows invasion of 
the bone by vascularised inflammatory pannus tissue. M-CSF is essential for early 
differentiation of osteoclast precursors into active osteoclasts, and is induced by 
TNFa from synovia! fluid cells and T cells. RANKL is produced by synovial 
fibroblasts and T cells in response to a number of cytokines and pro-inflammatory 
mediators, especially IL-1, TNFa and IL-17. RANKL binds to RANK on the 
osteoclast to induce final differentiation and bone-resorbing activity. RANKL is 
antagonised by osteoprotegerin (OPG), a soluble decoy receptor, which 
completely prevents bone lesions in experimental arthritis (233). There is an 
imbalance between RANKL and OPG in arthritis.
1.6. The role of IL-33 and ST2 in inflammation
The ST2  gene has long been known to encode an orphan receptor of the IL-1R 
family, with functions in innate and adaptive immunity, particularly Th2 responses. 
Recently IL-33 was described as the ligand for this receptor, and as expected was 
found to be a member of the IL-1 family of cytokines, and to have pro-Th2 
functions. I will now discuss some of the features of the IL-1 families of cytokines 
and receptors, and the current evidence for the role of the IL-33/ST2 interaction in 
inflammation.
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1.6.1. The IIL-1 family of cytokines
The IL-1 cytokine family currently consists of 11 members (summarised in table 
1.3; (1,234,235)), found close together on chromosome 2 in humans, except for IL- 
18 on chromosome 11. They share similar nucleotide sequences and protein 
structure, and exert their biological effects by binding to the IL-1R family of 
receptors.
LIGAND INTERACTIONS FUNCTION
(L-1a(IL-1F1) IL-1R1 + IL-1RAcP Cytokine
IL-1RII Decoy receptor
None (intracellular) Transcription factor
IL-1 P (IL-1 F2) IL-1R1 + IL-IRAcP Cytokine
IL-1RI! Decoy receptor
IL-1ra' (IL-1F3) IL-1R1 Cytokine antagonist
IL-18(IL-1F4) IL-18R + IL-1 SAP Cytokine
IL-ISbp"' Cytokine antagonist
IL-1F5 Unknown Unknown
IL-1F6 IL-1Rrp2 + IL-IRAcP Unknown
IL-1F7 IL-18R Unknown
IL-1F8 IL-1Rrp2 + IL-IRAcP Unknown
IL-1F9 IL-1Rrp2 + IL-1RAcP Unknown
IL-1F10 Soluble IL-1R Unknown
IL-33 (IL-1F11) ST2L Cytokine
sST2?" Decoy receptor?
None (intracellular) Nuclear factor
Table 1.3 Members of the IL-1 family o f cytokines
i|L-1 receptor antagonist binds to IL-1R1 with higher affinity than IL-1 a or 11-1(3 but without recruiting 
IL-1RAcp thus does not activate signalling; 2|L-18 binding protein binds to IL-18 to block binding to 
IL-18R; ^putative interaction yet to be directly shown.
1.6.2. The IL-1R family of receptors
The IL-1 family of cytokines bind to members of the IL-1R family of receptors, 
which are part of the TLR/IL-1R superfamily (summarised in table 1.4; (6,236)). 
These are a rapidly expanding group of receptors with wide-ranging effects on 
innate and adaptive immune function. They all share an intracellular signalling 
region (the so-called Toll-IL-IR  (TIR) domain) and similar signalling pathways. 
They are divided into three groups according to the extracellular ligand binding 
portion, or lack of it (see Figure 1.4). The IL-1R family have 3 immunoglobulin 
domains and bind cytokines of the IL-1 family, the TLR group have leucine-rich 
repeats and bind PAMPs and the adaptor group are intracellular and modify the 
signal transduction of these receptors.
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FAMILY RECEPTOR INTERACTIONS FUNCTIONS
Type 1 IL-IR f IL-1q, 11-1 (3, IL-1 ra Cytokine receptor
(IL-1R) IL-1RI1" IL-1a, 11-13 Decoy receptor
IL-18R" IL-18 Cytokine receptor
IL-1RAcp4 IL-1RI Accessory protein
IL.18AP& IL-18R Accessory protein
ST2L'’ IL-33 Cytokine receptor
MyD88 IL-1R/TLR regulation
IL-1Rrp2^ IL-1F6.7, and9 Unknown
SIGIRR® Unknown IL-1R/TLR regulation
TIGIRR" Unknown Unknown
IL-1RAPL* Unknown Unknown
B15R1" IL-13 Antagonist
Type 2 TLR 1-11 PAMPs Danger signals
(TLR) Toll, 18 wheeler Spatzl, Unknown Drosophila proteins
Type 3 MyD88 TLRs and IL-IRs Adaptor
(Adaptors) Mai / Tirap TLRs and IL-IRs Adaptor
TRAM TLRs and IL-IRs Adaptor
TRIP TLRs and IL-IRs Adaptor
Table 1.4 TLR/IL-1R superfamily of receptors
■•Type 1 IL-1 receptor; ^Type 2 IL-1 receptor not signal as it only has a short cytoplasmic tail; 3|L-18 
receptor; 4L-1 receptor accessory protein required for high affinity binding and signalling; ML-18 
receptor accessory protein required for high affinity binding and signalling; ^Membrane bound form of 
ST2, the putative second member of the receptor complex is unknown; I^L-1 receptor related protein 
2 has no known function; ^Single immunoglobulin IL-1R related protein (237) is a negative regulator 
of IL-1R and TLRs (238,239) expressed in the epithelium of the kidney, lung and gut (240); ^Three 
immunoglobulin IL-1R related protein; IL-1 receptor accessory protein like protein (241); ^®B15R is a 
soluble mediator from the Vaccinia virus with homology to IL-1 R which binds and neutralises IL-ip, 
thus subverting the immune response against it (242).
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^  Ig domain 
I  Leucine rich repeat 
^  Toll/IL-IR domain
I
TIR type 1 
IL1-R Family
TIR type 2 
TLR Family
TIR type 3 
adaptors
Figure 1.4 The TLR/IL-1R famiiy of receptors
1.6.3. IIL-1 family cytokines are pro-inflammatory
There is a huge body of work concerning the roles of IL-1 a, IL-1 (3, and IL-18, and 
their receptors, in inflammation and other processes (reviewed in (243-246)). I will 
give just a brief overview of their key functions.
IL-13 is the main secreted form of IL-1, and despite being only 24% identical, IL-a 
and IL-13 bind to the same receptor, IL-1R1, and have identical biological effects 
(thus referred to collectively as IL-1). IL-1 and IL-18 are expressed to some degree 
by a large variety of cell types depending on the stimuli given. However, in both 
humans and mice monocytes/macrophages are a key source of both secreted IL- 
13 and IL-18. Murine macrophages express IL-1 a as they become activated, and 
secrete it at much higher levels than is found in humans. IL-18 is also produced by 
dendritic cells (247). Epithelial cells of the lung, gut and skin (kératinocytes) 
produce IL-18 and IL-1. Kératinocytes in particular produce a large amount of IL- 
1a in both humans and mice. IL-1 and IL-18 are also found in the central nervous 
and endocrine systems, and so play an important role in linking these with the 
immune system.
IL-1 can affect almost every cell in the body as IL-1R is ubiquitously expressed. 
Whilst its major role is in immunity and inflammation, it also has roles in regulation
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of cell proliferation and differentiation (embryogenesis, tumourigenesis and 
invasion (248)), regulating the hypothalamus-pituitary-adrenal axis (appetite (244), 
sleep (249), temperature (250)), energy metabolism (glycaemic control, lipid and 
protein catabolism), bone resorption (251) and atherosclerosis (252). IL-18 is also 
an important pro-inflammatory mediator, although IL-18R expression is more 
restricted, being predominantly on T h i cells and NK cells, and therefore so are its 
effects. Additionally, it functionally antagonises IL-1 in bone metabolism by 
inhibiting osteoclast function (253), and has anti-tumour activities.
IL-1 is the prototypic proinflammatory cytokine due to its ability to regulate the 
expression of a wide range of mediators. This includes cytokines, chemokines, 
acute phase proteins, adhesion molecules, growth factors, clotting factors and 
enzymes. In fact, many of the actions of IL-1 are through increased inducible nitric 
oxide synthase (iNOS) and NO production, and increased cyclo-oxygenase 2 
(COX-2) and prostaglandin E2 (PGE2) production. Thus IL-1 directly and indirectly 
enhances innate protective mechanisms, T cell function through IL-2 and IL-2R, 
antibody production, haematopoiesis and inflammatory cell infiltration and 
activation.
IL-18 is also a very important pro-inflammatory cytokine, but does not have the 
wide-ranging effects IL-1 has. Many of the biological roles of IL-18 studied thus far 
are dependent on its induction of IFNy from NK cells, T cells and macrophages, 
and their activation to increase NO production, cytotoxic cell functions and 
intracellular microbe clearance. In this respect it shares many functions with IL-12, 
and the two are synergistic because they induce the expression of each others’ 
receptors. IL-12 is essential for Th i polarisation and memory cell production, and 
IL-18 from dendritic cells augments this (247). However, IL-12 and IL-18 together 
can induce more IFNy production from naïve T cells in the absence of antigen than 
its presence (29). These cells do not become memory cells but may have a role in 
innate immunity. A similar phenomenon is seen in the absence of IL-12 but the 
presence of IL-2. In this scenario IL-18 augments IL-4 and IL-13 production in the 
presence of antigen, and therefore Th2 polarisation and atopic inflammation, and 
IL-13 in the absence of antigen, with a potential role in innate inflammation (246).
The functions of IL-33 are in keeping with being a member of the IL-1 family, but 
will be discussed in detail later (section 1.6.8.).
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1.6.4. Regulation of IIL-1 I IL1R family interactions
IL-1 and IL-18 have potent biological effects, and are therefore tightly regulated. 
Regulation occurs at the level of gene expression, and protein translation, 
processing and release from the cell. In addition there are a number of soluble and 
cell-membrane associated factors which can antagonise IL-1 and IL-18 function 
(see figure 1.5). IL-1 in particular is barely detectable in  vivo, but evidence for its 
potency comes from the biological effects detected after injection of only ng/ml 
amounts, despite the constitutive presence of a huge excess of antagonistic sIL- 
Rll in the serum. In addition, administration of IL-Ira is being used clinically to 
rapidly and effectively neutralise IL-1 and induce remission of a number of 
inflammatory diseases (221).
1.6.5. IL-33 is a member of the IIL-1 family of cytokines
The IL-33  gene was identified in 2005 in both humans and mice (1), and had 
previously been identified in humans and mice as NF-HEV, a nuclear factor 
(254,255), and in dogs as DSV27, a gene upregulated in cerebral artery 
vasospasm (256). Unlike most of the other members of the IL-1 family it is found 
on chromosome 9 in humans, and chromosome 19 in mice. The structure of the 
gene in humans and mice is very similar (254).
The nucleotide sequences of murine and human IL-33 share approximately 50% 
homology (254) (see figure 1.4), and of the other family members it is most similar 
to IL-18 (1). Human and murine IL-33 have a predicted 12 3 strand trefoil 
structure, and so are very similar in size and shape to IL-1 a, IL-13, and IL-18. IL- 
13 and IL-18 have no signal peptide and require cleavage by caspase-1 in the IL- 
13 inflammasome before secretion of the active C terminus cytokine moiety (257). 
Similarly, IL-33 has no signal peptide and, at least in vitro, it is cleaved by 
caspase-1 at aa112. This yields a C terminus fragment which when used as a 
recombinant protein was found to be active as a cytokine (1). The in vivo  role of 
caspase-1 cleavage and the mechanism of IL-33 secretion are unknown.
S IL-1R II S IL-1R I
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Figure 1.5 IL-1, IL-18 and IL-33 agonists and antagonists
The IL-1 family of cytokines and their receptors interact in similar ways to allow tight regulation of 
their function. IL-1 binds to IL-1RI and recruits IL-IRAcP resulting in active signalling. This is a very 
potent interaction requiring the presence of only a few receptors, and so is regulated in a number of 
ways: i) binding to the decoy receptor IL-1RII does not result in signalling; ii) IL-Ra is homologous to 
IL-1 (3 and binds IL-1R1 with higher affinity than IL-1p or 11-1 a but does not recruit IL-1RAcp and so 
does not initiate signalling; iii) soluble forms of IL-1RI and IL-1RII bind IL-1 to prevent its interaction 
with the functional IL-1RI receptor on the cell membrane. IL-18 binds to the IL-18R and recruits IL- 
18AP for signalling. IL-18BP binds to IL-18 and prevents its interaction with the receptor. IL-33 binds 
to ST2L and results in signalling. The presence of an accessory protein is predicted, but has not yet 
been found. sST2 and ST2V are splice variants of ST2L that are secreted or membrane associated 
respectively. Possible regulatory interactions are indicated by question marks (?).
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N Terminus H e l ix  1____  H e l ix  2 Tu rn  H e l ix  3
hIL-33 MKPKMKYSTNKISTAKWKNTASKALC— FKLGKSQQKAKEVCPMYFMKLRSGLMIKKEAC 58
mIL-33 MRPRMKYSNSKISPAKFSSTAGERSVPPCKIRRSQQKTKEFCHVYCMRLRSGLTIRKETS 60
• k ' k ^ ' k - k i x ' k ^ ' k i c ' k i ^ i < : ' k i r - k - k ' k ' k : k ' k ' k - k i ^ ' k - k ' k ' k - k ' k ' k ' k ' : k ' k - k - k ' k - k - k ' k ' k - k ' k - k - k - k - k ' k ' k - k - ^ ' k ' k ' k - k - k ' k ' k ' k - k
hIL-33 YFRRETTKRPSLKTGRKHKRHLVLAACQQQSTVECFAFGISGVQKYTRALHDSSITGISP 118
mIL-33 YFRKEPTKRYSLKSGTKH— EENFSAYPRDSRKRSLLGSIQAFAASVDTL SIQGTSL 115
hIL-33 ITEYLASLSTYNDQSITFALEDESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVD 178
mIL-33 LTQSPASLSTYNDQSVSFVLENGCYVINVDDSGKDQEQDQVLLRYYESPCPASQSGDGVD 17 5
hIL-33 GKMLMVTLSPT— KDFWLHANNKEHSVELHKCEKPLPDQAFFVLHNMHSNCVSFECKTDP 22 6
mIL-33 GKKLMVNMSPIKDTDIWLHANDKDYSVELQRGDVSPPEQAFFVLHKKSSDFVSFECKNLP 235
C Terminus
hIL-33 GVFIGVKDNHLALIKV-DSSENLCTENILFKLSET 270
mIL-33 GTYIGVKDNQLALVEEKDESCN NIMFKLSKI 2 66
Figure 1.6 Amino acid sequences o f human and mouse IL-33
The sequences of human and murine IL-33 (1), GenBank accession numbers AY905581 and 
AY905582 respectively, aligned to show homology (55%). The full-length human protein is predicted 
to be SOkDa, and the murine 29.9kDa. Caspase-1 cleavage takes place at aa112, yielding 2 
fragments. The N terminus fragment contains a homeodomain-like helix-turn-helix (HTH) motif (***) 
required for localisation to the nucleus and its role as a nuclear factor. The 0 terminus is an 18kDa 
IL-1-like cytokine domain (^^ )^ that is also the sequence used for the recombinant protein.
IL-1 a is quite distinct from IL-13 and IL-18 in that it is largely an intracellular factor 
rather than a cytokine. It is rarely found extracellularly, although it can be 
presented at the cell surface or released from dying cells, where It has identical 
activity to IL-13- It is active without being cleaved and the N terminus region (aa1~ 
115) was found to target it to the nucleus where it may have transcription factor 
function (258,259). The N terminus of IL-33 (aa1-65) was found to contain a 
homeodomain-like helix-turn-helix (HTH) DNA-binding motif and was also found to 
localise IL-33 to the nucleus (254,255), where it may also play a role in 
transcriptional regulation. Thus IL-33 has structural and functional elements in 
common with both IL-13 (C terminus) and IL-1 a (N terminus).
Chapter 1: 56
The expression of IL-33 mRNA at the tissue level is shown in table 1.5 and at the 
cellular level in table 1.6 (summarised from (1,254,255), and is broadly similar to 
IL-1 a, IL-13 and IL-18 combined. The level of expression runs in descending order 
from top to bottom in each table. In contrast to ST2, the expression of IL-33 has 
not been examined in embryogenesis.
Thus IL-33 mRNA is expressed to some extent in virtually every murine tissue, 
although it is highest in the central nervous system (CNS) and at epithelial 
surfaces interacting with the environment (skin, lungs and gut). The major source 
would appear to be activated macrophages and resting dendritic cells, although 
both of these were derived by in vitro  methods. In humans the CNS was not 
examined, but expression was highest in skin and lung tissues. In contrast to mice 
it seemed to be expressed more in tissue cells such as fibroblasts and smooth 
muscle cells.
Expression is seen in murine lymphoid tissues, but not to any significant extent in 
lymphocytes. In keeping with this it is seen mostly in high endothelial venule 
endothelial cells (HEVECs) of human lymphoid tissue, as well as some scattered 
cells in the T and B cell areas, although the specific cell types were not identified. 
Chronically inflamed tissues take on some of the features of lymphoid tissue with 
HEVs surrounded by lymphoid aggregrates, and IL-33 was also found in HEVECs 
of Crohn’s intestine and rheumatoid arthritis synovium. Expression in HEVECs 
was much higher than in other types of endothelial cell, implying a specific role 
here. It should be pointed out that IL-33 protein expression has only been shown 
in the nucleus of HEVECs thus far, so its cellular source as a cytokine is unknown.
LOW MEDIUM HIGH
Mouse Colon Lymph node Spinal cord
Thymus Spleen Brain
Pancreas Lung
Peyer’s Patch Skin (ears)
Heart Stomach
Kidney
Human’ T and B cell areas:
Tonsils
Payer's Patch
Mesenteric lymph node
Table 1.5 Tissue expression of IL-33 mRNA
^Human lymphoid tissue IL-33 protein expressed in the nucleus
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RESTING ACTIVATED
Mouse BM’ derived macrophage - ++++
RT-PCR'" BM derived dendritic cell ++++ "
Epithelial cell + +
Th2 cell +
B cell +
Peritoneal macrophage -
Th1 cell -
Naïve T cell -
L fibroblast -
Human
RT-PCR Dermal fibroblast + +++++
Bronchial smooth muscle +++ +++++
Pulmonary artery smooth muscle +++++
Coronary artery smooth muscle ++++
Bronchial epithelial cell +++
Keratinocyte + ++
Mesanglal cell (kidney) ++
Small airway epithelial cell + +
Lung fibroblast - +
Monocyte derived dendritic cell ” +
Monocyte - +
Mammary epithelial cell +
Renal epithelial cell +
Splenocyte +
Prostate epithelial cell -
Th0/Th1/Th2 cells -
NK cell -
B cell -
Peripheral blood mononuclear cell -
ISH' Tonsillar HEVEC'"''’ +++
Payer's patch HEVEC +++
Mesenteric LN HEVEC +++
Nasal polyp EC" +
Human umbilical vein EC +
Placenta -
Crohn's intestine EC +++
RA synovium EC +++
HeLa epithelial cancer cell line -
Table 1.6 Cellular expression o f IL-33 mRNA
^BM = bone marrow; 2RT-PCR = real-time quantitative PCR; I^SH = in situ hybridisation; ^HEVEC = 
high endothelial venule endothelial cell; ^Tonsillar HEVEC IL-33 protein expressed in the nucleus; 
GEC = endothelial cell.
1.6.6. ST2 is a member of the IL-1 R receptor family
The ST2  gene was first identified in 1989 as a delayed early cell cycle gene in the 
BALB/c murine fibroblast cell line 3T3 stimulated by serum (260). It has also been 
identified as T1, induced by H a-ras  and v-m os  oncogenes, and serum, in 
quiescent murine NIH 3T3 cells (261,262), and glucocorticoid in proliferating cells 
(262). Homologous ST2  genes have been found in humans (263) (also identified
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as D ER 4  (264)), chicken (265) and salmon (266). The rat homolog is Fit-1, found 
as a Fos-responsive gene of rat fibroblasts (267). In humans it is on chromosome 
2 (268), and in mice on chromosome 1 (269), both closely linked to other members 
of the IL-1 R family.
The human gene structure (270) is shown in Figure 1.7, and the intron/extron 
structure is well preserved between species and other members of the IL-1R 
family (271). As with many members of the 1L-1R family there are a number of 
mRNAs generated from the same gene by differential splicing, resulting in several 
protein products (see Figure 1.5). The product of a short 2.7kb mRNA (272) is 
secreted from cells and is therefore termed soluble ST2 (sST2). It comprises 3 
immunoglobulin domains with a short tail which is homologous to the extracellular 
portions of IL-1R1 and IL-1R2. A longer 5kb mRNA gives rise to ST2L, the 
membrane anchored receptor (273). The 5’ end is identical to sST2, but at the 3’ 
end it has a transmembrane portion and a cytoplasmic tail containing the TIR 
domain, and has homology to IL-1R1 along its length.
Promoters
Haem Non-haem STOP
p - »  r - ^  sST2
■ ■■■ ■ àu
1a 1b 2 3 4 5 5E 6 7 9 10
STOP
sSTL
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mRNA
transcription
ST2L
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Protein
translation
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Figure 1.7 Structure o f the human ST2 gene
The human ST2 gene contains two promoters, specific to haematopoietic or non-haematopoietic 
cells. Exon usage for mRNA transcription is indicated. Exon 5E is only used in ST2V (not shown). 
sST2 is identical to the extracellular portion of ST2L, with the addition of 5 aa’s.
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There are 2 promoters which regulate production of the mRNA. In humans (274) 
and mice (275) the promoters are cell-specific, with the distal promoter dominant 
in haematopoietic cells, and the proximal promoter dominant in non- 
haematopoietic cells. Either promoter can result in production of sST2 or ST2L 
mRNA by differential 3’ processing. The distal promoter is constitutive and serum 
independent (276) and has GATA consensus sites in human and mouse. One of 
these binds GATA-3 with enhanced activity (277), and enforced GATA-3 
expression induced ST2L expression on 004"" cells (278). The proximal promoter 
is growth responsive and interacts with AP-1 and helix-loop-helix transcription 
factors (279). In rats (280) the situation is different, with the distal promoter 
specific to ST2L and the proximal specific to sST2, but both can be used in the 
same cell. The function of these 2 products will be discussed in more detail later.
More recently other variants have been found. ST2V is a truncated form of sST2 
found so far in humans (281) and chickens (265). It uses the stop codon 
containing exon 5E (see Figure 1.5) and therefore has a hydrophobic tail instead 
of the third immunoglobulin domain, which allows it to be anchored in the cell 
membrane. In humans it is expressed mostly in stomach, small intestine and colon 
tissue (282). ST2LV is a form of ST2L found in chickens (265) which has the 
transmembrane portion deleted, and is released as a soluble protein from 
transfected cells. The functions of these are unknown at the moment.
The expression profile of ST2 mRNAs has been more extensively studied than IL- 
33. Tissue distribution is shown in table 1.7, and a summary of the cellular 
distribution in table 1.8.
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HUM AN^ MOUSE""
sST2 ST2L sST2 ST2L
Adult Spleen y y y y
Bone marrow y y
Thymus y y
Lung y y y' f ..
Stomach y y n n
Small intestine y y n n
Colon y y n n
Liver y y n n
Kidney y y n n
Placenta y y n n
Testis y y n n
Brain* y/n n n n
Heart'" y/n y/n n n
Skeletal muscle'" n n n n
Pancreas'" n n n n
Skin (ears)'" y y
Embryo Liver y y
Spleen y y
BM y y
Eye (retina) y n
Bone (osteoblast) y n
Skin (dermis) y n
Table 1.7 Expression of ST2 mRNAs in mouse and human tissues
■'Human data from (270) unless otherwise stated. ^Mouse data from (283) unless otherwise stated. 
3ST2L constitutively expressed in the lung, sST2 only after LPS stimulation (284). ^Brain and heart 
expression found by Li (270), but not by Kumar (285). Expression of sST2 and ST2L in skin only 
after UV irradiation.
Soluble ST2 is widely expressed during embryogenesis, deposited in the 
extracellular matrix of non-haemopoietic tissues (283), and may be an early 
marker of osteogenesis (286). ST2L expression in the embryonic mouse is 
restricted to haemopoietic tissues (283). In the adult mouse both sST2 and ST2L 
are restricted to haematopoietic tissues (283) and to the lung (284). They are 
inducible in the skin by inflammation, but it is not known if this expression is from 
resident or infiltrating cells (285). In contrast, ST2 mRNAs are found almost 
ubiquitously in human tissues (270). It is likely this reflects the presence of 
inflammation within the human tissues at the time of collection.
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MOUSE HUMAN
RESTING ACTIVATED RESTING ACTIVATED
sST2
Cell lines Fibroblast N y yAlveolar macrophage Y increased
Th2 y increasedTh1 n
B cell n
Non-lymphoid’ Y y
T  Cells Fibroblast N y
Mammary epithelium Y
Bronchial epithelium y IncreasedPA endothelium y increasedPA smooth muscle y increased
Lung fibroblast y increasedAlveolar macrophage y increasedTh2 y y
ST2L
Cell lines Fibroblast Y y y increasedHUVEC y increasedAlveolar macrophage Y
Mast cell Y yTh2 Y yTh1 N n
B cell N n
Non-lymphoid’ Y y
1“ cells Fibroblast N y n nBronchial epithelium n yPA endothelium y decreasedPA smooth muscle n yAlveolar macrophage y increasedAstrocyte Y
Tissue mast cell Y
BM mast cell Y
Th2 Y increased / increasedTh1 N n
Natural Killer N
DC N
Monocyte y increased
Macrophage N
Kératinocytes yB cells N
Table 1.8 Expression o f ST2 mRNAs in various cell types
^Many immortalised cell lines have been found to express sST2 or ST2L, largely non-lymphoid lines. 
2Human Tc2, NK2 and NKT2 cells express ST2L also (287).
The predominant cells expressing ST2L constitutively in mice are mast cells, 
which express high levels of ST2L at all stages of development (288,289). It is 
also found on a murine alveolar macrophage cell line, and in human alveolar
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macrophages (284) and circulating monocytes (290). Importantly, ST2L is a 
specific marker for antigen-experienced T helper type 2 (Th2) cells (291,292) and 
not T h i, which express the IL-18R (293). ST2L also identifies human Th2 cells 
(293), but these cells may need to be activated first (294). It Is also on IL-10 
producing Tregs in mice (295), but not humans (294).
Soluble ST2 is generally only expressed in cells activated by growth or 
inflammatory mediators. It Is expressed in the developing mammary epithelium at 
puberty, but not at terminal differentiation during pregnancy and lactation (296). 
Fibroblasts (297,298), alveolar macrophages (284) and Th2 cells (294) have all 
been shown to release sST2 when stimulated by pro-inflammatory mediators. Low 
level sST2 expression is seen in a number of bronchial and pulmonary artery cell 
types, but this is markedly upregulated after activation (284).
Despite their similarity to the extracellular portion of IL-1R1 neither sST2 nor ST2L 
bind IL-1 a or IL-1p (283). Several putative ligands for ST2L were reported 
(299,300), but did not have any functional relevance in vivo. sST2-Fc bound to 
bone-marrow derived macrophages (293,301), dendritic cells (141) and a 
glioblastoma cell line (300). Human sST2 binds a to B cell myeloma line (302) and 
a monocyte line (303), but the mechanism is unknown. Partly because the ligand 
was unknown there has been some debate over the signalling pathways initiated 
by ST2L. Initial studies indicated that, in common with other IL-1R family 
members, ST2L could activate NF-kB (304), but later studies suggested it did not 
(305). The recent discovery of IL-33 as the natural ligand for ST2L (1) showed 
definitively that ST2L signalling pathways are similar to the other IL-1R and TLR 
family members (see Figure 1.6). However, in some situations ST2L may be a 
negative regulator of TLR signalling ((306); see section 1.6.7.1.)
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Figure 1.8 ST2L signalling pathways after IL-33 ligand binding
The signalling mechanism is very similar to IL-1R1 signalling (reviewed in (6,307)). IL-1 R and IL-18R  
bind IL-1 and IL-18 respectively, but require an accessory protein for signalling. This has not been 
identified yet for ST2L. There are a number of soluble antagonists for IL-1 and IL-18. sST2 may 
perform this role for IL-33, but this has not yet been shown directly. On ligand binding ST2L initially 
interacts with MyD88 through the TIR  domain. This is indispensable for signalling. IRAK, IRAK4 and 
TRAF6 then assemble and activate NF-kB through degradation of IkB. IL-1 R and IL-18R also do this, 
and in addition activate A P -1 . ST2L was previously shown to activate AP-1 when over-expressed or 
stimulated by an anti-ST2 antibody (305). The end result is up-regulation of pro-inflammatory genes 
in the nucleus.
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1.6.7. Innate Immune functions of IL-33 and ST2
Most members of the Toll/IL-IR  superfamily are involved in innate immunity 
through activation of NFkB. Expression of IL-33 and ST2 proteins can occur in 
many structural and immune cells involved in the innate response, as detailed 
above. In a model of innate immunity, treatment of mouse ears by UV irradiation 
causes a marked local inflammatory response in the skin. An increase in ST2 
mRNAs was seen 48hrs later, but it is not known if this is from resident or 
infiltrating cells (285). However, the functional contribution of IL-33/ST2 to innate 
immunity has focused mainly on the role of sST2 and ST2L on macrophage 
function, and the ability of IL-33 to induce a type 2 innate response.
1.6.7.1. ST2 modulates macrophage function
In addition to fibroblasts, alveolar macrophages produce sST2 when stimulated by 
LPS or pro-inflammatory cytokines (284). sST2 has been shown to bind to 
monocytes/macrophages by an unknown receptor, resulting in downregulation of 
LPS-induced pro-inflammatory cytokine release (284,301,303,308). LPS can even 
increase the binding of sST2 to macrophages (301). Treatment with sST2 in vivo  
can reduce LPS-induced acute lung injury (284) and endotoxic shock (301), and 
ischaemic reperfusion injury in the intestine (308) and liver (309). Anti-ST2 
antibodies caused an increase in endotoxic shock mortality (301). In the ALI model 
the peak level of sST2 in BALE occurred after peak inflammatory cytokine release, 
in keeping with the role of sST2 as a regulatory mechanism to limit innate 
inflammation. The exact mechanism of action of sST2 is not yet clear, but there 
does appear to be a direct effect through binding to a cell-surface receptor, as well 
as potentially sequestering the ligand for ST2L. Downstream events may include 
downregulation of TLR1 and TLR4 expression (301,309), reduced IkB degradation 
and NFkB nuclear translocation (303), and increased IL-10 expression (308).
Alveolar macrophages and monocytes expresses ST2L constitutively (284,290), 
and levels are upregulated by activation. In contrast BM-derived macrophages do 
not express ST2L at all (301). When co-transfected with IL-1R or TLR4, ST2L was 
able to down regulate signalling by sequestering MyD88 and Mai and preventing 
NF-kB activation (306). This is in stark contrast to ST2L activating NFkB when 
bound by IL-33, but may reflect the fact that this is an artificial system where ST2L 
may be acting without a natural ligand or accessory receptor, whereas IL-33 
signalling was investigated in mast cells naturally expressing high levels of ST2L
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(1). However, these results do indicate ST2L could also act as a negative regulator 
of innate immunity. In keeping with this, macrophages from ST2" '^ mice produced 
more pro-inflammatory cytokines in response to TLR2, 4 and 9 stimulation than 
wildtype (306). Endotoxic shock can be prevented by pre-treatment with a sub- 
lethal dose of LPS (endotoxin tolerance), thought to act in several ways to reduce 
the severity of inflammation and mortality. ST2" '^ resulted in increased LPS- 
induced pro-inflammatory cytokines in vivo and loss of endotoxin tolerance, 
although mortality from LPS shock was not affected (306). It is not clear if these 
results could be in part due to the loss of sST2 regulation also. Similar to 
endotoxin tolerance, pre-treatment with TLR2 agonists can protect against 
peritonitis-induced shock. ST2 mRNA was upregulated in the spleens on mice with 
tolerance to TLR2 ligands (310), though it is not clear if this is sST2 or ST2L 
mRNA, or both.
Overall there is no doubt that sST2 and ST2L may be powerful modulators of 
innate inflammation, but the respective roles of each, and in particular the possible 
antagonistic or direct actions of sST2 remain to be elucidated. ST2L may be 
involved in the transition from innate to adaptive immunity, as inhibiting TLRs 
tends to predispose to Th2 responses. The role of IL-33 in these models has not 
yet been examined.
1.6.7.2. IL-33 induces a systemic type 2 innate response
Structurally, IL-33 has much in common with the prototypic pro-inflammatory 
cytokines IL-1 a, IL-1 (3 and IL-18, although thus far there is very little functional 
information on IL-33. Schmitz et al (1) used recombinant IL-33 to induce a potent 
type 2 innate response in mice. This was characterised by an increase in type 2 
cytokines and total IgE and IgA in the serum, eosinophils in the blood, and an 
increase in eosinophils and mucous producing Goblet cells at mucosal surfaces in 
the lung and gut. Although they also demonstrated IL-33 activates NFkB through 
binding to ST2L on mast cells in  vitro, the cellular source of IL-33 and the 
responding cells in  vivo  are not known, and it has not yet been confirmed that IL- 
33 acts through ST2L in vivo.
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1.6.8, Th2 immune functions of IL-33 and ST2
The main focus of research on the ST2  gene has been its role as a marker for Th2 
cells, and its potential role in the initiation of Th2 responses, and in Th2 effector 
mechanisms. This evidence is summarised below.
1.6.8.1. ST2 is expressed in CD4* Th2 cells
A number of studies have demonstrated ST2  gene expression preferentially in 
CD4‘^  Th2 cells. For instance, Th2 cell lines, and not Th1, express ST2L (292,302), 
and while naïve 004"^ cells do not express ST2L (311,312), it has been 
established as a cell surface marker distinguishing Th2 cells from T h i or Th17 in 
mice (291,292,313) and humans (293). However, the situation is not as simple as 
this.
In vitro  studies have shown that ST2L is specifically a marker of well-differentiated 
antigen-experienced Th2 cells. The haemopoietic cell promoter for ST2 contains a 
number of GATA binding sites and ST2L expression is increased by GATA-3 
binding (277), and over-expression of GATA-3 results in naïve CD4^ cells taking 
on a CD44'^'CD45RB'°CD62L'° antigen-experienced phenotype (278). E x vivo  it is 
on cells with the CD4"'CD62L'° phenotype, and which co-express IL-4 and IL-5, 
and not IFNy (291,314). The percentage of cells expressing ST2L in  vitro  
increases with every round of antigen stimulation under Th2 polarising conditions 
whether polyclonal (311), or antigen-specific (315). Initially IL-4 and IL-10 are 
produced, then ST2L and IL-5 expression increase in parallel.
ST2L expression is influenced by other factors. Cytokines such as TNFa, IL-1, IL- 
4, IL-5 and IL-6 all increase expression of ST2L in  vitro, and IFNy decreases it 
(311,312). IL-13 has no effect (311). However, ST2L expression is not dependent 
on these, as it is expressed at normal levels in IL-4'^" (291,312,316), IL-10'^' (291) 
and IL-4/13'^' (48) mice. Although it is expressed in IL-5'^‘ mice, it is only at one 
third of the level seen in wildtype mice (291), suggesting a link between IL-5 and 
ST2L regulation (see section 1.6.8.4.).
Antigen dose also influences ST2L expression. In neutral in  vitro  culture conditions 
a lose dose of antigen resulted in increased ST2L expression and IL-4 production, 
whereas at high doses, ST2L expression was reduced and IFNy was produced 
(312). However, in  vivo  ST2L'" cells are found in the highest number at the site of
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inflammation, such as the footpad in L m a jo r (317), the lung in airways 
inflammation (141,318) and S m anson i (314) then with reducing frequency in 
draining, then distant, lymph nodes.
Thus although ST2L is a marker for Th2 cells, it is not a marker for all Th2 cells, 
and in humans is only expressed in activated Th2 cells, which can also produce 
sST2 (294).
1.6.8.2. ST2 is expressed in Th2 effector cells
As previously mentioned, mast cells are the major expressers of ST2L in mice, 
and an important Th2 effector cell, rapidly releasing pro-inflammatory mediators 
after degranulation by IgE binding. ST2L has also been found on human type 2 
CD8'" cytotoxic T cells, NK cells, and NKT cells (287,293). ST2  expression in other 
Th2 effector cells such as eosinophils or basophils has not yet been 
demonstrated.
1.6.8.3. ST2 modulates Th2 inflammation
Apart from its presence on Th2 cells and effector cells, there is further evidence 
that ST2  is expressed in and may play a role in Th2 responses. For instance, 
sST2 is elevated in the serum of mice with allergic airways disease very early in 
the response (3 hours), before even mRNA is detected (6 hours), and preceding 
the peak of Th2 cytokines (24 hours). There is also a second peak at 36 hours 
(319). ST2L expression on CD4^ cells increases in acute airways inflammation 
(318) and in a model of chronic asthma (320). ST2 mRNAs are increased in rats 8 
hrs after induction of contact hypersensitivity (321). The opposite is true for T h i 
responses, where ST2  expression is suppressed. Overexpression of IP-10, a T h i 
chemokine, induces a T h i response and reduces ST2L^ cell numbers in airway 
inflammation by 60% (322).
However, although the expression of ST2  has been shown in experimental Th2 
diseases, assessing its function requires manipulating its expression or function 
directly. There are a number of approaches that have been taken to assess the 
role of sST2 and ST2L in modulating Th2 immune responses:
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a) Polyclonal antibody serum inducing complement lysis
A polyclonal anti-ST2 antibody caused complement-induced lysis of ST2L'^ cells in 
vitro. When given to BALB/c mice susceptible to L m a jo r through a dominant Th2 
response this induced healing through a shift towards a Th1 response (292). It is 
likely this is through loss of Th2 cells, as mast cells do not play a prominent role in 
the response to L m ajor. It could also be due to lysis of cells binding sST2 at their 
surface (eg macrophages). Neither of these possibilities can be discounted, but 
these results do demonstrate that cells expressing ST2L (or binding sST2) have 
an important role in Th2 responses.
b) Non-lytic monoclonal antibodies
In vitro  crosslinking of ST2L on Th2 cells with a non-lytic anti-ST2 monoclonal 
antibody promotes proliferation and cytokine production (311) via the JNK pathway 
(305), suggesting that ligation of ST2L in vivo may be important in Th2 cell 
activation.
In vivo  monoclonal anti-ST2 has been shown to reduce allergic airways 
inflammation induced by adoptive transfer of either Th2 cells (291) or antigen- 
pulsed dendritic cells (141), and virally induced Th2 airway inflammation, but not 
Th i (323). In each of these models anti-ST2 was used to putatively block 
interaction of ST2L with its ligand, but cell activating properties cannot be 
excluded.
c) ST2-FC fusion protein
An sST2-Fc fusion protein has also been used to block ST2L function by 
sequestering the presumptive ligand. However, it must be remembered that sST2- 
Fc has been shown to bind to a number of cells, including macrophages, B cells 
and dendritic cells, and may have functions independent of ST2L. Nevertheless, 
administration of sST2-Fc has been used successfully to modulate Th2 responses. 
In vitro  there was a reduction in cytokine release from polarised antigen-specific 
Th2 cells, no effect on T h i cells, and ThO cells had reduced IL-4 and IL-5, and 
increased IFNy (315). In vivo  there was a reduction in Th2 airway inflammation 
(141,291,315) but not T h i (315). In addition, sST2-Fc was found to boost the Th2 
response and pathology seen in carbon tetrachloride (CCD-induced hepatic 
fibrosis, dependent on CD4"' cells and IL-4Ra (IL-4 and IL-13 signalling) (324).
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Thus sST2-Fc may have both pro- and anti-Th2 actions, the mechanisms of which 
may be different depending on the circumstances.
d) transgenic overexpression o f sST2
Over-expression of sST2 by gene transfer resulted in reduced allergic airways 
disease (319) and although it did not prevent a Th2 response it did reduce the 
number of IL-5 secreting cells in N  bras iliens is  infected lungs (325).
e) ST2 gene disruption
The ST2  gene has been knocked out in several different ways, all on the T h i 
dominant C57BI/6 background (325-327). In general, the phenotype seen is not a 
dramatic one. As with overexpression of sST2, ST2'^' did not reduce the Th2 
response, but did reduce the number of IL-5 secreting cells in N  brasiliens is  
infected lungs (325). There was reduced primary granuloma formation, but not 
secondary, in lungs challenged with S m anson i eggs (326).
1.6.8.4. ST2 and IL-5 regulation appear to be linked
A number of lines of evidence point to the fact that ST2  and IL -5  gene expression 
are linked, more so than with any other Th2 cytokine. Both ST2  and IL-5  genes 
contain GATA binding sites and are regulated by GATA-3, the archetypal Th2 
transcription factor (41,277). In fact, in vitro  all ST2L"^ cells produced IL-5, although 
not all IL-5 producers were ST2L^ (314). In IL-5“^ “ mice the amount of ST2L 
expression was much reduced (291) whilst in ST2'^' mice the number of IL-5 
producing cells was reduced (325). In vivo ST2‘ ‘^ mice and ST2-Fc transgenic mice 
both have lower levels of IL-5 in N  brasiliens is  infection although all other 
responses are normal (325). Both ST2L^ and ST2L Th2 cells were found in L 
m ajor, with ST2L^ cells producing most of the IL-5 (328), and correlating with non­
healing lesions (317).
1.6.8.5. ST2 may have a negative regulatory role in Th2 responses
Virtually all studies that have demonstrated a role for ST2 in Th2 inflammation 
have focused on a pro-inflammatory function. However, a very recent study has 
shown that ST2 may play a role as a negative regulator of Th2 function (329). This 
study showed that ST2‘ '^ mice developed worse allergic airways inflammation than 
ST2^^^ mice. It went on to demonstrate a key role for ST2 in regulating T cell 
function in this model. Th2 cells from ST2‘ ‘^ mice produced more cytokines in  vitro
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than ST2^^^, and transfer of ST2'^' Th2 cells resulted in worse allergic airways 
inflammation than transfer of ST2^^^ Th2 cells, even in lymphocyte deficient Rag'^' 
recipient mice. This is supported by the finding that T cells from the ST2'^ mice 
produced significantly higher levels of cytokines, particularly Th2 cytokines, than 
cells from ST2'' '^" mice when stimulated by antigen, or polyclonally with anti-CD3 
and anti“CD28 antibodies (data not shown). Thus S T2  may act as a “brake” on 
cytokine production, although the mechanism is unknown.
I.6.8.6. ST2 is not essential for Th2 responses
Just as it has been shown that Th2 responses can develop in the absence of IL-4 
(45-47), some studies have shown that blocking ST2  function or ST2'^‘ does not 
affect Th2 responses. Interfering with ST2L signalling during L m a jo r infection 
using a non-lytic anti-ST2 mAb or sST2-Fc did not affect Th2 differentiation, the 
frequency of ST2L"^ or ST2L- cells, or the non-healing nature of the lesion (330). in  
vitro  naïve T cell function, and Th1 and Th2 polarisation were unaffected by ST2" "^, 
as were mast cell development and function (326,327). There was no difference in 
eosinophilic ain/vay inflammation (327), outcome of N  bras iliens is  infection 
((325,327)), or secondary granuloma formation in response to S m anson i eggs 
(326). Mice expressing high levels of an sST2-Fc transgene also cleared N  
brasiliens is  normally (325).
Interestingly, even in these models where disease outcome was unaffected, there 
were detectable differences in Th1/Th2 cytokine production. It was noted that the 
percentage of IL-5 producing cells in the lungs of N  bras iliens is  infected mice was 
reduced in both ST2^ and sST2-Fc transgenic mice, with a corresponding 
reduction in BAL eosinophilia (325), and that draining lymph nodes from the lungs 
of mice with 2° S m anson i granulomas produced less IL-4 and IL-5 (326). in 
addition, CD4^ cells from L m a jo r infected mice with disrupted ST2 signalling were 
more responsive to IL-12 and produced more IFNy (330). Whilst these provide 
further evidence of the link between ST2 and Th2 function, it was not sufficient to 
materially alter the course of the infection. It is likely that given the importance of 
Th2 responses to parasite clearance there will be a number of back-up 
mechanisms by which they can arise, particularly under strong stimulation.
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1.6.8.7. IL-33 and Th2 responses
Whilst it stimulates the release of Th2 cytokines from in vitro  polarised Th2 cells 
(1), IL-33 has not yet been shown to play a role in established Th2 responses, but 
given its potent type 2 innate inflammatory properties it is likely it will play a role in 
differentiation to Th2 responses, and/or in the Th2 effector response.
1.6.9. Thi or Th17 autoimmune functions of IL-33 and ST2
Although there has been less work on the role of ST2  and IL-33 in Th1 responses, 
there is evidence of a potentially important regulatory role. IL-33 is expressed in 
the nucleus of HEVs from Crohn’s bowel and RA synovium, although its function 
there is unknown (255). Experimentally, ST2-Fc is highly effective in blocking the 
induction and disease progression of the Th1/Th17 mediated CIA model in DBA/1 
mice (331). ST2" "^ exacerbated a streptozocin-induced T h i model of autoimmune 
diabetes (332).
1.6.10. IL-33 and ST2 in human disease
Soluble ST2 expression can be detected by ELISA (333) in a number of different 
human diseases, and often correlates with seventy. However, a definite 
pathological role has yet to be identified.
1.6.10.1. Elevated sST2 in innate inflammation and trauma
Patients with sepsis have a markedly elevated serum sST2 compared to normal 
subjects (334). Trauma or abdominal surgery also elevated sST2 levels, but not by 
as much (334). Serum sST2 is elevated after cardiac surgery (335) and in cardiac 
muscle under strain (336), and is a predictor of mortality or the need for transplant 
in patients with heart failure (337). It is also elevated by myocardial ischaemia 
(336,338) and correlates with the rise in creatine kinase and the fall in left 
ventricular function (337), and can predict mortality after myocardial infarction 
(338). Subarachnoid haemorrhage (SAH) leads to an inflammatory reaction in the 
subarachnoid space, and can precipitate a systemic inflammatory syndrome. 
Cerebrospinal fluid has higher elevated levels of sST2 than the serum following 
SAH, implying it is being released locally (339). Thus sST2 is released after 
several very different triggers of innate inflammation.
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1.6.10.2. Elevated sST2 in Th2 inflammation
Serum sST2 is elevated in a number of human diseases with significant Th2 
pathology. It is elevated in stable atopic asthmatics, and a further rise during 
exacerbation correlated well with the severity (340). Serum and BAL sST2 were 
elevated in acute eosinophilic pneumonia, and returned to normal after successful 
treatment with corticosteroids (341). Serum sST2 was also elevated in patients 
with an exacerbation of interstitial pulmonary fibrosis (342). In addition, the ST2  
gene may have a role to play in the susceptibility to atopic inflammation. 
Functional SNP polymorphisms have been found in the promoter of the ST2  gene, 
and are associated with atopic dermatitis. High risk polymorphisms resulted in 
increased promoter activity and were associated with an increase in serum sST2 
and total IgE (343).
1.6.10.3. sST2 and Th i inflammation
Elevated sST2 was found in the serum of some patients with autoimmune 
diseases including systemic lupus erythematosis, RA, Wegener’s granulomatosis 
and Behcet’s disease (344). However, the numbers were rather small, and not all 
patients had sST2 present, so larger studies are needed to see if this correlates 
with disease severity.
1.6.10.4. sST2 and malignancy
CD4+ cells isolated from malignant effusions expressed more ST2  mRNA, and the 
effusion fluid contains more sST2, than patients with effusions secondary to TB or 
heart failure (345). ST2L expression could be used to distinguish mycosis 
fungoides lesions from skin lesions of adult T-ceil leukaemias (346), and also to 
distinguish anaplastic large cell lymphoma from other lymphomas (347). Soluble 
ST2 is also an indicator of low risk of recurrence in lymph node negative breast 
cancer (348). Thus ST2  expression can have significant implications for planning 
treatment and predicting survival. As well as being a marker for some kinds of 
tumour, ST2  could also play a functional role. Levels of ST2  expression were 
found to be low in a human glioblastoma cell line and tumour samples (349). 
Transfecting sST2 into the cell line reduced the ability of the cells to proliferate 
when not anchored, and suggests that sST2 can influence tumour growth and 
survival. ST2  expression occurs in osteogenic osteosarcoma, and inhibiting it in 
these cells abrogated the formation of osteoid by these tumours, indicating a role 
for ST2 in osteoblast differentiation (350).
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1.7 Hypothesis
On the basis of the current evidence I hypothesise that the 1L-33/ST2 axis has 
important pro-inflammatory roles in different types of inflammation, and therefore is 
potentially an important target for modulation of Immune responses.
1.8 Aims
In order to test this hypothesis I will demonstrate that:
1. IL-33 initiates an innate immune response in the lung in the absence of
antigen
2. IL-33 is dependent on ST2  gene expression for its pro-inflammatory
effects
3. IL-33 may have role in asthma, a Th2 driven allergic disease, using murine
allergic airways disease as a model.
4. IL-33 may have a role in rheumatoid arthritis, a Th1/Th17 driven
autoimmune disease, using murine collagen-induced arthritis as a model.
These studies will Identify IL-33 as a novel target for therapeutic intervention in
many different types of inflammation and human diseases.
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Materials and Methods
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2.1. Buffers and Reagents
Solutions/buffers and reagents used in all experiments are listed in appendix 1 
(solutions/buffers) and appendix 2 (reagents).
2.2. Mouse Strains
All mice were housed in University of Glasgow Biological Services facilities 
according to United Kingdom Home Office regulations, with free access to food 
and water. Severe combined immunodeficient (SCID) mice were kept in filter top 
cages with sterilised food and water. All experiments were undertaken in the same 
facility under project licence 60/3119. I held personal licence number 60/9140. The 
strains of mice used and their sources are summarised in Table 2.1.
STRAIN GENETIC MODIFICATION SOURCE
BALB/c None Harlan Olac
BALB/c ST2 gene knockout Prof Andrew Mackenzie 
University of Cambridge
BALB/c SCID Harlan Olac
DBA/1 None Harlan Olac
DBA/1 ST2 gene knockout Bred at University of 
Glasgow
Table 2.1 Strains of mice used in experiments 
2.2.1. Commercially available mice
Wildtype BALB/c (H-2^), SCID mice (C.B-17 on the BALB/c background) and 
DBA/1 (H-2^) mice were purchased from Harlan Olac (Bicester, Oxon, UK).
2.2.2. ST2 gene knockout mice
In some experiments I used mice which had the ST2  gene disrupted to delete the 
majority of exons 4 and 5 (326). In homozygotes this results in ST2 knockout mice 
(ST2'/-) no expression of either soluble ST2 or ST2L. BALB/c ST2^ mice had 
previously been obtained from Professor Andrew Mackenzie, BBRC, University of 
Cambridge.
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2.2.3. Breeding DBA/1 ST2  ^ mice
The BALB/c strain is resistant to arthritis so in order to carry out these experiments 
ST2^ mice on the susceptible DBA/1 background were required. Female BALB/c 
ST2 "^ mice were mated with male DBA/1 mice to produce ST2^^' heterozygous Fi 
mice. Female Fi heterozygotes were identified by polymerase chain reaction 
(PCR) and backcrossed for 7 further generations with wildtype male DBA/1 mice. 
Male and female Fg heterozygotes were mated and ST2^ homozygote offspring 
used to set up breeding pairs.
2.2.3.I. Screening for ST2 gene expression by PCR
Mice to be used in breeding were identified as wildtype (ST2^ "^ )^, heterozygous 
(ST2+/-) Qp homozygous (ST2'^ ) for the disrupted ST2 gene by polymerase chain 
reaction (PCR). The same method was used in both BALB/c and DBA/1 strains as 
the gene disruption was the same. All techniques were performed using gloves 
and guaranteed DNAase/RNAase free plasticware.
a) DNA extraction
All centrifugations were at 14000rpm at 4°C. Tail tips were digested overnight at 
55°C in 0.5 ml tail lysis buffer. The tail digest was mixed with 0.5ml 
phenol/chloroform/isoamyl alcohol and centrifuged for 5 minutes. The top layer, 
containing the DNA, was decanted into a fresh eppendorf taking care not to disturb 
the protein layer (see Figure 2,1).
DNA layer
Protein
Debris
Figure 2.1 Extracted DNA is In the top buffer iayer
This was mixed with 0.5ml chloroform and centrifuged for 5 minutes. The top DNA- 
containing layer was decanted again and 0.8ml of ice cold 100% ethanol was 
added, mixed well, and left at -20°C for 20 minutes for the DNA to precipitate. This 
was centrifuged for 15 mins, the supernatant was poured off, and 0.5ml of ice cold
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70% ethanol added to the DNA pellet. This was centrifuged again for 15 minutes, 
and the supernatant poured off. The pellet was air-dried for 25 mins at 55°C in a 
vacuum-dryer, and resuspended in 50pl water for injection. The DNA was stored 
at 4 ”C until PCR was performed for genotyping.
b) Polymerase Chain Reaction for ST2 gene disruption
Reaction buffer (19pl) and sample DNA (Ip l) were mixed in PCR tubes. DNA 
samples from mice known to be ST2‘^ "^ or ST2^ were used as positive
controls. Pure water (1pl) was used as a negative control. PCR was performed 
using the following protocol:
1. 1 cycle 94°C 3 minutes
2. 30 cycles 94°C 45 seconds
60°C 30 seconds
72'C 90 seconds
3. 1 cycle 72°C 10 minutes
4. Stored at 4°C until run on DNA detection gel
c) DNA detection gei
The samples were mixed with 5pl loading buffer, run on a 2% agarose gel with 
0.005% ethidium bromide for 30 mins at lOOmV in TAE buffer, then viewed under 
ultraviolet (UV) light. A DNA sample ladder was used to estimate the size of the 
bands detected. Primers 1 and 3 amplified the 500 base pair (bp) wildtype band, 
and primers 2 and 3 amplified the 200bp disrupted ST2  band (see appendix 2, 
table 1 for primer sequences). An example of the gels obtained is shown in Figure
2 .2 .
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Figure 2.2 A DNA detection gel as viewed under UV light
I  = DNA ladder
2 - 7  = Samples. All heterozygous in this example
8 = ST2+/- heterozygous control
9 = ST2+/+ wildtype control (500bp)
10 = ST2 /- homozygous control (200bp)
I I  = Negative control (no sample DNA)
DNA from the tail-tips of mice to be used in breeding was amplified by PCR, run on a 2% agarose 
gel with 0.005%  ethidium bromide, and then viewed under UV light to illuminate the resulting bands.
2.3. Cell culture
Cells were always handled under sterile conditions, and were washed in sterile 
wash medium by centrifuging at 1400rpm for 5 mins at 4°C unless otherwise 
stated. Live cells were counted in a Neubauer haemocytometer (Weber Scientific 
International Ltd, UK) using an aliquot diluted with a 0.1% (w/v) solution of trypan 
blue to stain non-viable cells. The number of live cells in 25 central squares was 
counted and the number of cells per ml calculated using the following formula:
Cells/ml = count x dilution factor xIO^
All cells were cultured at a final concentration of 1x10® per ml in complete RPMI 
medium, and at 37°C in a 5% CO2 atmosphere. Additional antigens for cell 
restimulation were added to cell culture where indicated
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2.3.1. Cytokine and chemoklne production
To assess lymphocyte synthetic function cells were cultured in flat-bottomed 24 
well culture plates (Nunc, Roskilde, Denmark) for 96 hrs. The supernatant was 
then removed and frozen at -20°C until further analysis.
2.3.2. Proliferation assay
To assess lymphocyte proliferation cells were cultured in triplicate for 72 hrs in 
round-bottomed 96 well tissue culture plates (Nunc, Roskilde, Denmark). Tritiated 
(®H)-thymidine (15kBq in lOpI sterile wash medium) was added for the last 8 hrs of 
culture. Cells were harvested onto glass fibre filter paper (Wallac, Milton Keynes, 
UK) using a 295-0054 Betaplate 96 well harvester (Wallac). ®H-thymidine 
incorporation was measured using a Matrix 96 Direct Beta Counter (Wallac). All 
procedures were performed according to local radiation safety guidelines.
2.4. IL-33 Purification
Recombinant human and murine interleukin (rh and rmlL)-33 were produced and 
purified within the department by Dr Damo Xu. Briefly, IL-33 cDNA was cloned 
from IL-1 stimulated human or murine fibroblasts by real time (RT)-PCR using 
specific primer pairs (see appendix 2, table 2 for sequences). The sequence- 
confirmed IL-33 cDNA was inserted into expression vector PQE (Quiagen) and 
fused with a His-tag before being transformed into Escherich ia  co ii strain M15. The 
IL-33 protein was induced by IPTG and purified by Ni-NTA affinity chromatography 
(Quiagen). The IL-33 was then run through a polymyxin B column to remove 
endotoxin. The purity of IL-33 was more than 97% by SDS gel, and endotoxin 
levels were less than 0.01eu/ug of protein Limulus Amoebocyte Lysate QCL-1000 
pyrogen testing (Biowhittaker).
2.4.1. Testing the bioactivity of IL-33
Peripheral lymph nodes were removed from naïve BALB/c ST2^ '^  ^ and ST2‘ '^ mice 
(Figure 2.3). A single cell suspension was created by crushing the lymph nodes 
gently through Nitex mesh (Cadisch, UK), washing them twice, resuspending in 
5ml complete medium and filtering again through Nitex to remove debris. The cells 
were counted and kept on ice until plated out for cell culture. T lymphocytes were 
stimulated using plate-bound anti-CD3 with or without IL-33. Flat-bottomed 24 well
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cell culture plates were coated by incubating with 200pl of 2pg/ml anti-CD3 in 
sterile PBS at 37°C for 3 hours. The wells were washed twice with complete 
medium before adding the cells at 1x10® cells/ml. IL-33 was added at 10ng/ml to 
some wells. All conditions were cultured in triplicate for 3 days and supernatants 
collected for analysis.
The bioactivity of IL-33 was confirmed by measuring the increase in IL-5 
concentration by enzyme-linked immunosorbent assay (ELISA). Batches of IL-33 
with similar bioactivity were used in experiments. Specificity was confirmed by 
culture with ST2"^" cells, where no increase in IL-5 production was seen with the 
addition of IL-33 (Figure 2.4).
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Figure 2.3 Murine lymphoid organ anatomy
1 Cervical 6 Sub-carinal (retrocardiac)
2 Mediastinal 7 Spleen
3 Axillary 8 Mesenteric
4 Brachial 9 Inguinal
5 Thymus 10 Popliteal
Adapted from the National Institute of Allergy and Infectious Diseases (part of the National Institute of Health) website: 
http://www.niaid.nih.gov/Dir/services/animalcare/MouseNecropsy/lymph.html
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Figure 2.4 Testing the bioactivity o f IL-33
Lymph node T cells were stimulated with anti-CD3 with or without IL-33 for 3 days. Culture 
supernatants were harvested and the concentration of IL-5 measured by ELISA. Results are the 
means ± SD of triplicate assay wells.
2.5. Murine models of human diseases
As discussed in the introduction, asthma and RA are complex multi-factorial 
diseases, with heterogeneity of genetics, pathophysiology, severity and response 
to treatment. The underlying mechanisms are not yet fully elucidated, and much 
research remains to be done. Although the study of human subjects is essential to 
guide research and translate experimental findings into clinically applicable data, it 
is limited by a number of factors. Firstly, it is usually only possible to study people 
who already have established disease, and so it is difficult to elucidate initiating 
factors. In addition, it can be almost impossible to separate the effects of just a 
single factor from many other confounding factors. Legal, ethical and safety 
considerations also restrict the amount and type of tissue that can be studied, 
often limiting the scope of investigation to snapshots of processes involved, rather 
than dynamic studies.
Therefore, much important work has been performed using in vivo animal models 
of disease. In particular the mouse has been used extensively for a number of 
reasons. On a practical level mice are not endangered, and a number of
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genetically well characterised in-bred strains are readily available. There is also an 
extensive commercially available “toolbox” of immunological agents with which to 
carry out investigations. The mouse immune system is well studied and 
understood, and is similar to human in many regards. The mouse genome can be 
manipulated to selectively knock out or amplify factors of interest in order to 
assess their functional importance. Any tissue can be examined in detail at a 
number of time points, allowing exploration of dynamic processes, and 
experiments can be controlled to isolate the effect of a single factor at a time.
Disadvantages are that mice do not naturally develop asthma or arthritis, and so 
any disease model will be artificial. Also there remain important differences 
between human and murine immunity (reviewed in (351)) which means caution 
must be taken when applying murine findings to human disease. Despite these 
shortcomings, murine models have been invaluable in studying specific aspects of 
the inflammatory processes seen in asthma and arthritis, which can then be 
applied to humans for further study.
2.5.1. Murine allergic airways disease
The advantages and disadvantages of using mice to model asthma have been 
extensively debated and reviewed (352-356). Although none of the many models 
in use has all the hallmarks of human asthma, many features are present: a 
peribronchial and perivascular inflammatory infiltrate rich in eosinophils and 
lymphocytes, a Th2 cytokine bias, mucus hypersecretion, Increased serum IgE, 
and changes in airway physiology. However, in addition to differences in immune 
function, mice have structurally and functionally different airways to humans, with 
fewer bronchial divisions, more bronchial-associated lymphoid tissue (BALT) and 
smooth muscle present only in the larger airways. Therefore, some key features of 
human asthma are not easily modelled or measured, in particular AHR and 
chronic inflammation (357).
2.5.1.1. Designing a murine model o f asthma
A number of different approaches have been used to model asthma, including 
active sensitisation and challenge, transfer of antibody, transfer of allergen-specific 
lymphocytes and transient gene transfer (354). It should be remembered that 
differences in models can result in variable results even when studying the same 
phenomenon.
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As I was most interested in studying the acute allergic response to an allergen I 
used a short sensitisation and challenge protocol in BALB/c mice using ovalbumin 
(OVA) as the allergen, adapted from Stock et al ((128); Figure 2.5). This type of 
model is widely used and gives reproducible results. The following factors were 
taken into account when considering what model to use:
a) Mouse strain
Strains of mice differ in their ability to exhibit various features of asthma. AFIR is 
best demonstrated in A/J mice although it is also seen in BALB/c mice. BALB/c 
mice are pre-disposed to make strong Th2 type inflammatory responses, and have 
been shown to exhibit greater allergic airways inflammation than other strains.
b) Aliergen and adjuvant
Various allergens have been used, including live organisms (fungi, parasites), 
complex proteins (from house dust mites and cockroaches) and simple proteins 
with or without adjuvants (OVA with alum). I used sterile chicken OVA as the 
model allergen as simple proteins give a reliable effective dose and reproducible 
response. Live organisms and complex proteins can vary widely in the response 
elicited even in congenic mice. Simple proteins alone do not stimulate strong 
responses so an adjuvant is given to boost the response. In this case I used alum 
as it also induces a Th2 type response (145).
c) Route and timing o f administration
Active sensitisation and challenge mimics the events happening after allergen 
challenge in human asthma, albeit over a much shorter time-scale. Systemic 
sensitisation (intraperitoneal (IP)) followed by local challenge (intranasal (IN)) 
given from 7 days up to several weeks afterwards has been shown to give the 
optimal degree of allergic airways inflammation. In pilot experiments I found a 
single sensitisation and a single challenge 7 days later were sufficient to induce 
allergic airways disease, whilst 3 consecutive challenges gave maximal 
inflammation (data not shown). Flowever, the dose of OVA and the number of 
challenges given could be varied to increase or reduce the level of inflammation.
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2.5.1.2 Allergen sensitisation
All mice, Including negative control groups, were sensitised on day 1 with 100pg of 
OVA in 100pl of sterile PBS mixed with 100pl of 2% alum injected 
Intraperitoneally. The same sensitisation protocol was followed in all experiments.
2.5.1.3 Allergen chaiienge
The mice were anaesthetised using 250-350pl of avert!n injected IP. Once they no 
longer withdrew from whisker stimulation they were challenged with either 2pg or 
10pg of OVA in 30pl sterile PBS IN. PBS alone was used as a negative control. 
Where indicated rmlL-33 was added to the OVA or PBS and administered at the 
same time. The mice were placed in a warm box until they recovered 
consciousness, and supplementary oxygen given if required. Mice were 
challenged either 3 times (days 9, 10 and 11) or twice (days 9 and 11). The 
optimum dose and number of challenges were determined by pilot experiments 
(see section 4.2 for data).
t IP Sensitisation
Day 1
OVA lOOfjg 
+ Alum
t t t
D9 (DIO) D ll
OVA 2 -  lOgg 
+ /-  2gg mlL-33
Cull
IN Challenge i
Figure 2.5 A murine modei of aliergic airways disease
Mice were sensitised to OVA by IP injection on day 1, with alum used as a Th2 adjuvant. The 
airways were challenged with IN OVA on days 9 - 1 1 .  Where indicated rmIL-33 was given IN at the 
same time as OVA. Mice were culled 24 hours after the final challenge and various tissues collected 
for analysis.
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2.5.1.4 Tissue harvesting
The mice were culled 24 hours after the last challenge by anaesthetising with 
SOOpI avertin IP, and then exsanguination to collect serum. Various tissues were 
then harvested and analysed.
a) Serum
The chest wall was opened and blood withdrawn from the right ventricle using a 
1ml syringe and 23 gauge needle. It was then centrifuged at 14000rpm at 4°C for 
30 mins, and the serum decanted and stored at -20°C until analysed.
b) Bronchoaiveoiar lavage
The trachea was exposed by dissection of the superficial neck structures and 
cannulated using a 1ml syringe with a 23 gauge needle. The needle was sheathed 
in plastic tubing (0.58mm ID, 0.78mm OD; VWR International) extending 1~2mm 
from the end to prevent the needle passing through the posterior wall of the 
trachea. The needle was held in place by blunt forceps to effect a seal. The lungs 
were inflated carefully with 800pl PBS and the fluid withdrawn after 10 seconds. 
This process was then repeated with a fresh 800pl aliquot of PBS and the two 
aliquots pooled and kept on ice until further processing. Total cell counts were 
performed as described (section 2.3). After removal of cells for differential cell 
counting (see below), the remaining BAL fluid was centrifuged at 1400rpm for 5 
minutes at 4°C and the supernatant frozen at -20°C until analysed.
c) Differential cell count
In order to determine the relative frequency of different cell types 5x10"^  cells were 
removed from the BAL and spun onto a slide at 300rpm for 6 mins using a 
Cytospin (Thermo Shandon, Cheshire, England). The resulting cytopreps were air- 
dried then fixed in methanol for 10 minutes. They were stained by the 
Romanovsky method using Rapi-Diff II and coverslips fixed in place with DPX. 
Macrophages, eosinophils, neutrophils and lymphocytes were identified using 
standard morphological criteria under xlOO oil immersion microscopy, and the 
relative frequency of each was determined by counting 400 consecutive cells. The 
number of cells per ml in the original BAL was then calculated from the total cell 
count. Squamous epithelial cells were often seen, but were not included in the 
analysis. The slides were blinded and randomised before counting to eliminate any
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bias. Figure 2.6 shows examples of these cell types as seen under x40 
microscopy.
50 |im
»
Figure 2.6 Leukocytes seen in mouse bronchoaiveoiar lavage fluid
This figure represents the standard morphology of various leukocytes seen in mouse 
bronchoaiveoiar lavage fluid at x40 magnification.
1 = macrophage -  mononuclear \A/ith pale foamy cytoplasm
2 = eosinophil -  multi-lobed or ring nucleus with eosinophilic cytoplasm
3 = neutrophil -  multi-lobed nucleus with pale cytoplasm
4 = lymphocyte -  mononuclear with very little cytoplasm 
The insert shows ciliated squamous cells at the same magnification.
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d) Draining lymph nodes
The heart and lungs were removed en bloc from the chest cavity and the 
mediastinal and subcarinal draining lymph nodes (DLNs) draining the lung were 
removed into ice cold wash medium and kept on ice. A single cell suspension was 
created by crushing the lymph nodes gently through Nitex, washing them twice, 
resuspending in 5ml complete medium and filtering again through Nitex to remove 
debris. The cells were counted and kept on ice until plated out for cell culture. 
Cells were cultured with or without 1 mg/ml OVA for both proliferation and 
cytokine/chemokine cultures.
e) Lung histology
The heart/lung block was removed intact and the trachea cannulated. The lungs 
were inflated with 1ml 10% neutral buffered formalin (NBF), the trachea tied off 
using cotton thread, and then the whole block immersed in 10% NBF for at least 
48 hrs. The lungs were mounted in paraffin blocks, and 6pm sections stained with 
haematoxylin and eosin (H&E; kindly performed by Mr. Roderick Ferrier, 
Department of Pathology, Western Infirmary, Glasgow). Sections were examined 
at X20-100 magnification and peribronchial and perivascular inflammation 
assessed.
Scoring svstem
There is no single validated scoring system for allergic airway inflammation seen 
in mice. I used a semi-quantitative system to assess the degree of eosinophilic 
infiltration seen (see Figure 2.7):
0 No eosinophils
1 Eosinophils make up less than 10% of total infiltrate or total
infiltrate is <20 cells
2 Eosinophils make up 10%-50% total infiltrate
3 Eosinophils make up more than 50% total infiltrate
A total of 10 fields were scored for each mouse. Each field had to contain both a 
bronchus and a vessel in close proximity. The average field score for each mouse 
was calculated, and then the results expressed as the mean score for each group. 
All scoring was performed on slides which had been blinded. In some experiments
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the scoring was validated by a second blinded observer to ensure inter-observer 
agreement. The results obtained were the same.
A) Score 0 B) Score 1
D) Score 3Score 2
Figure 2.7 Lung histoiogy from allergic airways inflammation
Shown here are examples of different grades of allergic airways inflammation in BALB/c mice using 
the experimental protocol described.
2.5.2. Murine collagen-induced arthritis
As with asthma, there is no single model which exactly mimics human RA, 
although various models have been developed which can exhibit some of the 
cardinal features of human disease, such as auto-antibody production, chronic 
synovitis and joint destruction, and even systemic features (vasculitis, interstitial 
pneumonitis, and subcutaneous nodules) (229,358-362).
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2.5.2.1. Designing a model of rheumatoid arthritis
A model of antigen-specific collagen-induced arthritis (CIA) was used, which 
shares many of the immunological and pathological features of human RA 
(reviewed in (362)). The response to collagen is well categorised, and it has been 
widely used both in studying the pathogenesis of disease, and in testing novel 
therapeutics. It depends on both T and B cell immunity, resulting in a Th1/Th17 
type response with production of arthritogenic antibodies.
The mice are immunised intradermally (ID) with heterologous collagen type-11 (Oil) 
and an adjuvant, and the response boosted by IP challenge with Oil (see Figure 
5.1). The following factors were taken into consideration when designing the 
model:
a) Mouse strain
Susceptibility to arthritis is linked to the expression of certain MHC-class II 
molecules. Most commonly used strains of mice, including BALB/c (H-2^), are 
resistant to arthritis. However, DBA/1 mice (H-2'^) are highly susceptible to arthritis 
(362). Other genetic factors, such as variability in cytokine expression also play a 
role. As we only had ST2^ mice on the BALB/c background, this necessitated 
breeding this trait onto the DBA/1 background (see section 2.2.3.).
b) Antigen and adjuvant
Cll was used as the antigen as the anti-CII !gG2a antibodies produced cross-react 
with mouse Cll in the joint, and activate complement there, thus localising the 
systemic response to cause joint pathology. DBA/1 mice will respond to chicken, 
bovine, porcine and human Cll. I used bovine Cll as it is widely used, results in a 
high incidence of disease and gives reproducible results.
Collagen alone will not induce arthritis. Co-administration of Complete Freund’s 
Adjuvant (CFA) biases towards a Th i type response, and is essential for the 
production of arthritogenic antibodies. The amount of antibody produced depends 
on the concentration of M ycobacte rium  tubercu los is  present in the CFA (363). 
Recently, high doses were even shown to induce arthritis in strains previously 
thought to be resistant to CIA (364).
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2.5.22. Antigen immunisation
I used a commercially available reagent kit (Chondrex) which contained both 
bovine Cll (2mg/ml in 0.05M acetic acid) and CFA.
a) Emulsion preparation
An emulsion of Cll and CFA was produced by mixing equal volumes of each in a 
small universal on ice to prevent denaturing. This was best achieved by rapidly 
drawing up and ejecting the mix using a 1ml syringe. The emulsion was 
considered stable when a drop remained as a solid clump and did not dissipate 
when placed on the surface of water.
b) Collagen injection
On day 1 the mice were anaesthetised using halothane, and a single ID injection 
of 50pg Cll in 50pl emulsion (1 mg/ml) was made at the base of the tail using a 1 ml 
syringe with a 27 gauge needle. The mice develop a local skin reaction with 
ulceration at the injection site.
c) Boosting the response
The response was boosted on day 21 by mixing equal volumes of Cll and sterile 
PBS, and then injecting 50pg Cll in 50pl PBS (1 mg/ml) IP.
d) Treatment with rmlL-33
The effect of rm IL-33 on the severity of arthritis was assessed. Where indicated 
mice were treated by injecting 0.8pg rm IL-33 in 200pl sterile PBS IP for 5 
consecutive days starting on day 21.
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2.5.2.3. Footpad measurements
The thickness of the front and rear footpads was measured using callipers on day 
21, as a baseline, and then every 1-2 days following this. The increase in footpad 
thickness was calculated from the baseline measurements. The clinical score for 
each footpad was also assessed using the following criteria:
Score
No inflammation 0
Red toes or footpad 1
Red, swollen footpad 2
Loss of function (limping) 3
The incidence of disease and the average increase in footpad thickness and total 
clinical score per mouse were calculated for each group. Only those mice which 
developed disease were included in clinical score and footpad analysis.
2.5.2.4. Tissue harvest
At various time points after boosting, the immune response was assessed by 
culling the mice by neck dislocation, and harvesting the draining lymph nodes, 
spleens and joints.
a) Lymph node and spleen cultures
The popliteal DLNs and spleens were harvested (see Figure 2.3) and pooled for 
each group. They were kept on ice until single cell suspensions were prepared (as 
in section 2.5.1.5.d). In addition, the red blood cells from spleens were lysed after 
the first wash using 1ml of Red Cell Lysis buffer for 1 minute, then washing a 
further two times. Cells were cultured at 1x10®/ml in complete medium with 
lOOpg/ml bovine Cll for cytokine/chemokine production and proliferation.
For use in culture bovine Cll was dissolved in sterile 0.05M acetic acid at 4 “C 
overnight on a rotating mixer to give a concentration of 2mg/ml. This was then 
dialysed twice against 2 litres of PBS using dialysis cassettes. The resulting 
solution of Cll in PBS was kept at -20“C until use. It was used in culture at 
100pg/ml. For consistency the same batch of Cll was used in all experiments. 
Chondrex Cll was not used in culture as it tended to precipitate out and form large 
gel-like structures in culture medium, therefore Cll from Sigma was used.
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2.6. Administration of IL-33
In some experiments I used IL-33 alone to demonstrate its biological effects on the 
innate immune system. Recombinant IL-33 was produced as described previously 
(section 2.4) and administered as described below.
2.6.1. Intraperitoneal administration of IL-33
Recombinant IL-33 (human or murine) was injected IP for 7 days, at a dose of
O.Spg per mouse in 200pl sterile LPS-free saline (see Figure 3.1).
2.6.2.1. Tissue harvest
Mice were culled by neck dislocation 24 hours after the last injection, and various 
tissues harvested. Serum, BAL and lungs were collected and processed as 
described previously (section 2.5.1.5.), and in addition peritoneal wash and 
spleens were also collected.
a) Peritoneal Wash
The peritoneum was instilled with 6ml sterile LPS-free PBS using a 10ml syringe 
and 21 gauge needle. This was then withdrawn after 10 secs and kept in a 
universal on ice until processing. The total cell count was performed, and 5x10"^ 
cells removed for cytospin and differential count as described for BAL fluid (section 
2.5.1.5.c). The remaining sample was centrifuged at 1400rpm for 5 mins at 4°C to 
pellet the cells, and the supernatant kept at -20“C until further analysis.
b) Spleen harvest
The spleen was removed and kept in ice cold wash medium until processing. 
Spleens were weighed, then a single cell suspension prepared (see section
2.5.2.4.) Differential counts were performed on cytospins of 5x10^ cells as 
described for BAL fluid (see section 2.5.1.5.c).
2.6.2. Intranasal administration of IL-33
IN administration of rm IL-33 was undertaken in a similar fashion to OVA challenge 
in the airway inflammation model (see section 2.5.1.4.). Mice were anaesthetised 
using 250-350pl avertin IP, and then 2pg of rm IL-33 in 30pl sterile LPS-free PBS 
was given IN. Mice were allowed to recover in a warm box with supplemental 
oxygen if required. This was done for 7 consecutive days (see Figure 3.8).
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2.6 2.1. Tissue harvest
Mice were anaesthetised 24 hours after the final dose with SOOpI avertin, culled by 
exsanguination and tissues harvested. Serum, BAL, peritoneal wash, spleens and 
lungs were all processed as previously described (sections 2.5.1.5. and 2.6.2.1).
2.7. Enzyme-linked immunosorbent assay
Enzyme linked immunosorbent assays (ELISAs) were used to determine the 
concentration of cytokines, chemokines and antibodies in serum, BAL, peritoneal 
wash and cell culture supernatants. All ELISAs were carried out in flat-bottomed 
96 well Immulon 4 assay plates (Thermo Labsystems, Franklin, USA) using 0.05% 
Tween-20 in PBS for washing. Analysis was performed on an MRX-II microplate 
reader (Dynex Technologies, UK) running Revelation software v1.5, and sample 
values calculated from the standard curves generated (see Figure 2.8).
A) ELISA protocol 1 B) ELISA protocol 2
C) Immunoglobulin ELISA D) Multiplex
3.500
3 000
2000
1 500
1 000
0.000
-1 000
0.100 10.000 1000.000ng/ml
Figure 2.8 Standard curves for ELISA and multiplex
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2.7.1. Cytokine and chemokines
Most cytokines and chemokines were measured using commercially available 
capture and detection antibody pairs, each recognising discrete epitopes. 
Recombinant murine cytokines and chemokines were used to create doubling 
dilution (1:2) standard curves on each plate. All samples were applied in triplicate 
where possible, and diluted 1 : 5 - 1 :1 0  where concentrations were above the limit 
of the standard curve. The protocol followed depended on the source of the 
antibody pairs.
2.7.1.2. Protocol 1 -  BD sourced antibodies and standards
Unless otherwise indicated, a volume of 50pl per well was used for all stages, 
antibodies, standards and samples were diluted in ELISA assay buffer A, and all 
incubations were at room temperature.
Cytokine
Capture
Antibody
(ftg/ml)
Detection
Antibody
(ng/ml)
Top
standard
(ng/ml)
IL-4 2 2 10IL-5 4 4 10
IFNy 1 0.5 40
Table 2.2 BD sourced antibodies and standards
Plates were coated with the capture antibody overnight in ELISA coating buffer A 
at 4°C. They were then washed twice and non-specific binding blocked by 
incubating the plates at 37°C for 1 hr with 200pl ELISA assay buffer A. The plates 
were washed twice before applying the samples and standards, which were 
incubated for 2 hrs, and then the plates washed 4 times. The detection antibody, 
conjugated to biotin, was added and incubated for 1 hr, washed 4 times, then 
plates incubated with extravidin-peroxidase (1:1000) dilution for 30 mins. The 
plates were washed 6 times, and 100pl 3’3’5’5’-tetra-methylbenzidine (TMB) 
substrate added to each well. The plates were incubated for up to 30 mins in the 
dark and then colour development measured at 630nm.
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2.7.1.3. Protocol 2 -  R&D Systems sourced antibodies and standards
Unless otherwise stated a volume of lOOpI per well was used, and antibodies, 
standards and samples were diluted in ELISA assay buffer B. All incubations were 
at room temperature.
Cytokine
Capture
Antibody
(ng/ml)
Detection
Antibody
(pg/ml)
Top
standard
(ng/ml)
lL-13 4 0.3 2
IL-13 4 0.2 2.5
Eotaxin-1 0.8 0.4 0.5
Eotaxin-2 2 0.075 4
TCA-3 2 2 1
TARC 2 0.2 1
Table 2.3 R&D Systems sourced antibodies and standards
Plates were coated with the capture antibody overnight in ELISA coating buffer B. 
They were then washed twice and non-specific binding blocked by incubating the 
plates for 1 hr with 300pl ELISA blocking buffer. The plates were washed twice 
before applying the samples and standards, which were incubated for 2 hrs, then 
the plates washed 4 times. Eotaxin-2 detection antibodies were diluted in ELISA 
assay solution B with the addition of 2% heat-inactivated normal goat serum. The 
others were diluted as normal. The biotinylated detection antibody was incubated 
for 2 hrs, the plates washed 4 times, and 100pl streptavidin-peroxidase (1:1000) 
added and incubated for 20 mins. The plates were washed 6 times, and the TMB 
substrate added and incubated for 20 mins in the dark. The reaction was stopped 
using lOOpI stop solution and colour development measured at 450nm with a 
570nm correction filter.
2.7.2. Immunoglobulins
Total IgE and IgA, and antigen-specific IgE, IgGI and lgG2a were measured using 
commercially available antibodies, kits and standards (R&D Systems). Standards 
were available for total IgE and IgA only, and were used at doubling dilutions in 
duplicate. Antigen-specific Igs were measured by comparing OD values directly. 
All samples were applied in triplicate where possible. Unless otherwise indicated a 
volume of 100pl per well was used, incubations were at room temperature, and 
antibodies, standards and samples were diluted in ELISA assay buffer A.
Chapter 2: 97
2.7.2.1. Total IgE
Total IgE was measured using a commercially available mouse anti-lgE kit. The 
concentrations of antibodies and avidin-horseradish peroxidase (HRP) varied 
according to batch and were used as recommended by manufacturer (typically 
1:250). Plates were coated with the capture antibody overnight in ELISA coating 
buffer B at 4°C. They were then washed twice and non-specific binding blocked by 
incubating the plates for 1 hr with 2G0pl ELISA assay buffer A. The plates were 
washed twice before applying the standard (starting at 100ng/ml) and samples at 
1:10 -  1:50 dilution. Samples and standards were incubated for 2 hrs, then the 
plates washed 4 times. The biotinylated detection antibody and avidin-HRP were 
added at the same time and the plate incubated for 1 hour. The plates were 
washed 6 times, and 100pl TMB substrate added. The plates were incubated for 
30 mins in the dark, and then the reaction stopped using lOOpI stop solution. The 
colour development was measured at 450nm with a 570nm correction filter.
2.7.2.2. Total IgA
Total IgA was measured using a commercially available antibody pair and purified 
monoclonal mouse IgA as a standards. Plates were coated with the capture 
antibody (2pg/ml) overnight in ELISA coating buffer B at 4°C. They were then 
washed twice and non-specific binding blocked by incubating the plates for 1 hr 
with 200pl ELISA assay buffer A. The plates were washed twice before applying 
the standard (starting at 1000ng/ml) and samples (BAL 1:10 -  1:50; peritoneal 
wash 1:20 -  1:100; serum 1:1000 -  1:5000). Samples and standards were 
incubated for 2 hrs, then the plates washed 4 times. The biotinylated detection 
antibody (2pg/ml) was added and the plate incubated for 1 hr. The plates were 
washed 4 times, and extravidin-peroxidase (1:1000) added and incubated for 30 
minutes. The plates were washed 6 times and lOOpI TMB substrate added for 30 
mins in the dark. The reaction was stopped using lOOpI stop solution and colour 
development was measured at 450nm with a 570nm correction filter.
2.7.2.3. Antigen-specific IgE
Antigen-specific IgE was measured using components of the total IgE kit. Plates 
were coated overnight with lOpg/ml OVA in ELISA coating buffer B at 4°C. They 
were then washed twice and non-specific binding blocked by incubating the plates 
at 37°C for 1 hr with 200pl ELISA assay buffer A. The plates were washed twice 
before applying the samples. No standards were available. Samples were diluted
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to 1:50, applied in duplicate in doubling dilutions, and incubated at room 
temperature for 2 hrs. The remainder of the protocol was identical to the total IgE 
kit.
2.7.2.4. Antigen-specific lgG1 and lgG2a
Antigen-specific IgGI and lgG2a were measured using commercially available 
anti-mouse IgGI and lgG2a antibodies conjugated to biotin (R&D Systems). 
Plates were coated with overnight with lOpg/ml OVA in ELISA coating buffer B at 
4 “C. They were then washed twice and non-specific binding blocked by incubating 
the plates at 37°C for 1 hr with 200pl ELISA assay buffer A. The plates were 
washed twice before applying the samples. No standards were available. Samples 
were diluted to 1:250 -  1:500 for IgGI and 1:25 -  1:50 for IgG2a, and applied in 
duplicate. Tripling (1:3) dilutions were used for IgGI and doubling (1:2) dilutions 
for lgG2a. The samples were incubated for 2 hrs, then washed 4 times. 
Biotinylated detection antibody was added at 1:1000 for IgGI and lgG2a and 
incubated for 1 hour. The plates were washed 4 times, and extravidin-peroxidase 
(1:1000) added for 30-60 mins. The plates were washed 6 times, and then lOOpI 
of TMB substrate added for 30 mins. The reaction was stopped at this point using 
lOOpI stop solution, and the plates analysed at 450nm with 570nm correction.
2.8. Multiplex Bead Analysis: Cytokines and Chemokines
Where indicated cytokines and chemokines in serum, BAL or culture supernatants 
were analysed using BioSource Multiplex Bead Immunoassays analysed on a Bio- 
Rad Bioplex analyser. Extensive instructions were provided with the kit used and 
followed closely (BioSource Mouse Cytokine Twenty-Plex -  measuring FGF, 
VEGF, GM-CSF, IFNy, TNFo, IL-1a, IL-1|3, IL-2, IL-4, IL-5, IL-6, IL-10, IL- 
12p40/p70, IL-13, IL-17, IP-10, KG, MCP-1, MIG, MIP-1a). The number of samples 
measured with one kit was doubled by diluting out the reagents to half the 
concentration using the recommended BioSource Mouse Extracellular Protein 
Buffer Reagent kit. This did not affect the sensitivity of any of the assays. A 50pl 
sample was sufficient, but where possible all assays were performed in duplicate.
The principle is similar to that of ELISAs, being a solid phase sandwich assay. 
Briefly, capture antibody coated beads were applied to the wells, and then the
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plates incubated with standards and samples for 2 hrs. During this time analytes 
bound to the capture antibodies on beads with a defined spectral property specific 
to each analyte. After washing, biotinylated detection antibodies were added for 1 
hr, and the plates washed again. Streptavidin conjugated to the fluorescent protein 
R-Phycoerythrin (RPE) was then added for 30 mins and the plates washed a final 
time. The Bio-Rad Bioplex then analysed the amount of fluorescence on each type 
of bead to determine the concentration of each analyte from the standard curves 
generated (see Figure 2.8).
The advantages of this method are that the sensitivity and range of values over 
which reliable concentrations are measured is greater than with ELISAs, and that 
multiple cytokines and chemokines can be measured from the same sample.
2.9. Statistics
All experiments were performed at least twice to ensure reproducibility of results. 
To compare different groups, data from individual mice are presented as means 
with standard error of the mean (SEM). For normally distributed data Student’s 2 
sample f-test was used to calculate p values, and for skewed data the Mann- 
Whitney U test was used (Minitab Statistical Software, Minitab Inc., State College, 
PA, USA). A p value of 0.05 or less indicates statistical significance.
2.9.1. Power Calculations
Power calculations were worked out using Minitab, with a significance level of 0.05 
and a power value of 0.95.
2.9.1.1. Allergic airways inflammation
From previous experience a difference in eosinophilia of 10% was thought to 
represent a physiologically significant change, with a standard deviation of 5%. 
Using Minitab this gave a minimum group size of 8 mice (Figure 2.10A).
2.9.1.2. Collageminduced arthritis
From previous experience a difference in clinical score per mouse of 3 would be 
regarded as significant, with a standard deviation of 2. Using Minitab this gave a 
minimum group size of 13 (Figure 2.1 OB).
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A) Allergic Airways Inflammation
Power and Sample Size
2-Sample t Test
Testing mean 1 = mean 2 (versus not =)
Calculating power for mean 1 = mean 2 + difference 
Alpha = 0.05 Assumed standard deviation = 5
Sample Target Actual 
Difference Size Power Power
10 8 0.9500 0.9602
B) Collagen-Induced Arthritis 
Power and Sample Size
2-Sample t Test
Testing mean 1 = mean 2 (versus not =)
Calculating power for mean 1 = mean 2 + difference 
Alpha = 0.05 Assumed standard deviation = 2
Sample Target Actual
Difference Size Power Power
3 13 0.95 0.956112
Figure 2.9 Power caicuiations from Minitab
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The role of lL-33 in innate inflammation
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3.1, Introduction
IL-33 is a novel cytokine which binds to and signals through ST2L. Current 
knowledge of its in  vivo  function is limited to C57BI/6 mice, where systemic (IP) 
administration of human IL-33 over 7 days induced many of the features of a 
systemic Th2 effector response in naïve mice (1). In keeping with the known 
functions of ST2L, there was an increase in Th2 cytokines, total IgA and IgE, and 
systemic eosinophilia, with pathological changes seen in the lung and gut. Thus 
the IL-33/ST2L interaction can result in innate Th2 type eosinophilic inflammation.
Administration of IL-4 or IL-13 directly to the airways results in many of the 
features of asthma, including eosinophil accumulation, mucus hypersecretion and 
AHR, independent of antigen (89,103). IL-33 mRNA is expressed constitutively in 
murine lung tissue, and in human bronchial and pulmonary artery smooth muscle 
and resting bronchial epithelial cells (1). There are also cells constitutively 
expressing ST2L in the lungs, mainly mast cells (288). Pro-inflammatory signals 
can induce ST2  expression in macrophages (284), and sST2 release from 
fibroblasts (285).
I hypothesised that administration of IL-33 to the airways of mice would result in 
innate Th2 type inflammation in the absence of antigen. Our lab had produced 
recombinant murine IL-33, and I would be using BALB/c mice to examine the role 
of IL-33 in inducing an innate inflammatory response by analysing the local and 
systemic effects of both intraperitoneal and intranasal routes of administration. By 
using ST2^ mice I confirmed that the response seen was dependent on 
expression of the ST2  gene, and by using SCID mice, which lack lymphocytes, I 
began to elucidate the cell types that may be involved.
3.2. The effects of rhIL-33 are not strain specific
As there is very limited published data on the use of recombinant IL-33 as a 
reagent, the first step was to demonstrate that the systemic effect of human IL-33 
is not specific to C57BI/6 mice. The in vivo effects in BALB/c mice were confirmed 
by following a similar protocol to Schmitz et al (1) and injecting 0.8pg of rhIL-33 IP 
for seven consecutive days (Figure 3.1). Tissues were collected for analysis the 
day after the final injection. A dose of 0.8pg was chosen as Schmitz had shown
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that 0.4pg was sufficient and we wanted to ensure an adequate dose to see a 
response.
Cull 
Day 8
rTTTTTT J
Day 1
Intraperitoneal 
200pl sterile PBS 
± 0.8pg rh IL-33 or rm IL-33
Figure 3.1 Intraperitoneai administration of IL-33
Recombinant human (rh) and murine (rm) IL-33 were produced as described and 0.8jjg injected 
intraperitoneaily in 200pl sterile PBS for 7 consecutive days. The day after the last injection the mice 
were culled and spleens, peritoneal wash, serum, BAL and lungs harvested for analysis.
3.2.1. IP rh IL-33 induces a systemic Th2 effector response in BALB/c mice
Similar to C57BI/6 mice (1), treatment with IP rh IL-33 increased spleen weight 
(Figure 3.2A), reflecting an increase in total splenocytes, and increased the 
percentage of eosinophils in the spleen (Figure 3.2B). In keeping with the rise in 
eosinophil numbers, serum lL-5 was markedly elevated (Figure 3.2C). In contrast 
to C57BI/6 mice, serum IL-13 was undetectable, as was IL-4. Other serum 
cytokines were either undetectable (IL-1(3, IFNy) or unchanged (IL-6, IL-10, IL-12).
3.2.2. IP rhlL-33 induces Th2 pathology in the lung
In C57BI/6 mice IP rh IL-33 induced pathological changes at distant mucosal sites, 
with perivascular eosinophilic infiltrates, goblet cell hyperplasia and mucus 
hypersecretion in the lung (1). Although perivascular eosinophilia was also a 
feature in BALB/c mice, there was no goblet cell hypertrophy or mucus 
hypersecretion (no data shown). This is in keeping with the lack of IL-13 (89).
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Figure 3.2 IP rhlL-33 is biologically active in BALB/c mice
BALB/c mice were given O.Spg rhlL-33 IP for 7 days and tissues harvested. (A) Individual spleens 
were weighed. (B) Spleens were pooled, a single cell suspension prepared, and the percentage of 
eosinophils determined by differential cell counts of cytopreps. (C) The concentration of serum IL-5 
was determined by sandwich ELISA. The results shown are means ± SEM {n=5;*p<0.05,
***p<0.001).
3.3. Murine IL-33 has the same effects as human IL-33
Having established that human IL-33 activity is not restricted to C57BI/6 mice, I 
also needed to demonstrate that recombinant murine IL-33 has the same effect in 
mice as human IL-33, and is therefore just as useful, and more appropriate, as a 
reagent. In addition, I wanted to confirm that the activity of IL-33 is dependent on 
expression of the ST2  gene. To achieve both these aims rm IL-33 was 
administered systemically to BALB/c ST2"^ ^^  and ST2^ mice using the same 
protocol as before (figure 3.1). As the figures will indicate IL-33 had no effect in 
ST2‘ ‘^ mice, so for simplicity the results are not discussed here.
3.3.1. IP rm IL-33 induces a systemic Th2 effector response
rm IL-33 increased the weight of the spleens (Figure 3.3A) and the percentage of 
eosinophils (Figure 3.3B) by the same amount as rh IL-33. In addition a rise in the 
percentage of neutrophils (Figure 3.3C) was also seen that had not occurred with 
rh IL-33 in either C57BI/6 or BALB/c mice.
The serum cytokine profile was very similar to that seen after rh IL-33. In keeping 
with the rise in eosinophil numbers, IL-5 was markedly increased (Figure 3.4A),
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but again no IL-13 or IL-4 were detected. Other cytokines were either undetectable 
(IL-1|3, IFNy, IL-6, IL-10) or unchanged (IL-12).
As eosinophils, and other inflammatory cells, Infiltrated tissues distant from the 
injection site the levels of chemokines were also examined in serum. Both eotaxin- 
2 and TARC (Figures 3.48 and 3.4C) were elevated, although the rise in eotaxin-2 
was not quite statistically significant (p=0.056). Eotaxin-1 levels were not 
increased by rm IL-33.
Serum total IgA was unaffected by rm IL-33, but total IgE was increased two-fold 
(data not shown).
3.3.2. IP rm IL-33 induces Th2 pathology in the lung
In keeping with the effect of rh IL-33 in C57BI/6 mice and BALB/c mice, rm IL-33 
induced a Th2 response in the lungs when given IP. A few eosinophils were seen 
perivascularly, at a similar level to that seen with human IL-33 (data not shown). 
There was no change in the BAL cell numbers (Figure 3.5A), and virtually all the 
cells were macrophages, with no eosinophils seen at all. There was, however, an 
increase in BAL IL-5 (Figure 3.5B) and some of the chemokines (eotaxin-1 and 
TARC; Figures 3.50), albeit not statistically significant.
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Figure 3.3 IP rmlL~33 increases spleen size and ceiiuiarity
BALB/c mice were given 0.8pg rm IL-33 IP for 7 days and tissues harvested. (A) Individual spleens 
were weighed. Spleens were pooled, a single cell suspension prepared, and the percentage of (B) 
eosinophils and (C) neutrophils determined by differential cell counts of cytopreps. The results 
shown are means ± SEM (n=2-4; ***p<0.001).
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Figure 3.4 iP rmiL~33 increases serum IL~5 and chemokines
BALB/c mice were given 0.8pg rm IL-33 IP for 7 days and tissues harvested. Serum cytokines and 
chemokines were measured by sandwich ELISA; (A) IL-5 (B) eotaxin-2 (C) TARC. The results 
shown are means ± SEM (n=2-4; *p<0.05, **p<0.01).
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Figure 3.5 IP rmlL-33 induces Th2 pathology in the lung
BALB/c mice were given 0.8pg rmlL-33 IP for 7 days and tissues harvested. (A) H&E stained lung 
sections were examined for eosinophilic inflammation. (A) Cell counts, (B) IL-5 and (C) chemokines 
were measured In BAL fluid. The results shown are means ± SEM (n=2-4).
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3.3.3. IP rmlL-33 Induces a local Th2 effector response In the peritoneum
Having shown that IP injection of IL-33 causes a systemic inflammatory response 
it seemed logical to examine the peritoneal fluid to determine the extent of the 
local inflammatory response.
Cells in the peritoneal wash of PBS treated mice consisted almost exclusively of 
macrophages. After rm IL-33 administration there was an influx of inflammatory 
cells into the peritoneal cavity (Figure 3.6A). This consisted of eosinophils,
neutrophils and macrophages (Figures 3.6B, 3.6C and 3.6D). There were
proportionally more eosinophils, with an 80-fold increase (0.48 ± 0.48% to 39 ±
4.2%, p<0.001). Neutrophils increased 4-fold (0.85 ± 0.12% to 3.62 ± 1.84%, NS), 
and the percentage of macrophages decreased (98.2 ± 0.12% to 56.6 ± 3.6%, 
p<0.001). Very few lymphocytes were seen in PBS and rm IL-33 groups.
Very high levels of IL-5 were seen in the peritoneal wash after rm IL-33 treatment 
(Figure 3.7A). An increase in IL-13 was also seen (Figure 3.7B), which had not 
been seen in serum. Other cytokines were unchanged (IL-10) or undetectable (IL-
4. IL-ip, IL-6, IL-12, TNFa and IFNy).
As there had been a large influx of eosinophils and other inflammatory cells, 
chemokine levels were also examined. Eotaxin-1, eotaxin-2 and TARC (Figures 
3.7C, 3.7D and 3.7E) were increased, although the increase in TARC was not 
quite statistically significant (p=0.055).
IgA levels in the peritoneum were increased almost ten-fold in the rm IL-33 treated 
group (Figure 3.7F), although serum levels were not affected (data not shown).
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Figure 3.6 IP rmlL-33 increases the peritoneal inflammatory ceil infiltrate
BALB/c mice were given 0.8pg rm IL-33 IP for 7 days and tissues harvested. (A) Total cell numbers 
in the peritoneal wash were counted. Differential cell counts were performed on cytopreps to 
determine the percentage of each cell type present, and the absolute number of (B) eosinophils, (C) 
neutrophils and (D) macrophages calculated. The results shown are means ± SEM (n=2-4; *p<0.05,
**p<0.01).
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Figure 3.7 IP rmlL-33 increases peritoneal cytokines, chemokines and IgA
BALB/c mice were given 0.8pg rm IL-33 IP for 7 days and tissues harvested. Levels of cytokines, 
chemokines and IgA were determined by sandwich ELISA; (A) IL-5 (B) IL-13 (C) eotaxin-1 (D) 
eotaxin-2 (E) TARC and (F) IgA. The results shown are means ± SEM (n=2-4; *p<0.05, **p<0.01,
***p<0.001).
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3.4. IL-33 initiates innate Th2 type eosinophiiic 
infiammation in the lungs of wildtype and SCID mice
In the previous section I showed that rm IL-33 directly induced a strong local Th2 
type response when injected intraperitoneaily. Since both IL-33 and ST2 are 
expressed in the lung, I hypothesised that rm IL-33 given directly to the lungs 
would also induce a local Th2 type response.
The possible dosing schedule for IN IL-33 was investigated in initial pilot 
experiments. A dose response was seen over the range of 0.1 -  2pg per mouse, 
but doses above 2pg were not examined (Figure 3.8A). A single dose of 2pg rm IL- 
33 was sufficient to induce a measurable cytokine (IL-5 at 24 hours), chemokine 
(eotaxin-2 and TARC at 24 hours) and cellular (macrophages at 96 hours, 
eosinophils at 120 hours) response in the BAL (Figure 3.88), but had no effect in 
ST2^ mice (Figure 3.8C).The strength of the response was increased by repeated 
dosing for up to 7 days (results presented In this chapter), but dosing beyond this 
was not examined. Had more rmlL-33 been available it would have been ideal to 
extend these studies to higher doses and over longer periods at both low and high 
doses to more thoroughly investigate the in  vivo  biological function of IL-33, but 
the limiting factor was the rate it could be produced, purified and tested in the lab.
Therefore BALB/c mice were given 2pg intranasal rmlL-33 for seven consecutive 
days and tissues harvested to analyse the response (Figure 3.80). In order to 
make preliminary studies of which cell types might be important in the response 
SCID mice, which lack lymphocytes, were also used.
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Figure 3.8 intranasal administration of IL-33
Recombinant murine IL-33 was produced as described and given intranasally (IN) in 30p! sterile 
PBS. (A) Doses of 0 to 2pg/ml were given over 7 consecutive days and the mice culled on day 8. (B) 
A single dose of 2|jg/ml was given and the mice culled at various time points thereafter. (C) A single 
dose of 2pg/ml was given to ST2^/+ and ST2-/- mice and the mice culled at 24 hours (for cytokine 
analysis) or 120 hours (for eosinophil counts), in all experiments BAL fluid was collected and cell 
counts, cytokines and chemokines measured as described (n=3). (D) To investigate the effects of IL- 
33 in the airway more fully 2pg/ml was given for 7 consecutive days and the mice culled on day Band 
serum, BAL and lungs collected for analysis.
3.4.1. IN rmlL33 induces a Th2 type response in the airway
IN administration of rm IL-33 increased BAL total cell counts (Figure 3.9A) in both 
wildtype and SCID mice. Analysis of the cell types involved revealed a similar 
pattern in wildtype and SCID mice. However, the magnitude of the cellular infiltrate 
was 10-fold less in SCID mice. The infiltrate consisted mostly of eosinophils 
(Figure 3.98), although macrophages (Figure 3.9C) and neutrophils (Figure 3.9D) 
were also increased. Lymphocytes were seen at only very low levels and were not 
increased by mlL-33. The dominant cell in the BAL changed from virtually 100% 
alveolar macrophages In PBS challenged mice, to being over 70% eosinophils in 
wildtype and 40% in SCID mice.
The pattern of cytokines and chemokines in the BAL was also similar in wildtype 
and SCID mice, with the main difference again being the magnitude of the 
response. IL-5 and IL-13 were increased ten fold more in wildtype than SCID mice 
(Figure 3.1 OA and 3.1 OB). IL-10 was just detectable in both groups receiving rm IL- 
33, but there was no difference between wildtype and SCID mice. Other cytokines
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were either undetectable (GM-CSF, IFNy, IL-1a/p, IL-2, IL-4, IL-6, IL-12, and IL- 
17), or didn’t change (TNFa), with rm IL-33.
Eotaxin-1, eotaxin-2, TARC and MIP-1a (figure 3.10C-F) were increased in 
wildtype mice, and less so in SCID mice. IP-10, KC, MCP-1 and MIG were not 
detectable in either.
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Figure 3.9 IN rmlL-33 increases BAL cell counts
BALB/c wildtype and SCID mice were given 2pg rm IL-33 IN for 7 days and tissues harvested. (A) 
BAL total cells were counted. Differential counts were performed on cytopreps and the number of (B) 
eosinophils, (C) macrophages and (D) neutrophils calculated. The results shown are means ± SEM 
(n=5; **p<0-01,***P<0.001).
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Figure 3.10 IN rmlL-33 Increases BAL cytokines and chemokines
BALB/c wildtype and SCID mice were given 2pg rmlL-33 IN for 7 days and tissues harvested. BAL 
cytokines and chemokines were measured by sandwich ELISA or Multiplex; (A) IL-5 (B) IL-13 (C) 
eotaxin-1 (D) eotaxin-2 (E) TARC (F) MIP-1a. The results shown are means ± SEM (n=5; *p<0.05,
**p<0.01).
3.4.2. IN rm IL-33 induces eosinophilic inflammation in the lung
Both wildtype and SCID mice treated with rm IL-33 exhibited marked eosinophilic 
inflammation in histological lung sections (Figure 3.11A-D), with larger airways 
affected more than smaller airways. The inflammatory response in wildtype mice 
appeared worse, with greater total number of cells, more eosinophils, and more 
areas of inflammation per section. The eosinophils tended to be more perivascular 
than peribronchial in both. The lung eosinophil score (Figure 3.11 E) was increased 
markedly in both WT and SCID mice. Unfortunately the score was not sensitive 
enough to pick up a statistically significant difference as the WT group scored at 
the top of the scale on every section, and so the score is probably an 
underestimate. There appeared to be an increase in goblet cells in both, but much
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more prominent in wildtype in keeping with the increased levels of IL-13. However, 
to assess goblet cells more accurately these sections would need to be stained 
specifically for mucus, for example using periodic acid Schiff (PAS) stain.
3.4.3. IN rm IL-33 increases BAL but not serum IgA
Treatment with IN rmlL-33 did not increase serum IgA levels (Figure 3.12A). 
However, as with IP rmlL-33 there was a marked increase in local IgA, this time in 
the BAL fluid (Figure 3.12B). As expected no IgA was detected in SCID mice as 
they do not possess B cells. IgE levels were not examined in BAL.
3.4.4. IN rmlL33 induces a systemic Th2 type response
Both IP and IN routes of administration resulted in evidence of a systemic 
response. IN rm IL-33 induced a doubling in mean serum levels of total IgE (Figure 
3.13A), although this did not quite reach significance (p=0.06). Serum IL-5 (Figure 
3.13B) was increased, and this time serum IL-13 (Figure 3.13C) was also 
increased. A similar pattern was observed in SCID mice, but the magnitude was 
much less. The difference between wildtype and SCID was did not quite reach 
significance (p=0.06 for both IL-5 and IL-13). Other cytokines were either 
undetectable (GM-CSF, IFNy, IL-1a/(3, and IL-2) or not affected by rm IL-33 (IL-6, 
IL-10, IL-12, IL-17, and TNFa).
IN rm IL-33 resulted in a slight, but not significant, increase in many serum 
chemokines (eotaxin-2, TARC, IP-10, KC, MCP-1, MIG, and MIP-1a) but there 
was no difference between wildtype and SCID mice. Interestingly, rm IL-33 induced 
an increase in serum eotaxin-1 only in SCID mice (Figure 3.13D).
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Figure 3.11 IN rmlL-33 Induces eosinophilic airway Inflammation
BALB/c wildtype and SCID mice were given 2pg rm IL-33 IN for 7 days and tissues harvested. H&E 
stained lung sections were examined for eosinophilic inflammation; (A) WT PBS (B) SCID PBS (C) 
WT rmlL-33 (D) SCID rm IL-33. (E) The lung eosinophil score was assessed as described (n=5).
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Figure 3.12 IN rm IL-33 Increases BAL IgA
BALB/c wildtype and SCID mice were given 2pg rm IL-33 IN for 7 days and tissues harvested. The 
concentration of IgA in (A) serum and (B) BAL was measured by sandwich ELISA. The results 
shown are means ± SEM (n=5; ***p<0.001).
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Figure 3.13 IN rmlL-33 Increases serum IL-5, IL-13, eotaxln-1 and IgE
BALB/c wildtype and SCID mice were given 2pg rmlL-33 IN for 7 days and tissues harvested. The 
concentration of (A) IgE, (B) IL-5, (C) IL-13 and (D) eotaxin-1 were measured by sandwich ELISA. 
The results shown are means ± SEM (n=5; **p<0.01).
3.5. Discussion
In this chapter I have demonstrated that:
1. IL-33 has the same functions in BALB/c and C57BI/6 mice
2. Murine and human IL-33 have the same systemic effects
3. IL-33 induces local innate inflammation
4. IL-33 activity is dependent on ST2  gene expression
5. IL-33 can initiate innate Th2 inflammation in the lung
6. SCID mice have reduced lung inflammation compared to wildtype in 
response to IL-33
I will discuss each of these findings in more detail.
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3.5.1. IL-33 has the same functions in BALB/c and C57BI/6 mice
The systemic effects of human IL-33 in C57BI/6 and BALB/c mice are very similar. 
In both there is an increase in spleen weight and eosinophil counts consistent with 
the rise in serum IL-5, which is vital for eosinophil maturation (reviewed in (365)) 
and mobilisation from the bone marrow (366). C57BI/6 mice were shown to have 
perivascular eosinophil infiltration and goblet cell hyperplasia in the lung, whereas 
BALB/c mice had perivascular eosinophil Infiltration, but airway goblet cell 
hyperplasia was absent. This is consistent with the lack of IL-13 in the serum and 
the essential role of IL-13 in mucus production (89). A local rise In IL-13 was seen 
with IP and IN administration, and there was a rise in serum IL-13 after IN IL-33, 
so the reason for the lack of serum IL-13 after IP IL-33 in BALB/c mice is 
unknown.
Laboratory mouse strains vary in their response to biological stimuli and this is 
particularly true when studying factors involved in Th1/Th2 regulation. For 
instance, C57B1/6 mice have a T h i biased immune response to the parasite 
Leishm ania  m ajor, and quickly clear infection, whereas BALB/c mice have a 
predominantly Th2 response, and quickly succumb (367). The fact that both mice 
have such similar responses to IL-33 is important for 2 reasons. Firstly, 1 will use 
BALB/c mice to study the role of IL-33 in antigen-specific allergic airways 
inflammation (see Chapter 4), so to allow direct comparison it was necessary to 
use BALB/c mice to study innate inflammation. Secondly, this is evidence of the 
wider applicability and relevance of these effects, as they are not restricted to one 
strain.
3.5.2. Murine and human IL-33 have the same systemic effects
I went on to show that murine IL-33 has a very similar systemic effect to human IL- 
33 when given IP to BALB/c mice. The response is dominated by a rise in serum 
IL-5 associated with an increase in spleen size and eosinophil numbers. In 
addition a rise in spleen neutrophils was seen. LPS can induce a neutrophilic 
response, but no neutrophil rise was seen in ST2'^' mice implying this is a genuine 
IL-33 dependent phenomenon, and not due to LPS contamination. Serum IgE was 
also seen to rise. This was attributed to a rise in IL-4 in G57BI/6 mice (1), although 
as with BALB/c, no IL-4 was detected in serum. C57BI/6 mice had shown an 
increase in mRNA expression of IL-4, -5 and -13 in various tissues, but this was 
not examined in BALB/c mice. Perivascular eosinophilic inflammation was seen
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with both human and murine IL-33, but no serum IL-13 or goblet cell hyperplasia, it 
is not clear if this is a generalised effect in all tissues, or if tissues with mucosal 
surfaces (the lung and the gut) are specifically affected. Further work examining 
other tissues is required. Thus the effect of recombinant murine IL-33 in BALB/c 
mice is consistent with the biological activity of human IL-33 in BALB/c and 
C57BI/6 mice. These results indicate that not only is the amino acid sequence and 
structure conserved between species, but also the likely biological function.
In order to investigate the mechanisms by which eosinophils infiltrate the 
pulmonary tissue I also measured the level of chemokines in the serum and found 
eotaxin-2 and TARC to be elevated. Eotaxin-2 is a potent factor attracting 
eosinophils across the endothelium (368) by binding to CGR3. This transmigration 
is increased in the presence of IL-5, through eosinophil activation, and also in the 
presence of IL-1p, through endothelial cell activation. In this model it may be a 
combination of a direct effect of the IL-1 (3-like IL-33 absorbed into the circulation 
acting on endothelial cells, and an indirect effect of IL-5 on circulating eosinophils. 
TARC acts through CCR4 (369), which is not expressed on eosinophils, but is 
present on airway CD3* T cells (370) and on human CD4* iNKT cells (371), and is 
thought to be a major factor in the maintenance of Th2 dominance in asthma. 
There is likely to be a lot of overlap between these two subsets, it is not known 
whether any of these cells are found in the infiltrate. The cellular targets and 
source of cytokines and chemokines are unknown.
3.5.3. IL-33 Induces local Innate Inflammation In the peritoneum
Having shown that IL-33 results in a systemic Th2 type response after IP 
administration, it was logical to examine the extent of local inflammation in the 
peritoneum. Treatment with IL-33 resulted in a massive influx of inflammatory 
cells, mostly eosinophils, but also neutrophils and macrophages. In keeping with 
this a large amount of IL-5 was found, and there was a marked increase in 
eotaxin-1 and -2, both of which are powerful eosinophil chemoattractants through 
binding to CCR3.
Neutrophils also express CCR3 and migrate in response to eotaxin-1 (372), which 
may explain the presence of some neutrophils in the peritoneum. However, it is 
not clear why human IL-33 did not attract neutrophils into the peritoneum, whereas 
murine IL-33 did. One possibility is contamination of the murine IL-33 with LPS or
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another pro-inflammatory bacterial product, but the fact that ST2^ mice did not 
have neutrophils in the peritoneum would argue against this, and suggests it is a 
genuine IL-33 mediated phenomenon. A further possibility is that the native murine 
IL-33 likely has different binding affinity for murine ST2, and therefore the 
downstream response generated may differ slightly. Further work examining the 
structure and kinetics of the IL-33 / ST2 interaction, and differential downstream 
signalling of human and murine IL-33, would be required to investigate this.
Macrophages were also elevated in the peritoneum. They express CCR4, which is 
thought to be important for their innate immune functions (373), so the elevated 
peritoneal levels of TARC, which acts via CCR4, would explain why IL-33 
attracted macrophages into the peritoneum.
Mast cells are thought to constitute up to 5% of cells recovered from the 
peritoneum, but can be difficult to identify and purify. IL-33 has recently been 
shown to have a role in mast cell maturation and activation (374-376), but mast 
cells were not identified in the peritoneum after IL-33 treatment. However, I did not 
use any mast cell specific stains, nor any indirect measures of mast cell 
accumulation and function, such as tissue myeloperoxidase levels, so it may still 
be that mast cells play an important role in the peritoneal inflammation induced by 
IL-33. There was also a large increase in peritoneal IL-13, and it is possible that 
this reflects the presence of mast cells, as they have been shown to produce IL-13 
after IL-33 stimulation even in the absence of IgE (377). Mast cells mature in the 
tissues, and the immature forms found in the blood are not active, which may 
explain why IL-13 is found at much higher levels in the peritoneum than the serum.
IgA levels were also markedly elevated in peritoneal fluid. It is not known if this is 
due to non-specific capillary leak of plasma proteins, including IgA, into the 
peritoneum, or IL-5 induced up-regulation of production by peritoneal B1 
lymphocytes (378).
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3.5.4. IL-33 activity Is dependent on ST2 gene expression
All of the measures of inflammation, both systemic and local, were also examined 
in ST2“^“ BALB/c mice, but were all negative, implying that these effects of IL-33 
are dependent on ST2  gene expression. This is important for a number of 
reasons.
As discussed in the introduction (section 1.6), the IL-33  and ST2  genes are 
expressed in various cells and tissues either constitutively or induced by pro- 
inflammatory mediators. IL-33 has been shown to bind to and signal through ST2L 
on the cell surface, and result in Th2 type inflammation in mice. ST2'^‘ mice and 
exogenous sST2 administration have been shown to modulate immune responses 
(306,315,331). Therefore IL-33 seems to play a role in initiating and regulating 
immune responses by acting as a cytokine. More recently IL-33 has been found 
intracellularly in the endothelium of chronically inflamed tissues, where it may 
function as a nuclear factor rather than a cytokine (255), and independent of ST2  
expression. However, its role in the nucleus is unknown. As the present results are 
ST2  dependent they are in keeping with the role of IL-33 as a cytokine.
Human and murine IL-33 have only 55% homology at the amino acid level (1), 
therefore it is possible that the effects seen with human IL-33 are due to cross­
reaction with a different receptor in vivo. It is also possible that both human and 
murine IL-33 could bind to an additional receptor other than ST2L. Also, rh and 
rm IL-33 were both produced from transfection into E  co li which may result in the 
presence of pro-inflammatory contaminants. For instance, low doses of LPS have 
been shown to predispose to a Th2 type antigen-specific response in the airway 
(119). it is therefore possible that recombinant IL-33 could be processed as an 
antigen and a low dose of contaminating LPS bias towards a Th2 type antigen- 
specific response. These confounding possibilities are excluded by the negative 
results seen on ST2" '^ mice.
Taken together these results further validate the use of rh and rm IL-33 for use as 
biological reagents, by demonstrating they have almost identical roles in different 
strains of mice, dependent on ST2  gene expression. Initial studies of ST2  gene 
function were hampered by the lack of a known ligand until it was found to be IL- 
33, and so some of the data presented were inconsistent or conflicting. This likely 
reflects not just differences in the model systems used, but also drawbacks in the
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approaches taken. In some experiments ST2^, lacking both ST2L and sST2, were 
used to define the role of ST2L. No conclusions can be reached about the relative 
contributions of each when both are lacking, and the effects seen after the loss of 
a receptor such as ST2L do not necessarily mirror the effects seen when that 
receptor is stimulated by ligand binding. In other experiments anti-ST2 antibodies 
or recombinant sST2 were used to block ST2 function, but a stimulating action 
either through ST2L or via another receptor could not be excluded. In addition, 
recombinant sST2 was conjugated to the Fc portion of lgG1 for purification 
purposes. Not only is this is a physically large molecule that could have steric 
hindering effects, it could be effective through binding to FcyR receptors, which 
are known to have potent immunomodulatory properties (reviewed in (379)). The 
identification of IL-33 as the ligand for ST2L opens up the potential to use 
recombinant IL-33, IL-33 gene knockout mice, and anti-IL-33 antibodies as 
reagents to confirm and extend previous results.
3.5.5. IL-33 can Initiate innate Th2 inflammation In the lung
As mentioned in the introduction to this chapter, administration of IL-4 or IL-13 
directly to the airways results in many of the features of asthma. Since IL-33  and 
ST2  are expressed in the lung, I hypothesised that IL-33 would induce an innate 
Th2 type response.
Administering IL-33 to the airways of mice did induce a strong Th2 type response 
with accumulation of inflammatory cells in the BAL dominated by eosinophils, but 
also including neutrophils and macrophages. In keeping with this, eotaxin-1 and -2 
were elevated, as were TARC and MIP-1a. MIP-1a binds to CCR1, and is 
important in transendothellal migration of most inflammatory cells, but particularly 
monocytes/macrophages (380). IL-5 and IL-13 were also elevated in the BAL, as 
they both had been in the peritoneal wash, but IL-4 was not seen. No change in 
serum IgA was seen, but IgA was elevated in BAL. This could be due to capillary 
leak, but most IgA in bronchial secretions is the result of active transport into the 
lumen (381). Eosinophilic inflammation was also seen peribronchially and 
perivascularly, with goblet cell hyperplasia of the epithelium.
in addition a systemic Th2 type response was also seen. IL-5 and IL-13 were 
elevated in serum after IN IL-33, which was in contrast to the IP route of 
administration, where only IL-5 was elevated. In C57/BI6 mice both IL-5 and IL-13
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were elevated in serum after IP IL-33 (1). It is not clear why this difference occurs 
between IN and IP IL-33. The levels of IL-13 in BAL and in the peritoneal wash 
were similar. The level of IL-13 in serum after IN IL-33 was actually slightly higher 
than in BAL, suggesting that the IL-13 may be produced in perivascular cells, or 
even at distant sites, such as lymphoid tissues or the liver.
Total serum IgE was also found to be elevated. Interestingly the severity of asthma 
correlates better with an increase in total IgE rather than antigen-specific IgE 
(382).
Therefore, like IL-4 and IL-13, IL-33 can also induce many features of asthma 
independent of antigen, although which of these effects are direct, and which are 
through induction of cytokines such as IL-5 and IL-13 is not known. IL-25 has also 
been shown capable of inducing profound eosinophilic airway inflammation in 
naïve mice, also through increased IL-5, IL-13, eotaxin-1 and eotaxin-2, but also 
with the addition of increased IL-4 (109,110). In both these cases (IL-33 and IL-25) 
the pathological changes seen are very similar to those seen after direct instillation 
of IL-13 (89), which suggests these cytokines are acting upstream to induce IL-13 
production. Further work is needed to elucidate the hierarchy of cytokine release 
and function in the allergic airway, and so determine the relative contribution of 
each.
3.5.6. SCID mice have reduced lung inflammation compared to wildtype
An almost identical response was seen in SCID mice as with wildtype mice, but 
ten-fold less in magnitude. SCID mice (383) have a lack of B and T lymphocytes, 
due to a defect in VDJ recombination of antigen receptors (384). However, other 
immune cell lineages are unaffected and function normally. In fact, they have 
increased numbers of some cells such as NK cells (385). Therefore the response 
to IL-33 must be largely, but not entirely, dependent on a lymphocyte subset. It 
seems unlikely that the effect of IL-33 was due to an effect on mainstream 
lymphocytes as they require antigen priming first, although this data does not 
exclude this possibility as there may be a population of pre-existing primed T cells 
in the naïve wildtype mice. However, SCID mice also lack iNKT cells (38), The 
possible role of INKT cells in innate and adaptive inflammation has been 
discussed in more detail in Chapter 1. Of relevance here is that although they are 
constitutively present in the lungs in only small numbers (386), they can express
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large amounts of cytokines immediately after activation, which can occur in the 
absence of antigen (387,388). In addition, repeated stimulation results in 
predominantly Th2 cytokine release (152). NKT2 cells have been shown to 
express ST2L (287) Therefore it is possible the innate effects of IL-33 in the lung 
are mediated by this subset of cells, which are increasingly shown to play major 
roles in autoimmunity, allergy, tumour immunity and response to infections 
(reviewed in (389)). The residual inflammation that occurs in SCID mice must be 
due to other non-lymphoid cells expressing ST2L in the lung, the most likely 
candidate being mast cells, which can produce Th2 type cytokines when 
stimulated. It may be that these are in fact the first cells to respond in wildtype 
mice, in which case iNKT or other lymphocytes may simply amplify the response. 
Further work is needed to define precisely which cells respond directly to IL-33, 
and which are activated indirectly.
The one aspect of the response where SCID mice did not have a reduction in the 
outcome measured was the serum level of eotaxin-1, which was increased quite 
markedly. The reason for this is not clear. It may be that SCID mice show different 
kinetics in the response to IL-33, and had we looked at other time points the 
pattern of release in both WT and SCID mice would be apparent. However, given 
that all other measures were reduced this seems unlikely. It is possible that other 
mediators we have not examined may also be increased in SCID mice and 
account for the increase in eotaxin-1. For instance, IL-25 can be produced by 
activated mast cells (390)), and when instilled into the airways can induce eotaxin- 
1 expression (110). Further studies are required to elucidate the downstream 
mechanism of actions of IL-33 in both WT and SCID mice.
3.6. Conclusions
In this chapter I have demonstrated that IL-33 has the same functions in BALB/c 
and C57BI/6 mice and that murine and human IL-33 have the same systemic 
effects. I have shown that regardless of the route of administration IL-33 initiates a 
local and systemic type 2 innate inflammatory response that is dependent on ST2  
expression. The local response in the lung shares many features of asthma, and 
experiments with SCID mice suggest that both lymphoid and non-lymphoid cells 
may have an important role in the innate response triggered by IL-33.
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Having shown that IL-33 may have a role in innate immunity, in the following 
chapters I will demonstrate the potential role of IL-33 in modulating established 
Th2 (Chapter 4) and Th1/Th17 (Chapter 5) antigen-specific immune responses.
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Chapter 4
IL-33 and ST2 In allergic airways disease
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4.1. Introduction
In Chapter 3 I demonstrated that rmIL-33 administered directly to the airways in 
the absence of antigen could elicit an innate Th2 type effector response. This 
effect was dependent on the presence of the ST2  gene products, in particular 
ST2L, the receptor for IL-33. Th2 type responses in the airway play a vital role in 
the initiation and persistence of asthma. Previous investigations into the role of the 
ST2  gene demonstrated that serum sST2 is elevated in exacerbations of asthma 
(340). In murine models of OVA-induced Th2 airway inflammation, ST2L and sST2 
are expressed in acute and chronic disease (318,320) and inhibition of ST2L 
function, by blocking antibodies or sST2-Fc decoy receptors, reduced airway 
inflammation (141,291,315). This suggests a pro-inflammatory role for ST2L. In 
contrast to these findings, studies of OVA-induced Th2 airway inflammation using 
two strains of ST2 ''" mice have demonstrated no effect with C57BI/6 mice (327) or 
enhanced inflammation with BALB/c mice (329). Thus the roles of ST2  gene 
products and IL-33 still require considerable clarification in allergic airways 
disease.
To investigate this we prepared rm IL-33 as the physiological ligand for ST2L, and 
used ST2^ mice on the Th2-dominant BALB/c background. The experiments 
described in this chapter relate to the induction of allergic airways inflammation in 
BALB/c mice, and the effect of IL-33 in the effector phase by administering rm IL- 
33 into the airways during allergen challenge. I used ST2"^ mice to confirm the 
specificity of action of IL-33 in this model.
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4.2. Intranasal administration of IL-33 exacerbates 
allergic airways inflammation
Allergic airways disease was Induced in BALB/c mice as described in the materials 
and methods (section 2.5.1). In pilot experiments I determined the optimal dose of 
OVA and number of challenges in 872""^^ and ST2^ mice. The response in ST2’ '^ 
mice was similar to ST2^^"', but at a lower level. With 3 IN doses of OVA the airway 
cellular response followed a dose response up to 50pg per mouse, but the 
percentage of eosinophils in the BAL did not increase above lOpg (Figure 4.1 A). 
In ST2^^^ and ST2^ mice a single dose of lOpg OVA was sufficient to induce a 
small but measurable airway response, and the kinetics were similar (Figure 4.1 B). 
In ST2+/+ mice 2 doses were sufficient to induce a strong airway response, 
whereas in ST2^ mice 3 doses were required (Figure 4.10).
The results shown here are representative of two experiments performed using the 
optimised protocol for mice (Figure 4.1 D). This protocol was designed to
elicit a moderate amount of airway inflammation, thus allowing any exacerbating 
effects of rm IL-33 to be apparent. The dose of rm IL-33 used was the same as for 
inducing innate eosinophilic airway inflammation (section 3.4). These results 
demonstrate that rm IL-33 administered to the airways at the same time as OVA 
during allergen challenge exacerbates allergic airways inflammation.
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Figure 4.1 Administration of iL-33 in aiiergic airways infiammation
In all allergic airway disease experiments ST2+/+ and ST2-/- BALB/c were sensitised on day 1 by IP 
injection of 100pg OVA in 100pl sterile PBS and lOOpl of 2% alum. (A) Allergic airway inflammation 
was induced by IN instillation of 30pl sterile PBS containing 2.5 to 50pg OVA on days 9,10 and 11 to
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determine the optimum dose to induce eosinophilic inflammation. (B) An IN dose of 10pg per mouse 
was administered on 1 (day 9), 2 (days 9 and 11) or 3 (days 9,10, and 11) occasions to determine 
the optimum number of allergen challenges. (C) A single IN dose of lOpg was administered and the 
airway response monitored to determine the kinetics of the response. BAL total and differential cell 
counts were performed as described in the materials and methods. (D) An optimised model of 
aiiergic airway inflammation was obtained with 2pg OVA ± 2pg rm IL-33 on days 9 and 11. Mice 
challenged with PBS or rmlL-33 alone were used as negative controls. Mice were culled 24 hours 
after the second challenge, and serum, BAL, lungs, and draining lymph nodes were obtained for 
analysis.
4.2.1. IL-33 exacerbates the inflammatory infiltrate in the lung
Following OVA sensitisation, airway challenge with OVA elicited typical 
peribronchial and perivascular eosinophilic inflammation, epithelial shedding and 
goblet cell hyperplasia. Challenge with rm IL-33 in the absence of antigen was 
able to induce a similar level of inflammation, and the combination of OVA and IL- 
33 was synergistic, producing a profound inflammatory response (Figure 4.2). A 
similar pattern was observed for the immunological parameters measured below.
4.2.2. IL-33 exacerbates inflammation in the airway lumen
Following OVA sensitisation, subsequent airway challenge with OVA or IL-33 
significantly increased the BAL eosinophil, macrophage and neutrophil cell counts, 
and the concentration of cytokines and chemokines (Figure 4.3). These increases 
were markedly enhanced following challenge with a combination OVA and IL-33.
IL-5 and IL-13 were each increased above control by a similar amount in mice 
given OVA or IL-33, and the combination produced a marked increase (Figure 
4.4A-B). The concentration of IL-4 was increased by OVA challenge, but not by IL- 
33, and the combination of OVA and IL-33 only increased IL-4 slightly (Figure 
4.40). Other cytokines were either undetectable (GM-CSF, IFNy, IL-2, IL-12, 
TNFa, IL-1a, IL-1(3 and IL-17) or unchanged (IL-10).
Eotaxin-1, eotaxin-2 and TARC were increased by OVA or IL-33 challenge alone, 
and more so by the combination of both (Figure 4.4D-F). Monocyte chemotactic 
protein 1 (MCP-1) and MIP-1 a were also increased, but not significantly, by the 
combination of OVA and IL-33. Other chemokines were either undetectable (TCA- 
3, IP-10, MIG) or unchanged (KG).
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4.2.3. IL-33 increases the antigen-specific recall response
The effect of IL-33 on the antigen-specific cell-mediated immune response was 
examined by restimulating freshly isolated DLN cells with OVA in vitro. Lymph
node cells from sensitised but not challenged mice (PBS group) proliferated in
response to OVA, and this was increased in the groups of mice challenged with 
either OVA or IL-33. The group challenged with a combination of OVA and IL-33 
had greater proliferation (Figure 4.5A), and also exhibited a high level of 
spontaneous proliferation ex vivo  (Figure 4.5B).
The pattern of IL-5 production by lymph node cells was the same as that seen in 
BAL, with a small increase from mice treated with OVA or IL-33, and a marked 
increase with the combination (Figure 4.6A). This effect was even more marked for 
IL-13 production, where mice treated with OVA or IL-33 did not produce any 
increase above control, but the combination did (Figure 4.6B). IL-4 production was 
increased in mice given OVA, but not those given IL-33. IL-10 was not increased 
in either the OVA or IL-33 groups. However, IL-4 and IL-10 production were both 
increased markedly in mice given OVA and IL-33 (figure 4.6C-D). IFNy and IL-12 
were at the bottom of the assay detectable limits, and were unaffected by IL-33.
The production of chemokines eotaxin-1, eotaxin-2 and TCA-3 by lymph node 
cells was unaffected by IL-33, however TARC was increased by OVA or IL-33, and 
enhance by the combination of both (Figure 4.6E).
4.2.4. IL-33 increases Th2 cytokines and chemokines in serum
IL-5 is a potent stimulator of eosinophil maturation and mobilisation from bone 
marrow. Although just detectable in mice given OVA or IL-33, serum IL-5 was 
increased by the combination (Figure 4.7A). The other key cytokines in this 
experiment (IL-4, 13, and IFNy) were not detectable in serum
OVA or IL-33 increased the levels of eoataxin-1, eotaxin-2 and TARC (Figure 
4.8B-D) in the serum, and IL-33 was able to enhance the effect of OVA. TCA-3 
was not detected.
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Figure 4.2 iL-33 increases the infiammatory ceii infiitrate in the iungs
H&E stained lung sections were examined by light microscopy and eosinophils identified by 
morphological criteria. (A) The extent of peribronchial and perivascular inflammation was scored as 
described. Data are means ± SEM (***p<0.001, n=7). Photos show representative sections from 
mice challenged with (B) PBS, (C) rmlL-33, (D) OVA and (E) OVA + rmlL-33.
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Figure 4.3 IL‘33 increases BAL ceii counts
BAL total and differential cell counts were performed as described in the materials and methods. 
Airway challenge with OVA and rm IL-33 resulted in increased (A) total cells, (B) eosinophils, (C) 
macrophages, (D) neutrophils and (E) lymphocytes, compared to OVA or IL-33 alone. Data are 
mean ± SEM (n=8; *p<0.05, **p<0.01, ***p<0.001).
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Figure 4.4 IL-33 Increases BAL cytokines and chemokines
BAL supernatants were harvested and stored at -20°C until cytokines and chemokines were 
measured by sandwich ELISA or multiplex. Airway challenge with OVA and rmlL-33 resulted in 
increased (A) IL-5, (B) IL-13, (C) IL-4 (D) eotaxin-1, (E) eotaxin-2 and (F) TARC compares to OVA or 
IL-33 alone. Data are means ± SEM (n=8; *p<0.05, **p<0.01, ***p<0.001).
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Figure 4.5 IL-33 Increases proliferation of DLN cells
Thoracic lymph nodes draining the airways (DLN) were harvested and single cell suspensions 
obtained. Cells were cultured in 96 well plates in (A) medium alone or (B) with 1 mg/ml OVA for the 
recall response. For the last 8 hours of culture ^H-thymidine was added and incorporation into cells 
measured at 96 hours by betascintography. Lymph node cells from mice challenged with OVA and 
rm IL-33 had increased (A) antigen-specific and (B) spontaneous proliferation compared to OVA or 
IL-33 challenge alone. Data are means ± SEM (n=8; **p<0.01, ***p<0.001).
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Figure 4.8 iL-33 increases DLN cytokine and chemoklne production
Thoracic lymph nodes draining the airways (DLN) were harvested and single cell suspensions 
obtained. Cells were cultured in 24 well plates with 1 mg/ml OVA for the recall response. 
Supernatants were harvested at 72 hours and frozen at -20°C until cytokines and chemokines were 
measured by sandwich ELISA or multiplex. Lymph node cells from mice challenged with OVA and 
rm IL-33 had increased (A) IL-4, (B) IL-5, (C) IL-13, (D) IL-10 and (E) TARC compared to OVA or IL- 
33 challenge alone. Data are means ±  SEM (n=8; *p<0.05, **p<0.01, ***p<0.001).
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Figure 4.7 IL-33 increases serum levels o f cytokines and chemokines
Serum was harvested and stored at -20°C until cytokines and chemokines were measured by 
sandwich ELISA or multiplex. Airway challenge with OVA and rm IL-33 resulted in increased IL-5 (A), 
eotaxin-1 (B), eotaxin-2 (C), and TARC (D), compared to challenge with OVA or IL-33 alone. Data 
are means ± SEM (n=8; *p<0.05, **p<0.01, ***p<0.001).
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4.3. Exogenous IL-33 has no effect on airways 
Inflammation In ST2 ' mice
In order to demonstrate that the effect of IL-33 in enhancing OVA-induced airways 
inflammation was specific, and depended on ST2L, the experiments above were 
repeated using BALB/c ST2'^‘ mice. Again pilot experiments were used to optimise 
the model in terms of the dose of OVA used for airway challenge, and the results 
shown are representative of two repeat experiments (figure 4.8). The dose of OVA 
and the number of challenges were higher than those used in examining rm IL-33 
in ST2^^^ mice in order to generate a similar level of baseline inflammation for 
comparison, and so any exacerbating or ameliorating effect of rm IL-33 would be 
apparent. In addition this protocol was used to compare ST2^^^ and ST2'^“ mice 
directly, as with lower doses and fewer challenges the ST2^ mice made very little 
response, and did not differ significantly from PBS negative controls.
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Figure 4.8 Administration of IL-33 in allergic airways inflammation in ST2 ' 
mice
On day 1 BALB/c mice were sensitised by IP injection of 100pg OVA in 100pl sterile PBS and 100pl 
of 2% alum. Allergic airway inflammation was induced by IN instillation of 30pl sterile PBS containing 
10pg OVA ± 2pg rmlL-33 on days 9 ,10  and 11. Mice challenged with PBS or rmiL-33 alone were 
used as negative controls. Mice were culled 24 hours after the second challenge. Serum, BAL, 
lungs, and draining lymph nodes were obtained for analysis as described in the materials and 
methods.
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Airway challenge with OVA in ST2'^' mice elicited eosinophilic inflammation and 
increased BAL IL-5 concentration similar in character to that seen in wildtype mice 
(Figure 4.9). In the ST2^ mice IL-33 administration did not enhance any features 
of airway inflammation, and there was no difference in any cellular or mediator 
variables from BAL, serum or lymph node cell restimulation with the addition of IL- 
33. This demonstrated that the presence of ST2L was specific and critical for the 
effects of IL-33 described in the experiments using wild-type mice above.
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Figure 4.9 iL-33 has no effect on airway inflammation in ST2 " mice
H&E stained lung sections were examined by light microscopy and eosinophils identified by 
morphological criteria. The extent of peribronchial and perivascular inflammation was scored as 
described. BAL total and differential cell counts were performed as described in the materials and 
methods. BAL supernatants were harvested and stored at -20“C until cytokines were measured by 
sandwich ELISA Airway challenge with OVA and rmlL-33 resulted in no increase in (A) tissue 
eosinophil score, (B) total BAL cells, (C) BAL eosinophils, or (D) BAL IL-5 compared to OVA or IL-33 
alone. Data are means ± SEM (n=5; ***p<0.001).
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4.4. ST2  ^ reduces allergic airways inflammation
It was noted that a higher dose of OVA given more often was required to elicit a 
similar level of inflammation as seen In wildtype mice, suggesting that in contrast 
to recent findings (329), ST2^ in BALB/c mice may result in reduced airways 
inflammation in our model. To test this hypothesis, wildtype and ST2^ mice were 
directly compared using the same protocol (figure 4.8). The results shown are 
representative of 3 repeat experiments.
4.4.1. ST2 ^  reduces the inflammation In lung tissue and the airways
ST2^ mice had a reduced eosinophilic infiltrate compared to wildtype (Figure 
4.1 OA). BAL celluiarity was also decreased (Figures 4.10B-D), which was largely 
due to a reduction in eosinophils, but also some reduction in macrophages. 
Neutrophils and lymphocytes were present at low levels, but there was no 
difference between the groups.
There was a small, but not significant, reduction in BAL IL-4, whereas IL-5 was 
markedly reduced (Figure 4.11A-B). No difference in IL-13 was seen, although 
basal levels were already quite low. IFNy and GM-CSF were not detectable.
The chemokines eotaxin-1, eotaxin-2 and TARC were all reduced in BAL (Figure 
4.11C-E). MIP-1a was also reduced, but not significantly, in ST2^ mice. Other 
chemokines were unchanged (KC) or undetectable (IP-10, MCP-1, MIG and TCA- 
3).
No cytokines or chemokines were detectable in the serum.
4.4.2. ST2'^ ' has no effect on the antigen-specific recaii response
Mixed lymph node cells from ST2'^' mice did not proliferate any less than wildtype 
in response to OVA restimulation (Figure 4.12A). The production of Th2 cytokines 
(Figure 4.12B-D) was unaffected by ST2^, as was chemokine production (eotaxin- 
1, eotaxin-2 and TARC). IFNy and GM-CSF were undetectable.
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Figure 4.10 Eosinophilic inflammation and BAL ceil counts are reduced in 
STZ'- mice
(A) H&E stained lung sections were scored for eosinophilic lung inflammation as described. BAL total 
and differential cell counts were performed as described in the materials and methods. Airway 
challenge with OVA in ST2^ mice resulted in decreased (B) total cells, (0) eosinophils, and (D) 
macrophages compared to challenge with OVA in ST2+/+ mice. Data are means ± SEM (n=8; 
*p<0.05, **p<0.01,***p<0.001).
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Figure 4.11 BAL cytokines and chemokines are reduced in S T 2  " mice
BAL supernatants were harvested and stored at -20°C until cytokines were measured by sandwich 
ELISA. Airway challenge with OVA in ST2-/- mice resulted in decreased (A) eotaxin-1, (B) eotaxin-2, 
(C) TARC compared to wildtype mice. Data are means ± SEM (n=8; *<p<0.05, **p<0.01,
***p<0.001).
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Figure 4.12 No reduction in DLN cytokine production in ST2' '^ mice
Thoracic lymph nodes draining the airways (DLN) were harvested and single cell suspensions 
obtained. Cells were cultured in 24 well plates with 1 mg/ml OVA for the recall response. 
Supernatants were harvested at 72 hours and frozen at -20°C until cytokines were measured by 
sandwich ELISA or multiplex. Lymph node cells from ST2-/- mice had (A) no difference in 
proliferation, (B) slightly decreased IL-5 (NS), but no difference in (0) IL-13, or (D) IL-4. Data are 
means ± SEM (n=8).
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4.5. Discussion
In this chapter I have demonstrated that:
1. IL-33 exacerbates OVA-induced allergic airway inflammation
2. IL-33 alone can induce airway inflammation in sensitised mice
3. The effect of IL-33 in airway inflammation is dependent on ST2  
gene expression
4. ST2“'“ mice have reduced airway inflammation
I will discuss each of these points below in more detail.
4.5.1. IL-33 exacerbates OVA-induced allergic airway inflammation
When given at the same time as OVA challenge, intranasal IL-33 was able to 
exacerbate the effector phase of allergic airway inflammation. An increase In all 
inflammatory cells, but particularly eosinophils, was seen in the airway lumen 
(BAL) and in the tissues, although the actual pathology was similar to OVA alone. 
These pathological changes are likely to be mediated through IL-5 and IL-13, and 
the Th2 chemokines eotaxin-1, eotaxin-2 and TARC, all of which were increased 
in BAL and/or serum. Of note, however, IL-4 production was not significantly 
affected. The cells on which IL-33 acts, and therefore the source of these 
cytokines and chemokines, are unknown. I have already shown that IL-33 can 
induce an innate type 2 response, and it may be that ST2L expression on cells 
such as mast cells (288), macrophages (284) or even NKT cells plays a role. 
However, antigen sensitisation and challenge increases the expression of ST2L on 
Th2 cells (318), and so IL-33 may increase Th2 cell responses directly.
In keeping with this, mixed lymph node cultures from mice that received OVA and 
IL-33 proliferated spontaneously, and had increased proliferation after OVA 
restimulation in vitro. Increased levels of IL-5, IL-13 and TARC were seen, and in 
contrast to BAL, IL-4 and IL-10 production were also increased. Whether these 
increases were due to increased cell numbers, or increased production from 
individual cells, is unknown. It is notable that IL-33 was able to exacerbate 
inflammation despite a large increase in IL-10, which plays an immunosuppressive 
role in asthma (391).
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4.5.2. IL-33 alone can induce airway inflammation in sensitised mice
It was noticeable that IL-33 given to mice previously sensitised to OVA resulted in 
a very similar response to rechallenging with OVA. I have previously shown that 
IL-33 can induce an innate type 2 response in the lung. Pilot experiments as part 
of that work showed that, although a single dose of IN IL-33 could induce 
detectable levels of eosinophils in the BAL of some mice, at least 3 doses were 
required to elicit a significant increase in BAL eosinophils in all mice (data not 
shown). Even then the numbers seen were not as high as in these experiments. 
Therefore, although the innate effects of IL-33 may be contributing, possibly 
through the initiation and localisation of the response to the lung, the pre­
sensitisation of the mice seems important. Since sensitisation and challenge 
increases the expression of ST2L on Th2 cells, it is possible that IL-33 could 
directly activate Th2 cells in the absence of further antigen.
In contrast to the previous study by Schmitz et al (1), who showed systemic IL-33 
induces expression of IL-4 and IL-5 mRNA, IN IL-33 alone did not induce the 
expression of IL-4 protein in the BAL, serum or in DLN cultures, whereas it 
induced as much IL-5 as OVA did. This is in keeping with previous evidence that 
IL-33/ST2L plays a particular role in IL-5 expression. However, in combination with 
OVA, IL-33 did induce an increase in IL-4, particularly in DLN cultures, which 
suggests this is an indirect mechanism, and relies on enhancement of antigen- 
specific responses. This echoes the effect of IL-18 discussed in the introduction, 
where IL-18 can augment IL-4 and IL-13 in the presence of antigen, but only IL-13 
in its absence (29).
4.5.3. The effect of IL-33 in airways inflammation is dependent on ST2
As with the innate response, IL-33 had no effect on airway inflammation either 
alone, or in combination with OVA, in ST2-/- mice. Thus the effects seen are not 
due to adjuvant effects of contaminants such as LPS, and are dependent on the 
binding of IL-33 to ST2L.
4.5.4. ST2  ^ reduced airway inflammation
Here I have demonstrated that ST2-/- mice have a reduced histology score and a 
reduction in eosinophils and macrophages in the BAL, mediated by a reduction in 
BAL IL-5 and Th2 chemokines. Proliferation and cytokine production from DLN 
was largely unaffected, which is in contrast to the pronounced effect of IL-33 on
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DLN cells. Whilst this partly reflects the differences seen when modulating either a 
receptor or its ligand, it probably also reflects the fact that other compensatory 
mechanisms may be acting due to the redundancy seen in inflammatory cytokine 
networks. What it does highlight is the important role of IL-33/ST2L in eosinophil 
accumulation in the lung, through upregulation of IL-5, eotaxin-1 and eotaxin-2.
These result are in contrast with the recent report from Mangan et al (329), who 
showed that ST2-/- in BALB/c mice resulted in an increase in eosinophils in BAL, 
and a reduction in macrophages. They did not find a reduction in BAL IL-5, 
although they also showed no change in other BAL cytokines, or DLN cytokine 
production. This may reflect differences in the model, and that other mechanisms 
may have been able to overcome, or even overcompensate for, the loss of ST2.
It is interesting to note that Mangan et al (329) showed that IL-33 mRNA is 
upregulated in lung tissue after antigen challenge, and IL-33 may be one 
mechanism by which the Th2 effector response can be promoted. However, other 
mechanisms must also be important, as IL-33 does not appear to induce IL-4 
protein expression, and ST2-/- mice can still develop allergic airways inflammation.
When interpreting this data the presence of confounding factors must not be 
underestimated. There are many unknown variables in the interactions of IL-33, 
ST2L and sST2. I have not taken into account the expression of sST2 seen in 
airways inflammation in mice (319), and in asthma exacerbations in humans (340), 
and how it may interact with IL-33 and ST2L to modulate inflammation. The 
drawback of using ST2-/- mice is that both ST2L and sST2 are lost, so it is difficult 
to distinguish between their relative roles in inflammation.
4.6. Conclusions
In this chapter I have demonstrated that IL-33 exacerbates the effector phase of 
allergic airways inflammation, and that this is dependent on ST2  expression. I 
have also demonstrated that ST2-/- results in a reduction of allergic airways 
inflammation. Together these results highlight the importance of IL-33/ST2L in 
eosinophil accumulation in the tissues.
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Having examined the role of IL-33 in innate and allergic Th2 inflammation, in the 
next chapter I will investigate its potential role in autoimmune Th1/Th17 
inflammation.
150
Chapter 5
IL-33 and ST2 in collagen-induced arthritis
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5.1. Introduction
In the previous chapters I have shown that IL-33, a novel member of the IL-1 
family of cytokines, can induce an innate type 2 response, and can exacerbate the 
effector phase of an established Th2 response. The other IL-1 family members, IL- 
1 and IL-18, are pleiotrophic pro-inflammatory cytokines (243,245), and in addition, 
IL-18 has been shown to enhance both Th i and Th2 responses, depending on the 
circumstances (246,392).
Rheumatoid arthritis is an autoimmune inflammatory condition primarily affecting 
the joints. Initially characterised as a Th1 disease, it is becoming clear that T h i7 
cells mediate the effector phase of inflammation and joint destruction 
(205,208,213). TNFa and IL-1 have a prominent role in both inflammation and 
bone erosion, and inhibiting these is currently being targeted as a therapeutic 
option in the clinic .(215,221).
I hypothesised that the pro-inflammatory functions of IL-33/ST2 would not be 
restricted to Th2 type Inflammation. I therefore examined the role of IL-33/ST2 in 
CIA, a model of Th1/Th17 autoimmune arthritis. The data presented in this chapter 
represents pilot experiments performed to investigate this hypothesis. I induced 
CIA in the susceptible DBA/1 strain of mice and administered IP rmIL-33 during 
the effector phase, which exacerbated disease. I also induced CIA in ST2^ DBA/1 
mice, which had been bred in-house, which ameliorated disease.
5.2. IP rmlL-33 exacerbates CIA
CIA was induced as described in the materials and methods. The dose of rmlL-33 
used was the same as for inducing an innate type 2 response, and it was felt that 
5 subsequent doses after antigen boosting on day 21 would be sufficient, as in 
previous work even a single IP dose had measurable effects. Mice were culled at 
early (day 26), middle (day 31) and late (day 38) time points after rm IL-33 
administration to investigate the kinetics of the response (figure 5.1).
Intraperitoneal
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Figure 5.1 A murine model o f collagen-induced arthritis
Mice were immunised intradermaily at the base of the tail with 50|jg bovine collagen type II (Cll) in 
complete Freund’s adjuvant (CFA) on day 1, and the response boosted on day 21 with 50pg Cll in 
PBS intraperitoneally. Where indicated 200pl sterile PBS ± 0.8pg mlL-33 was given intraperitoneally 
for 5 consecutive days from day 21. Footpads were measured using callipers every 1-2 days from 
day 21, and the clinical score of each paw assessed at the same time. Mice were culled at various 
times during disease development and draining lymph nodes, spleen and ankle joints harvested to 
assess the immune response.
5.2.1. IL-33 exacerbates disease severity of CIA
Treatment with rm IL-33 did not increase the number of mice that developed 
arthritis (Figure 5.2A), which was close to 100% in both groups. However, it did 
Increase the average clinical score per affected mouse (Figure 5.2B). When this 
was examined further it became apparent that the number of affected paws per 
mouse was increased (Figure 5.3A), and also the thickness of the swelling (Figure 
5.3B). The clinical score per affected joint was not increased as loss of function 
was rarely seen (Figure 5.3C).
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5.2.2. IL-33 increases early spleen proliferation
The proliferation of mixed splenocyte cultures was increased at the early time 
point, and this was increased in the IL-33 group (Figure 5.4A). At later time points 
there was very little proliferation in either group. The proliferation of mixed DLN 
cells gradually increased at each time point, but there was no difference between 
the groups.
5.2.3. IL-33 Increases cytokine production in spleen and DLN
Treatment with IL-33 induced an early burst of cytokine production by mixed 
splenocyte cultures (Figure 5.4B). IL-17, TNFa, IL-12, and IFNy were all increased 
at the early time point compared to the untreated group. IL-17 production was 
sustained at a higher level at the late time point in the IL-33 group, but there was 
no difference in the other cytokines at this time point. In contrast, mixed DLN 
cultures from the IL-33 treated group produced higher concentrations of lL-17, 
TNFa, and IL-12 at the later time point (Figure 5.4C), but there was little difference 
at the early time point. IL-5 production was also increased at the early and late 
time points in spleen and DLN cultures respectively (Figure 5.5).
Of the other cytokines measured in culture supernatants, IL-lp , IL-4 and IL-10 
were undetectable, and IL-6 was unaffected by IL-33 treatment. No difference was 
seen between IL-33 treated and untreated mice in serum levels of cytokines or 
collagen specific IgGI and lgG2a.
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Figure 5.2 iL-33 increases the severity o f Ci A
Arthritis was induced in mice as described. (A) The incidence of arthritis was determined as the 
percentage of the group which had developed arthritis in at least one paw, and was unaffected by 
treatment with IL-33 (n = up to 20 mice per group). (B) The total clinical score of each mouse with 
disease was assessed, with the maximum being 12. Treatment with IL-33 increased disease 
severity. Results are expressed as mean ± SEM (n = up to 20; **p<0.01, ***p<0.001).
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Figure 5.3 IL~33 Increases the number o f diseased paws
Arthritis was induced in mice as described. Treatment with IL-33 increased (A) the number of arthritic 
paws per mouse and (B) the amount of swelling in arthritic paws. (C) The clinical score per individual 
paw was not significantly affected (n= up to 20; **p<0.01, ***p<0.001).
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Figure 5.4 IL-33 increases proliferation and cytokine production
Arthritis was induced in mice as described. Mice were culled at day 26 (early), day 31 (middle) and 
day 36 (late) and DLN and spleens harvested. Single cell suspensions were restimulated with Cll 
and proliferation and cytokine production measured. Treatment with IL-33 increased (A) early 
splenocyte proliferation (B) early splenocyte cytokine production and (0) late DLN cytokine 
production (X = not analysed). Statistics were not performed on in vitro analyses as organs from 
each group were pooled prior to preparation for cell culture.
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Figure 5.5 IL-33 increases IL-5 production
Arthritis was Induced in mice as described. Mice were culled at day 26 (early), day 31 (middle) and 
day 36 (late) and DLN and spleens harvested. Single cell suspensions were restimulated with Cll 
and IL-5 measured by sandwich ELISA. Treatment with IL-33 increased IL-5 production in (A) spleen 
and (B) DLN cultures. Statistics were not performed on in vitro analyses as organs from each group 
were pooled prior to preparation for cell culture.
Chapters: 158
5.3. ST2  ^ mice have reduced severity of CIA
CIA was induced in DBA/1 ST2^ mice using the same protocol as before (Figure 
5.1). ST2^ '^  ^ littermates were used as the control group. Unfortunately, the number 
of mice available from the breeding programme was below the number required to 
reach significance according to the power calculation, but there was a definite 
trend towards a reduction in disease severity. The experiment was repeated and 
the same results obtained.
ST2''^^ and ST2^ littermates developed a similar incidence of arthritis (2/3 and 3/4) 
respectively (Figure 5.6A). However, ST2'^' mice developed less severe disease, 
with a reduction in clinical score per affected mouse (Figure 5.68). The number of 
arthritic paws per mouse was reduced (Figure 5.7A), and also the thickness of the 
swelling (Figure 5.78), but the clinical score per arthritic joint was not (Figure 
5.7C).
No significant difference was seen in DLN or spleen proliferation, or in TNFa, IL-6, 
or IL-12 production (Figure 5.8A and 8). IL-1 [3 and IFNy were not detected, and IL- 
17 was not measured.
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Figure 5.6 ST2'^ ' mice have reduced severity of CIA
Arthritis was induced in mice as described. (A) ST2'/- did not affect the incidence of arthritis (n=3-4). 
(B) The total clinical score of each mouse with disease was assessed, with the maximum being 12. 
ST2-/- reduced disease severity. Results are expressed as mean ± SEM (n=3-4). No statistics were 
performed due to the small number of mice available.
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Figure 5.7 ST2'^ ~ mice have fewer diseased paws
Arthritis was Induced in mice as described. ST2-/- mice had (A) decreased arthritic paws per mouse 
and (B) reduced swelling in arthritic paws. (C) The clinical score per individual paw was not 
significantly affected (n=3-4). No statistics were performed due to the small number of mice 
available.
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Figure 5.8 IL-33 increases proliferation and cytokine production
Arthritis was induced in mice as described. Mice were culled at the peak of disease severity {day 40) 
and DLN and spleens harvested. Single cell suspensions were restimulated with collagen and (A) 
proliferation and (B) cytokine production measured. Statistics were not performed on in vitro 
analyses as organs from each group were pooled prior to preparation for cell culture.
Chapter 5: 162
5.4. Discussion
The pilot data in this chapter indicates that IL-33 may exacerbate CIA, whilst ST2‘ '^ 
may ameliorate disease. Specifically, neither IL-33 nor ST2^ affected disease 
incidence, but IL-33 Increased the number of arthritic joints per affected mouse, 
and the amount of joint swelling per arthritic paw, whilst ST2'^‘ reduced these 
measures.
An increase in cytokines known to play Important roles in arthritis was seen. Whilst 
some of the increased cytokine production seen in splenocytes could be due to 
increased proliferation and numbers of cytokine producing cells, there was no 
increased proliferation in DLN. Of particular interest were the marked increase in 
IL-17 and TNFa from the DLN cells. Therefore IL-33 could exacerbate arthritis 
indirectly through the induction of TNFa and IL-17. Both of these play crucial roles 
in the initiation and persistence of joint inflammation, and in cartilage and bone 
erosion. However, it is unknown exactly where the inflammatory cytokine came 
from and whether IL-33 induces these cytokines directly or indirectly. It was also 
interesting to note that, in contrast to IL-33, ST2  ^ seemed to have little effect on T 
cell function. This is similar to the results seen with allergic airway inflammation.
IL-5 was elevated by IL-33 treatment, which is in keeping with previous data in the 
allergic airway model, and in the literature, that IL-33/ST2 modulates IL-5 
production. It is of note that IL-33 can induce IL-5 production even despite the 
ongoing Th1/Th17 response. The possible functional relevance of this unknown, 
although elevated Th2 cytokines (IL-4 and IL-13) are part of the pattern of 
cytokines found in the synovial fluid in very early synovitis (393) which predict 
progression to RA.
5.5. Conclusions
Overall, although this preliminary data suggests that the function of IL-33/ST2 
plays a role in CIA, and therefore may be important in diseases other than those 
mediated by Th2 type inflammation, these studies need to be repeated with 
sufficient numbers to ensure robust biological and statistical significance, and the 
analysis extended to elucidate possible mechanisms of action.
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6.1 Summary of Results
The hypothesis on which the work in this thesis is based was that the novel 
cytokine IL-33 and ST2, its receptor, have an important pro-inflammatory role in 
regulating innate and adaptive inflammation. The data generated demonstrates 
that this hypothesis is valid.
In Chapter 3 I established the use of rm IL-33 as a useful reagent for investigating 
the in  vivo functions of IL-33 and ST2. I went on to show that IL-33 induces local 
and systemic type 2 inflammation dependent on the expression of ST2. Direct 
administration of IL-33 to the airways resulted in eosinophilic airway inflammation, 
and pathological changes similar to asthma, mediated by elevated IL-5, IL-13, 
eotaxin-1, eotaxin-2 and TARC. Experiments with SCID mice revealed that innate 
and/or structural cells are sufficient to initiate this response, but lymphocytes 
greatly enhance the response. The exact cell types involved were not identified.
In Chapter 4 I showed that IL-33 administered with antigen at the time of airway 
challenge exacerbated Th2 mediated allergic airway inflammation, including both 
local tissue effector responses and DLN T cell responses. In addition, IL-33 
induced allergic airway inflammation in pre-sensitised mice in the absence of 
further antigen challenge. Both of these effects were dependent on ST2 
expression. ST2^ mice developed less severe inflammation in the airways despite 
having normal T cell recall responses.
In Chapter 5 I presented pilot data that raise the intriguing possibility that IL-33 and 
ST2 do not just modulate type 2 responses. IL-33 exacerbated the severity of CIA, 
and enhanced DLN T cell responses, whilst ST2'^‘ mice had reduced disease 
severity, without affecting DLN T cell responses. However, these data need to be 
confirmed using appropriate numbers of mice to ensure robust biological and 
statistical significance.
This series of experiments clearly demonstrate that IL-33 and ST2 play an 
important role in inflammation. Figure 6.1 summarises some of the known and 
hypothetical interactions that could be involved in the IL-33/ST2 axis, and the 
possible outcomes.
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6.2 Unanswered questions
A number of key questions arise from this work, which are discussed in more 
detail below:
1. Which cells express IL-33 and ST2 expressed in vivo
2. Is IL-33 a cytokine, a nuclear factor, or both?
3. How do IL-33 and ST2 interact?
4. How can ST2L both enhance and suppress inflammation?
5. What role do IL-33 and ST2 play in Th2 cell function?
6. What role might IL-33 and ST2 play in inflammatory diseases?
6,2.1. Which cells express IL-33 and ST2 in vivo?
in  vitro  studies and cDNA libraries have shown IL-33 and sST2 are expressed in 
epithelial and dendritic cells, and also in activated fibroblasts and macrophages, 
with sST2 also released from Th2 cells, in  vitro studies and animal models have 
shown ST2L is expressed on mast cells and some macrophages, and is inducible 
on Th2 and other type 2 lymphoid cells. However, very little is known about which 
cells express IL-33, ST2L and sST2 at the protein level in humans. Identifying the 
cellular source of IL-33 and sST2 and the target cells expressing ST2L will be of 
paramount importance in characterising the in vivo roles of each. A number of 
techniques could be employed to do this. Surgically removed tissues could be 
examined for mRNA expression by real-time quantitative PGR or in-situ 
hybridisation, and protein expression analysed using immunohistochemistry, and 
in particular laser scanning cytometry, to label IL-33 and ST2L/sST2 in tissues 
using monoclonal antibodies. Expression in specific cell types could be analysed 
by digesting tissues, co-staining with antibodies to cell-specific markers, and 
sorting cells by flow cytometry into purified populations for further analysis and 
functional studies .
I have not directly examined ST2L expression and response to IL-33 at the cellular 
level, but the data in SCID mice suggest that lymphoid cells, possibly NKT cells, 
are the key cell in the response triggered by IL-33. However, even though SCID 
mice lack lymphoid cells, there remains a population of non-lymphoid cells, 
probably mast cells and/or macrophages, that can mount a response after IL-33
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stimulation. The precise contribution of each remains to be confirmed by repeating 
these experiments in mice specifically lacking NKT cells (eg mice) or mast
cells (eg Kit-W-sh mice). In the context of adaptive inflammation, IL-33 may play a 
role in the effector response, also through mast cells and macrophages, but it may 
also be able to directly activate pre-sensitised Th2 cells in the absence of further 
antigen, and enhance antigen-specific activation.
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Figure 6.1 The possible role of IL-33 and ST2 In Inflammation
This diagram illustrates some of the possible sources and downstream effects of IL-33 and ST2 
signalling. IL-33 mRNA is expressed in many cells types, and is upregulated by pro-inflammatory
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cytokines and PAMPs. The protein has thus far only been identified in the nucleus of endothelial 
cells, so in order to act as a cytokine it may be released from the cell when it is damaged, or it may 
be actively secreted by an as yet unidentified mechanism. ST2L and IL-1 RAcP comprise the cell 
surface receptor for IL-33, which activates NF-kB through a MyD88 dependent mechanism. ST2L 
can also sequester MyD88 to downregulate TLR and IL-1R signalling. Soluble (s)ST2 is also 
released from many cells following activation by cytokines or PAMPs, and has been shown to bind to 
IL-33 and reduce the subsequent inflammatory response by preventing its interaction with ST2L/IL- 
1 RAcP. sST2 can also bind to an unknown factor on the cell surface which is induced by TLR 
signalling, and can then downregulate TLR signalling. The overall outcome of IL-33 signalling or 
ST2L/sST2 modulation of TLR signalling is a shift towards Th2 type responses. The exact 
downstream effects depend on which cell the IL-33/ST2 axis is acting. IL-33 may act on Th2 cells to 
potentiate differentiation and increased Th2 cytokine release. In addition, it may be that IL-33 can 
induce the differentiation of Th2-like cells that preferentially produce IL-5 and IL-13. 11-33 may 
activate mast cells to release cytokines, and there may also be a role in activating NKT cells to 
produce Th2 cytokines. The effector cytokines released (IL-4, IL-5 and IL-13) can then have pro- 
allergic effects. Thus IL-33 may play a role in modulating immune responses by tipping the balance 
in favour of Th2 responses. ST2L/sST2 may also play a direct role in innate, Thi and T h i7 
responses in the absence of IL-33 by modulating the activation of macrophages and other cells 
through TLRs and IL-1R.
6.2.2. IL-33: cytokine, nuclear factor or both?
One of the features of the members of the IL-1 family is that they do not have a 
leading sequence. Therefore, most proteins of the family are located in the cytosol 
or nucleus. However, the proteins can be processed via caspase I digestion and 
released through a non-classical pathway upon inflammatory stimulation (257). IL- 
33 has many structural and functional elements in common with IL-1 a, which is 
usually present in the nucleus and acts as a nuclear factor, but can act as a 
cytokine by binding to IL-1R when released from the cell. This can occur if cells 
are damaged or lysed, and also by presentation at the cell surface or secretion. 
Due to the lack of an effective antibody and ELISA, the expression and location of 
IL-33 at protein level has not yet determined. IL-33 protein expression has 
currently only been seen in the nucleus of HEVECs from human lymphoid and 
chronically inflamed tissue (255), where it may have a role in transcriptional 
regulation, although its precise function is unknown. In contrast, although IL-33 
has not yet been directly identified extracellularly in  vivo, functional data in this
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thesis and from Schmitz et ai (1) clearly define a role for IL-33 as a cytokine 
promoting type 2 inflammation. Under resting conditions IL-33 may function as a 
nuclear factor, but at epithelial surfaces may act as a “danger signal” released 
either after cell damage or stimulation by pro-inflammatory signals. Cells 
expressing ST2L (macrophages and mast cells) would then be ideally placed to 
initiate an immediate innate response. The pro-inflammatory cytokines and 
chemokines released could then attract other immune cells and induce further 
expression of ST2L, and IL-33 may subsequently play a role in Th2 differentiation 
and effector function.
The downstream effects of IL-33 in these experiments involve the induction of pro- 
inflammatory cytokines and chemokines, and the influx of immune cells. Indirect 
effects as a result of initiating inflammatory cascades may explain how IL-33 can 
modulate Th2 and other types of inflammation. Many of these effects of IL-33 are 
also shared by Th2 cytokines, and this redundancy makes it difficult to ascertain 
which are the most important factors in vivo. Investigation of the functions of IL-33 
and ST2 in gene knockout mice, particularly IL-4" '^, IL-5" “^ and IL-13"^ ', and in cell 
deficient mice, particularly mast cells and NKT cells, will be important in identifying 
which cells and mediators are vital at which stage. It is possible that some of the 
effects of Th2 cytokines are mediated through IL-33 expression.
6.2.3. Interactions between IL-33 and ST2
Like the most members of the family (236), IL-33's function could be regulated by 
its own soluble receptor, and it is interesting to note that sST2 has been 
upregulated in several inflammatory conditions, including sepsis (334), tissue 
ischaemia (336,338), Th2 diseases (340,341) and autoimmunity (344). IL-33 and 
sST2 are often expressed by the same cell types after the same stimuli. Although 
it has not yet been shown, sST2 is likely to bind to IL-33 and act as a soluble 
decoy receptor. Thus, as with IL-1 and IL-1Ra (220), the activity of IL-33 may be 
regulated by release of IL-33 or sST2 in different amounts or at different times, 
even by the same cell. IL-33 binds to ST2L in vitro  (1), and I have shown here that 
both the innate and adaptive in vivo  functions of exogenous IL-33 are dependent 
on ST2 expression. As ST2'^‘ mice lack both ST2L and sST2, I cannot exclude a 
role for sST2 in these explaining these data, as it has been shown to bind to an 
unknown surface ligand, and have downstream effects on TLR and cytokine 
expression (284,301,303,308). However, this also raises the possibility that, like
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IL-1 a, IL-33 may be associated with the cell surface and bind to ST2L through cell­
cell contact, and sST2 could also interfere in this interaction.
6.2.4. ST2L has pro- and anti-inflammatory effects
One of the paradoxes of ST2L function has been that on mast cells and Th2 cells 
it is involved in activation, whereas in macrophages it is suppressive of TLR 
function. The molecular mechanism involved in these disparate effects of ST2L is 
currently unknown. It may be explained through the common use of MyD88 in 
signalling. When IL-33 binds to ST2L it can then signal through MyD88 to have 
pro-inflammatory actions via NFkB (1). However, the suppressive function on 
TLRs and IL-1R is mediated by ST2L sequestering MyD88 and preventing 
signalling (306). Thus the role of ST2L in the resting state, in the absence of IL-33, 
may be to limit TLR activation. ST2L expression is increased by TLR and pro- 
inflammatory cytokine signals, and could represent a mechanism to regulate 
inflammation. Interestingly TLR signalling generally favours Th i type responses, 
whereas previous studies and the data here demonstrates that IL-33/ST2L 
generally results in Th2 type inflammation, so crosstalk between T h i and Th2 
driving signals can occur in the same cell. This field requires further investigation.
6.2.5. IL-33 and ST2 in Th2 cell function
6.2.5.1. T cell activation
ST2L is established as a marker for some Th2 cells (291,292,328), but its function 
in Th2 responses is unknown. It has been noted that ST2L CD4* cells are most 
closely related to the site of infection or inflammation (141,291,292,314,317,318), 
and are less frequent at distant sites such as lymph nodes, perhaps suggesting 
they are important effector cells. In Chapter 4 I demonstrated that IL-33 induces 
allergic airway inflammation in pre-sensitised mice without further antigen 
stimulation, so ST2L expressing Th2 cells may be directly activated through ST2L. 
However, as has recently been shown in asthma, it cannot be excluded that at 
least some of these cells are NKT cells, which have also been shown to express 
ST2L. One way of distinguishing the relative roles of NKT and Th2 cells would be 
to give IL-33 to mice which lack lymphocytes (SCID mice) and have been 
selectively reconstituted with NKT and/or Th2 cells from OVA sensitised mice.
A recent report (329) showed that in vitro  polarised Th2 cells express more IL-5 
than wildtype Th2 cells, suggesting ST2L plays a suppressive role in Th2 cells.
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Apparently in keeping with this ST2^ mice with allergic airways disease had 
greater numbers of eosinophils in the BAL, despite normal DLN T cell responses 
in vivo. This data is in contrast to the observation that ST2L expression is 
associated with increased IL-5 expression both in vitro  and in vivo  
(291,314,325,328), and with my data which shows ST2^ mice have fewer 
eosinophils in BAL, mediated by lower IL-5 and chemokine levels. The reason for 
the discrepancy is unknown. As we were both using the same strain of ST2"^ ' mice, 
with the same ST2 gene disruption, the difference may lie in the model or the 
technique for counting eosinophils.
6.2.5.2. T cell differentiation
IL-33 may be ideally placed to be an important factor in influencing Th2 cell 
differentiation. It is particularly expressed in tissue cells at or near epithelial 
surfaces, where Th2 responses are important in parasite responses. It may be 
released early in the response as a danger signal which alerts the immune system 
to mount a Th2 response. It is also expressed in dendritic cells, so could also 
directly influence T cell differentiation at the time of antigen presentation. Naïve T 
cells express very little ST2L, but as the Th2 phenotype becomes more 
established ST2L expression increases. Also, as ST2 deficiency has no effect on 
the IL-4-dependent Th2 cell differentiation (325-327), IL-33 is perhaps more 
important in maintaining the Th2 cell phenotype rather than their development.
Another intriguing possibility is that IL-33/ST2L could influence T cells to 
differentiate along a non-classical Th2 pathway. Effective Th2 type responses are 
usually generated via an IL-4-dependent pathway (394), although they can occur 
in the absence of IL-4 (46,395) by undefined mechanisms. Subsequently GM-CSF 
was found to generate Th2 responses in the airway in the absence of IL-4 (48). In 
the data presented here IL-33 preferentially induced IL-5 and IL-13 and was 
unable to directly induce IL-4 expression, even in pre-sensitised mice. The 
existence of Th2-like cells, expressing IL-5 and IL-13, and not IL-4, has been 
shown in various models of parasite infection and allergy (45-47,145,318,395), 
and it may be that ST2L is a marker for these cells, and IL-33 a factor in their 
development. Thus IL-33 may be a differentiating factor for a specific subset of 
Th2 cells. It remains to be seen whether these cells represent a novel subset with 
unique effects.
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6.2.6. What role might IL-33 and ST2 play in inflammatory disease?
6.2.6.1. Asthma
The current results suggest that IL-33 plays a critical role in asthma, since all the 
key cells involved in asthma pathogenesis express ST2L. Therefore, the increased 
inflammatory response in allergic airway inflammation induced by IL-33 is likely to 
be due to multiple mechanisms. As discussed above, IL-33 may play a role in 
directly and indirectly activating Th2 cells and effector cells in the tissues or DLNs. 
However, ST2 ''' had little effect on DLN T cell recall responses, suggesting ST2L, 
and therefore IL-33, plays a more important role in the local response. Whether 
this represents ST2L on Th2 cells or effector cells is unknown. Although the role of 
IL-33 in T cell differentiation was not studied, it is possible that the increased 
inflammation is due to increased presence of a subset of Th2-like cells expressing 
increased IL-5 and lL-13.
Eosinophilia plays an important role in asthma pathogenesis. I found that the main 
effect of IL-33 is inducing eosinophilia by at least two mechanisms. It may have a 
role in the generation of eosinophils via enhancing IL-5 production. In support of 
this, ST2^ mice produced less IL-5 and developed a reduced eosinophilia in 
allergic airway inflammation. IL-33 may also promote the recruitment of 
eosinophils by inducing chemokine expression. Mast cells are another key cell in 
asthma which release pro-inflammatory cytokines and mediators, importantly, 
ST2L is highly expressed by most mast cells, our preliminary data suggest that IL- 
33 is capable of inducing inflammatory cytokine secretion and degranulation of 
mast cells (unpublished result). Thus, IL-33 is a novel pathogenic factor and 
should be a new therapeutic target.
6.2.6.2. Rheumatoid arthritis
IL-33 exacerbated footpad disease in CIA, and ST2^ reduced it. Similar to allergic 
airways disease, T cell recall responses were normal in ST2^ mice, suggesting 
that loss of ST2, and therefore IL-33, is more important in the tissues. CIA is 
thought to be a Th1 and/or Th17 mediated disease, so it seems unlikely this 
reflects a loss of ST2 from Th2 cells. Therefore innate effector cells are probably 
the more important target for IL-33 in rheumatoid arthritis. The pro-inflammatory 
effect of IL-33 in CIA is likely to be mediated indirectly through macrophages, and 
perhaps even mast cells, which have been shown to play an important role in 
initiating joint pathology (225).
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6.3 Conclusions
In conclusion, I have presented data in this thesis that suggests IL-33 and ST2 
play crucial roles in initiating and regulating innate, allergic and autoimmune 
inflammation, and is therefore a valid target for further research into the 
mechanisms by which it can diverse modes of inflammation. It also identifies it as 
a potential therapeutic target in a wide range of human diseases.
6.3.1. Future Work
IL-33 biology
Initial investigations into the biology of IL-33 in the lung were constrained by the 
rate at which rm IL-33 could be produced, purified and tested in the lab during the 
project. If more rm IL-33 and more time had been available it would have been 
possible to extend the studies of the effect of IL-33 in the airway. In particular a 
more detailed analysis of the effects of single and multiple applications over a 
range of doses in various compartments, such as BAL, lung parenchyma and 
serum, would allow elucidation of possible downstream mechanisms of action of 
IL-33. In order to determine how relevant these doses are it will be necessary to 
detect physiological levels of human IL-33 in vivo  in tissues such as BAL, lung and 
serum.
Lung biology
In this work I have made a detailed analysis of airway (BAL), systemic (serum) and 
lymph node responses involved in lung inflammation. However, had the timescale 
of this project allowed I would like to have extended the analysis of the 
parenchymal compartment, thus linking the systemic and airway responses. This 
could include lung digests to examine the levels of cytokines and chemokines 
within the lung itself, and levels of eosinophil cationic protein (ECP) would also 
give an indirect measure of the degree of eosinophilic inflammation. Flow 
cytometry would allow a more accurate direct quantification of the cells comprising 
the inflammatory infiltrate. It would also be useful to further characterise the 
pathology by using histological stains specific for goblet cells and mast cells, as 
these were difficult to confidently identify just using the H&E stain. In addition, 
indicators of mast cell function, such as tryptase levels in tissues, could be 
measured. Using laser scanning cytometry would also have allowed identification 
of specific lymphocyte subsets (T cells, NKT cells) in the lung.
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In the studies presented in this thesis I have focussed on the inflammatory 
response in the lung. However, it is also relevant to study the changes in airway 
physiology that may also occur in the presence of allergic type inflammation. I 
have performed preliminary studies measuring Penh, an indirect measure of 
changes in airway resistance (and thus AMR) in and ST2^ mice. These
studies were performed in a different model of airway inflammation carried out 
over a longer period of time, and so the results may not be applicable here. 
However, they do demonstrate that ST2  ^ mice develop the same level of AHR as 
ST2+/+ mice, despite having reduced eosinophilic inflammation (Kewin P et al, 
unpublished data). This dissociation of inflammation from AHR is in keeping with 
previous data that showed anti-IL-5 can profoundly reduce eosinophils numbers, 
but has no effect on AHR (95).
Joint biology
The data presented in Chapter 5 largely represents pilot data, partly because there 
were many difficulties encountered in the breeding programme, resulting in a long 
delay in mice being available. Had time allowed I would have liked to have 
repeated these studies with larger groups of mice to confirm the results seen. This 
would also allow a more detailed analysis of the response by looking at different 
time points, and also by giving IL-33 at different times to see when it is most 
effective. It would also be important to analyse the pathology in the joints in detail 
to see which cells and mediators are involved in the inflammatory lesion.
Priority areas for further work
I have already alluded to possible avenues of further investigation, but outlined 
below are some specific areas of research that are current priorités for furthering 
our understanding of the biology of IL-33 and ST2:
• Development of further reagents to enable analysis of IL-33, such as anti- 
IL-33 antibodies for neutralisation or detection, IL-33 transgenic and 
knockout mice, and specific sST2 and ST2L knockout mice
• Identification of the in  vivo  source of IL-33 as a cytokine, and its mechanism 
of secretion from the cell
• Identification of the cellular target of sST2 and the mechanism of its 
downstream effects
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• Elaboration of the signalling mechanisms used by ST2L and how they 
interact with and influence other IL-1R family member and TLR function
• Investigation of the role of IL-33 in T cell differentiation by in vitro  studies of 
the factors required to differentiate IL-5 and IL-13 producing Th2 like cells
• Confirmation of these cells as a distinct entity by adoptive transfer into 
immunodeficient mice and demonstrating they can initiate immune 
responses.
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Appendix 1: Buffers and solutions
buffers stored at room temperature unless otherwise stated.
2% Agarose gel:
Avertin:
2g agarose 
100ml TAE buffer
Heat in microwave until clear and boiling
Add 5|jl ethidium bromide (0.005%) and mix gently
Pour into gel tray with comb and allow to cool
3g 1,1,1 tribromoethanol 
3ml amyl alcohol 
Store at 4°C
Dilute 1:40 in PBS before use
Complete medium:
ELISA assay buffer A:
500ml RPMI medium
50ml heat-inactivated foetal calf serum
5m! penicillin/streptomycin
5ml L-glutamine
0.5ml 2-mercaptoethanol
+ 25mM HEPES for cultures from CIA experiments
10% heat-inactivated foetal calf in PBS 
pH 7.4
Made fresh and stored at 4“C
ELISA assay buffer B: 1% bovine serum albumin in PBS 
pH 7.4
Made fresh and stored at 4°C
ELISA coating buffer A:
ELISA coating buffer B:
ELISA blocking buffer:
70% Ethanol:
500ml distilled water 
4.2g NaHCOs 
pH to 8.4
500ml distilled water 
4.2g NaHCOs 
1.78g NazCOs 
pH 9.5
Stored at 4°C for up to 1 month
1% bovine serum albumin in PBS 
5% sucrose 
0.05% NaN3 
made up in PBS
7 parts 100% ethanol 
3 parts distilled water
FACS buffer: 2% foetal calf serum in PBS 
Store at 4 ”C
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PCR loading buffer: 
PBS x10:
PCR reaction buffer
TAE buffer:
Tail lysis buffer:
3H-Thymldine:
1% Trypan blue stock:
Wash medium:
Per sample
lOx PCR buffer 2pl
MgCl2 (50mM) Ipl
dNTPs (lOmM) 0.5pl
Taq DNA polymerase 0.5pl
Pure water 13pl
Primer 1 (10OD) 0.5pl
Primer 2 (10OD) 0.5pl
Primer 3 (10OD) 1pl
10mM Ir is  pH 8.0 
50mM EDTA 
lOOmM NaCi 
0.5% SDS
+ 500pg/ml proteinase K added at the time of use
37 MBq 3H-Thymidine (in 1ml sterile saline)
Dilute to 25ml with sterile wash medium 
Store sterile at 4°C in an approved area
0.2g trypan blue crystals 
20ml distilled water
Dilute 1:10 and filter through Nitex before use
500ml RPMI Medium 
5ml penicillin/streptomycin 
Store at 4°C
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Appendix 2: Reagents
Primer 5’............. 3'
Primer 1 TTG GCT TCT TTT AAT AGG CGC
Primer 2 OTA TCA GGA CAT AGO GTT GGG TAG G
Primer 3 TGT TGA AGG GAA GAG GTT AGG
Table A1 Primers used for ST2 PCR
All primers were obtained from Sigma, diluted to 10OD with pure water, and stored at -20°C until use
Primer 5'............. 3'
Human GGGATGGATGAGAGGAATTTGAGGTAT
GAGATGTGTAAGTTTGAGAGAGGTTAA
Mouse GGGATGGAGTTGAGTTTTAAGAGAGTG
GAGATGTTTAGATTTTGGAGAGGTTA
Table A2 Primers used for IL-33 RT~PCR
203
Reagent Supplier Use
All inorganic saits Sigma-Aldrich Buffers and solutions
Aii antibodies and standards Becton-Dickinson (BD) 
R&D Systems
ELISA
Agarose DNA detection
2% Ai hydrogel (alum) Brentag Biosector Mouse sensitisation
Amyl alcohol Sigma-Aidrich Mouse anaesthesia
Bovine coilagen type li Sigma-Aldrich Ceii culture
Bovine coiiagen type ii 
+ Complete Freund’s Adjuvant
Chondrex Induction of CIA
Bovine serum albumin Sigma-Aldrich ELISA
DPX Sigma-Aidrich Coverslip fixation
EDTA Sigma-Aldrich Tail lysis buffer
Ethidium bromide Sigma-Aidrich DNA detection
Ethanol (100% molecular biology grade) Sigma-Aldrich DNA extraction
Extravidin-peroxidase Sigma-Aldrich ELISA
Foetal calf serum (FCS) Flarlan Cell culture, ELISA
L-glutamine Invitrogen Cell culture
Goat serum invitrogen ELISA
■^Fl-thymidine Amersham Life Sciences Proliferation assay
2-Mercaptoethanol Sigma-Aldrich T cell culture
dNTPs (lOmM) PCR reaction mix
Ovaibumin (OVA; fraction V) Sigma-Aldrich Sensitisation and challenge in 
allergic airways disease 
Cell culture
PCR buffer (lOx) PCR reaction mix
Phosphate buffered saline (PBS) invitrogen Cell culture
Penicillin invitrogen Cell culture
Phenol/chloroform/isoamyi alcohoi (25:24:1) Sigma-Aldrich DNA extraction
Proteinase K Sigma-Aldrich Tail lysis buffer
Pure water for injection DNA extraction
Rapi Diff ii Cytoprep staining
Red cell lysis buffer Sigma Cell culture
RPMI medium invitrogen Cell culture
SDS Tail lysis buffer
Streptavidin-peroxidase ELISA
Streptomycin invitrogen Cell culture
Sucrose Sigma-Aldrich ELISA
Taq DNA polymerase PCR reaction mix
TMB Insight (KPL) ELISA
1,1,1-tribromoethanol Sigma-Aldrich Mouse anaesthesia
Tris Tail lysis buffer
Trypan blue Cell counting
Tween-20 Sigma-Aldrich ELISA washing
Table A3 Reagents and suppliers
rri
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